
<html lang="en"     class="pb-page"  data-request-id="d2403994-6eb7-485d-b16d-ddf6d84b552e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-13;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c00359;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity" /></meta><meta name="dc.Creator" content="Bettina Borreschmidt  Hansen" /></meta><meta name="dc.Creator" content="Tue Heesgaard  Jepsen" /></meta><meta name="dc.Creator" content="Mogens  Larsen" /></meta><meta name="dc.Creator" content="Rikke  Sindet" /></meta><meta name="dc.Creator" content="Thomas  Vifian" /></meta><meta name="dc.Creator" content="Mia Nørreskov  Burhardt" /></meta><meta name="dc.Creator" content="Jens  Larsen" /></meta><meta name="dc.Creator" content="Jimmi Gerner  Seitzberg" /></meta><meta name="dc.Creator" content="Martin A.  Carnerup" /></meta><meta name="dc.Creator" content="Anders  Jerre" /></meta><meta name="dc.Creator" content="Christina  Mølck" /></meta><meta name="dc.Creator" content="Paola  Lovato" /></meta><meta name="dc.Creator" content="Sanjay  Rai" /></meta><meta name="dc.Creator" content="Venkatarathnam Reddy  Nasipireddy" /></meta><meta name="dc.Creator" content="Andreas  Ritzén" /></meta><meta name="dc.Description" content="Herein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone co..." /></meta><meta name="Description" content="Herein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone co..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 28, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00359" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00359" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00359" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00359" /></link>
        
    
    

<title>Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00359" /></meta><meta property="og:title" content="Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0029.jpeg" /></meta><meta property="og:description" content="Herein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fragment-based lead generation efforts. A two-stage strategy was chosen with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose pocket-targeting substituent was followed by the introduction of a variety of P-loop-targeting functional groups. Combining the best moieties from both stages of the optimization afforded compound 40, which showed excellent potency and selectivity. Metabolism studies in vitro and in vivo together with an in vitro safety evaluation suggest that 40 may be a viable lead compound for the development of highly subtype-selective JAK1 inhibitors." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Herein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fragment-based lead generation efforts. A two-stage strategy was chosen with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose pocket-targeting substituent was followed by the introduction of a variety of P-loop-targeting functional groups. Combining the best moieties from both stages of the optimization afforded compound 40, which showed excellent potency and selectivity. Metabolism studies in vitro and in vivo together with an in vitro safety evaluation suggest that 40 may be a viable lead compound for the development of highly subtype-selective JAK1 inhibitors." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0029.jpeg" /></meta><meta name="twitter:title" content="Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00359"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00359">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00359&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00359&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00359&amp;href=/doi/10.1021/acs.jmedchem.0c00359" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 7008-7032</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00358" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00366" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Bettina Borreschmidt Hansen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bettina Borreschmidt Hansen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MedChem II, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bettina+Borreschmidt++Hansen">Bettina Borreschmidt Hansen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tue Heesgaard Jepsen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tue Heesgaard Jepsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MedChem II, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tue+Heesgaard++Jepsen">Tue Heesgaard Jepsen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mogens Larsen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mogens Larsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MedChem II, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mogens++Larsen">Mogens Larsen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rikke Sindet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rikke Sindet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MedChem II, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rikke++Sindet">Rikke Sindet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Vifian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Vifian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MedChem II, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Vifian">Thomas Vifian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mia Nørreskov Burhardt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mia Nørreskov Burhardt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MedChem II, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mia+N%C3%B8rreskov++Burhardt">Mia Nørreskov Burhardt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jens Larsen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jens Larsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MedChem II, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jens++Larsen">Jens Larsen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jimmi Gerner Seitzberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jimmi Gerner Seitzberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MedChem II, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jimmi+Gerner++Seitzberg">Jimmi Gerner Seitzberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin A. Carnerup</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin A. Carnerup</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">DMPK, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+A.++Carnerup">Martin A. Carnerup</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anders Jerre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anders Jerre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Skin Research, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Jerre">Anders Jerre</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christina Mølck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christina Mølck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Skin Research, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christina++M%C3%B8lck">Christina Mølck</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paola Lovato</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paola Lovato</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Skin Research, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paola++Lovato">Paola Lovato</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sanjay Rai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sanjay Rai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, GVK Biosciences Private Limited, 28 A, IDA Nacharam, Hyderabad 500076, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sanjay++Rai">Sanjay Rai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Venkatarathnam Reddy Nasipireddy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Venkatarathnam Reddy Nasipireddy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, GVK Biosciences Private Limited, 28 A, IDA Nacharam, Hyderabad 500076, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Venkatarathnam+Reddy++Nasipireddy">Venkatarathnam Reddy Nasipireddy</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Andreas Ritzén</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Ritzén</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MedChem II, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#f99d9f8b9d92b9959c96d48991988b9498d79a9694"><span class="__cf_email__" data-cfemail="64000216000f2408010b49140c051609054a070b09">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Ritz%C3%A9n">Andreas Ritzén</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3313-3753" title="Orcid link">http://orcid.org/0000-0002-3313-3753</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00359&amp;href=/doi/10.1021%2Facs.jmedchem.0c00359" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 7008–7032</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 28, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 February 2020</li><li><span class="item_label"><b>Published</b> online</span>28 May 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 July 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00359" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00359</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7008%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBettina%2BBorreschmidt%2BHansen%252C%2BTue%2BHeesgaard%2BJepsen%252C%2BMogens%2BLarsen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D13%26contentID%3Dacs.jmedchem.0c00359%26title%3DFragment-Based%2BDiscovery%2Bof%2BPyrazolopyridones%2Bas%2BJAK1%2BInhibitors%2Bwith%2BExcellent%2BSubtype%2BSelectivity%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7032%26publicationDate%3DJuly%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00359"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2072</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00359" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bettina&quot;,&quot;last_name&quot;:&quot;Borreschmidt Hansen&quot;},{&quot;first_name&quot;:&quot;Tue&quot;,&quot;last_name&quot;:&quot;Heesgaard Jepsen&quot;},{&quot;first_name&quot;:&quot;Mogens&quot;,&quot;last_name&quot;:&quot;Larsen&quot;},{&quot;first_name&quot;:&quot;Rikke&quot;,&quot;last_name&quot;:&quot;Sindet&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Vifian&quot;},{&quot;first_name&quot;:&quot;Mia&quot;,&quot;last_name&quot;:&quot;Nørreskov Burhardt&quot;},{&quot;first_name&quot;:&quot;Jens&quot;,&quot;last_name&quot;:&quot;Larsen&quot;},{&quot;first_name&quot;:&quot;Jimmi&quot;,&quot;last_name&quot;:&quot;Gerner Seitzberg&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;A. Carnerup&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Jerre&quot;},{&quot;first_name&quot;:&quot;Christina&quot;,&quot;last_name&quot;:&quot;Mølck&quot;},{&quot;first_name&quot;:&quot;Paola&quot;,&quot;last_name&quot;:&quot;Lovato&quot;},{&quot;first_name&quot;:&quot;Sanjay&quot;,&quot;last_name&quot;:&quot;Rai&quot;},{&quot;first_name&quot;:&quot;Venkatarathnam&quot;,&quot;last_name&quot;:&quot;Reddy Nasipireddy&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Ritzén&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;7008-7032&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00359&quot;},&quot;abstract&quot;:&quot;Herein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fragment-based lead generation efforts. A two-stage strategy was chosen with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose pocket-targeting substituent was followed by the introduction of a variety of P-loop-targeting functional groups. Combining the best moieties from both stages of the optimization afforded compound 40, which showed excellent potency and selectivity. Metabolism studies in vitro and in vivo together with an in vitro safety evaluation suggest that 40 may be a viable lead compound for the development of highly subtype-selective JAK1 inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00359&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00359" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00359&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00359" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00359&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00359" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00359&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00359&amp;href=/doi/10.1021/acs.jmedchem.0c00359" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00359" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00359" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00359%26sid%3Dliteratum%253Aachs%26pmid%3D32462873%26genre%3Darticle%26aulast%3DHansen%26date%3D2020%26atitle%3DFragment-Based%2BDiscovery%2Bof%2BPyrazolopyridones%2Bas%2BJAK1%2BInhibitors%2Bwith%2BExcellent%2BSubtype%2BSelectivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D13%26spage%3D7008%26epage%3D7032%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291983" title="Nitrogen compounds">Nitrogen compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/13" title="Go to Volume 63, Issue 13"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/jmcmar.2020.63.issue-13/20200709/jmcmar.2020.63.issue-13.largecover.jpg" alt="Go to Volume 63, Issue 13"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit <b>1</b> with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fragment-based lead generation efforts. A two-stage strategy was chosen with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose pocket-targeting substituent was followed by the introduction of a variety of P-loop-targeting functional groups. Combining the best moieties from both stages of the optimization afforded compound <b>40</b>, which showed excellent potency and selectivity. Metabolism studies <i>in vitro</i> and <i>in vivo</i> together with an <i>in vitro</i> safety evaluation suggest that <b>40</b> may be a viable lead compound for the development of highly subtype-selective JAK1 inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Janus kinase (JAK) family of tyrosine kinases plays a central role in the cytokine-dependent regulation of proliferation, survival, differentiation, and function of diverse cells. It consists of four closely related proteins (JAK1, JAK2, JAK3, and TYK2) that transduce signaling from cytokine receptors by phosphorylation and subsequent activation of signal transducers and activators of transcription (STATs).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> JAKs are critically involved in immune response in health and disease.<a onclick="showRef(event, 'ref1 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref3">(1,3)</a> The understanding of the role of cytokines in the pathophysiology of immune-mediated diseases and the identification of the critical role of JAKs in cytokine signaling prompted the idea that inhibiting the activity of JAKs might provide a new immunomodulatory therapeutic approach. Tofacitinib, a first-generation JAK inhibitor targeting the activity of JAK1, JAK2, and JAK3, was the first drug with this mechanism of action that was approved by the FDA for the treatment of the autoimmune disease rheumatoid arthritis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Tofacitinib has been investigated in a wide range of autoimmune diseases including juvenile arthritis, inflammatory bowel disease, and dermatological disorders, <i>e.g</i>., psoriasis, atopic dermatitis, alopecia, and vitiligo.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> At present, five JAK inhibitors (ruxolitinib, tofacitinib, baricitinib, peficitinib, and upadacitinib) are approved as drugs and several more are in late-stage clinical development.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8−11)</a></div><div class="NLM_p">Subtype-selective inhibitors are currently in clinical trials with the rationale of maintaining the clinical efficacy of pan-JAK inhibitors while improving safety. In particular, selectivity over JAK2 should have the advantage of avoiding hematological side effects like neutropenia and anemia.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> One of the most advanced selective JAK1 inhibitors, abrocitinib, has been evaluated in Phase III clinical trials in atopic dermatitis with a favorable efficacy and safety profile.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a></div><div class="NLM_p last">We have recently reported the discovery of a series of pan-JAK inhibitors that were designed with topical application in mind.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The starting point for that work was a fragment screen of a kinase-targeted library of <i>ca</i>. 500 fragments screened against JAK2 at a single concentration (100 μM) using surface plasmon resonance (SPR). Hits were validated by the determination of <i>K</i><sub>D</sub> using SPR and determination of IC<sub>50</sub> in a biochemical enzyme inhibition assay for JAK1. In general, a good correlation was observed between these two measurements, suggesting that most fragments had little or no selectivity for JAK1 over JAK2. However, one compound (<b>1</b>) deviated from this trend: its potency toward JAK1 (IC<sub>50</sub> = 16 μM) was higher than expected from its affinity to JAK2 (<i>K</i><sub>D</sub> = 45 μM). Because of the JAK1 bias and good potency of this unique fragment, we selected it as the starting point for the discovery of subtype-selective JAK1 inhibitors reported herein.</div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hit expansion of compound <b>1</b> by commercial and synthesized analogues yielded a preliminary map of the structure–activity relationship (SAR) of the scaffold (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Deletion of the fluorine atoms was tolerated with a limited drop in potency (compound <b>2</b>), while removal of the pyrazole methyl group was not (compound <b>3</b>). Methylation of either of the nitrogen atoms of the pyrazole ring also abolished all activity (compounds <b>4</b> and <b>5</b>), suggesting that hydrogen-bonding interactions with this moiety are important for binding.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Fragment Hit and First Set of Analogues<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0020.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were determined in a time-resolved Förster resonance energy transfer (TR-FRET) biochemical assay for kinase inhibition with [ATP] = <i>K</i><sub>m</sub>. All values represent the geometric mean of at least two independent experiments; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a> for details.</p></div></div><div></div></div><div class="NLM_p">In the absence of crystallographic evidence, we assumed that compounds <b>1</b> and <b>2</b> interact with the kinase hinge region. In principle, docking should give a good indication of the binding mode of these compounds, but this scaffold can plausibly exist in multiple tautomeric forms, and each of these tautomers would have distinct binding modes. Prediction of the dominant tautomer in solution by quantum mechanical computations was attempted following the method of Ribeiro et al.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Gas-phase (vacuum) molecular geometries were optimized at the M06-2X/6-311G**+ level and were used to calculate solvation energies in water using the SM8 method.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Relative energies in water were calculated using the M06-2X functional<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and two different basis sets, but the results were ambiguous. In vacuum, the 1<i>H</i>-pyrazolopyridinol tautomer was strongly favored, but in water, either this tautomer or the 2<i>H</i>-pyrazolopyridone tautomer was favored depending on the basis set. Furthermore, the bioactive tautomer may be different from the dominant tautomer in solution, and because of these complications, we were unable to rely on docking to determine the binding mode of the scaffold. Instead, a pragmatic approach was taken: given the SAR outlined above, and with the assumption that the scaffold binds to the kinase hinge region, we set out to grow the difluoromethyl substituent of <b>1</b> by substituting larger lipophilic moieties that might be able to interact with the ribose pocket of the kinase.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Tautomers of Compound <b>2</b> with Relative Energies in kcal/mol Calculated Using Density Functional Theory (DFT)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0021.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Geometries were optimized in vacuum with the density functional M06-2X<sup>17</sup> and the 6-311G**+ basis set, and these geometries were used for the solvation energy calculations. Methods: A, M06-2X/6-311G**+ in vacuum; B, M06-2X/6-31G* with the SM8 water solvation model; C, M06-2X/6-311G**+ with the SM8 water solvation model.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a></p></div></div><div></div></div><div class="NLM_p">Gratifyingly, replacing the difluoromethyl group with a phenyl group (compound <b>6</b>) yielded a 7-fold improvement in potency relative to <b>1</b> (see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Because this series originated from our earlier work on non-subtype-selective JAK inhibitors,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> at the time compound <b>6</b> was prepared, we had only access to crystallography for JAK2. Because <b>6</b> showed a very modest level of selectivity for JAK1 over JAK2, we reasoned that the crystal structure of this compound in complex with JAK2 would be sufficient to establish its binding mode across the JAK kinase family. Thus, an X-ray crystal structure of compound <b>6</b> bound to the kinase domain of JAK2 was obtained (see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). This unequivocally established the bioactive tautomer of the scaffold as the 2<i>H</i>-pyrazolopyridone structure (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compound <b>6</b> engages the kinase hinge region with three hydrogen bonds to the backbone amides of Glu 930 and Leu 932, and a fourth water-mediated hydrogen bond to Pro 933 and the side-chain hydroxyl of Tyr 931. Except for the last one, these interactions would be expected to be identical in JAK1 because the only difference in the hinge is Tyr 931 in JAK2 that corresponds to Phe 958 in JAK1. The ligand carbonyl oxygen also nucleates a water network that connects it loosely to the side-chain carboxylate of Asp 939 in JAK2. This residue is a glutamic acid (Glu 966) in JAK1 but remains an aspartic acid in JAK3 and TYK2.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> The X-ray structure of compound <b>6</b> is consistent with the SAR derived in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Methylation of either nitrogen of the pyrazole would disrupt the hinge interaction, and deletion of the pyrazole methyl group would remove a productive lipophilic interaction. Methyl group deletion may even create a high-energy void that cannot be filled by protein side-chain rearrangement or a low-energy water molecule. Such effects could explain the dramatic loss of potency of <b>3</b> compared to <b>1</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0001.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray crystal structure of compound <b>6</b> in complex with JAK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPD">6TPD</a>, 2.0 Å resolution). The ligand <b>6</b> is colored green, the hinge loop is colored purple, the P-loop is colored orange, the DFG loop is colored blue, and the αC helix is colored red. Hydrogen bonds are shown as green dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Optimization of the Lipophilic Substituents<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0022.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0023.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">STAT IC<sub>50</sub> values were determined in a cellular reporter gene assay, and JAK IC<sub>50</sub> values were determined in a TR-FRET biochemical assay for kinase inhibition with [ATP] = <i>K</i><sub>m</sub>. All values represent the geometric mean of at least two independent experiments unless otherwise noted; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a> for details. Log <i>D</i><sub>7.4</sub> was determined using a shake flask assay, and aqueous solubility was determined using a high-performance liquid chromatography (HPLC) assay from dimethyl sulfoxide (DMSO) stock solutions of test compounds diluted in phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Only one determination was made.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Ligand lipophilic efficiency (LLE) based on JAK1 IC<sub>50</sub>.</p></div></div><div></div></div><div class="NLM_p">With the binding mode and key interactions established, structure-based optimization could be initiated (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The phenyl group of <b>6</b> does not appear to make optimal interactions with the lipophilic ribose pocket. Aliphatic moieties with more three-dimensional shape would likely offer a better fit. Thus, the first step should be optimizing this moiety by adding sp<sup>3</sup> carbons and simultaneously keeping lipophilicity at a minimum. The methyl group of <b>6</b> seems to fit well; nevertheless, a limited set of analogues with alternative small alkyl groups were targeted to map SAR at this position. The last accessible vector, i.e., the carbon atom next to the carbonyl, points toward the solvent front. It could potentially be exploited to modulate solubility and lipophilicity, and perhaps to further engage Glu 966 (the JAK1 residue corresponding to Asp 939 in JAK2) to improve selectivity for JAK1. Eventually, extending the ligand to contact the P-loop of the kinase was planned to further improve potency.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0002.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Strategy for lead generation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The biochemical kinase assays used in this work were performed with an adenosine triphosphate (ATP) concentration close to the <i>K</i><sub>m</sub> value of the respective enzyme (JAK1: 7 μM, JAK2: 4 μM, JAK3: 2 μM, TYK2: 13 μM). However, the intracellular concentration of ATP can reach millimolar, and for an ATP-competitive enzyme inhibitor, this leads to a dramatic increase in the IC<sub>50</sub> in a cellular assay compared to the biochemical assay used here. In addition, low permeability across the cell membrane can further reduce or abolish the activity of the tested compound. Thus, cellular STAT reporter gene assays were established for JAK1-STAT6 signaling (to assess JAK1 inhibition) and JAK2-STAT5 signaling (to assess JAK2 inhibition), and compounds were tested in these assays in parallel with the biochemical assays during the optimization campaign reported here.</div><div class="NLM_p">To optimize the lipophilic ribose pocket substituent of <b>6</b>, the phenyl group was replaced by a selection of mono- and bicyclic aliphatic ring systems (see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The cyclohexyl analogue <b>7</b> showed dramatically improved potency and also increased LLE, but very low solubility. This compound was the first with activity in the cellular STAT6 assay. Importantly, compound <b>7</b> exhibited a 10-fold selectivity for JAK1 over JAK2 in the biochemical assays. Although the reason for this jump in selectivity relative to compound <b>6</b> is unclear, this result prompted a thorough investigation into this chemical series. Smaller, less lipophilic substituents, e.g., cyclopentyl (<b>8</b>) and cyclobutyl methyl (<b>9</b>), afforded similar levels of potency with improved LLE and solubility. The racemic <i>cis</i>-methylcyclohexyl analogue <b>10</b> possessed improved potency in both enzymatic and cellular assays, albeit with a significant log <i>D</i> penalty. The design of this compound was inspired by the similar positioning of the methyl group of tofacitinib (<b>20</b>);<a onclick="showRef(event, 'ref4 ref20'); return false;" href="javascript:void(0);" class="ref ref4 ref20">(4,20)</a> see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and the discussion below. Racemic norbornane analogues <b>11</b> and <b>12</b> showed similar or even higher potency with slightly reduced log <i>D</i> and thus improved LLE with the same number of sp<sup>3</sup> carbons as <b>10</b>. Importantly, compared to <b>7</b>, compounds <b>11</b> and <b>12</b> achieved a 4-fold improvement in cellular potency with no increase in lipophilicity and much improved solubility. The racemic bicyclo[2.2.2]octane analogue <b>13</b> displayed no further improvement in potency, and its increased lipophilicity caused a drop in LLE and solubility. Thus, the norbornanes <b>11</b> and <b>12</b> were the best-performing analogues as they combined excellent potency with LLE on par with the smaller, less potent analogues <b>8</b> and <b>9</b>. The log <i>D</i> advantage of bicyclic over monocyclic scaffolds has been noted for bicyclic morpholine and piperazine analogues, although the effects for those compounds are partly due to increased basicity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Synthetic access to norbornane analogues of specific stereochemistry is restricted, so for synthetic expedience, we initially chose to optimize the cyclohexane derivative <b>7</b>. This would allow us to explore substitution toward the solvent front and the P-loop in detail, and if necessary, we envisaged that optimized substituents could be transferred back to the norbornane analogues.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0003.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking pose of <b>21</b> (cyan) overlaid with the X-ray structures of <b>6</b> (green) bound to JAK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPD">6TPD</a>) and tofacitinib <b>20</b> (yellow) bound to JAK1 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG">3EYG</a>). The protein from PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG">3EYG</a> is shown, and this was used to dock <b>21</b>. The hinge loop is colored purple, the P-loop is colored orange, the DFG loop is colored blue, and the αC helix is colored red. Hydrogen bonds are shown as green dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As noted above, a methyl substituent on the pyrazole appeared optimal based on the X-ray structure of <b>6</b>, but a limited exploration seemed justified to confirm this hypothesis. Deletion of the methyl group in <b>7</b> yielded a compound (<b>14</b>) with measurable, but ∼110-fold reduced JAK1 potency, thus confirming the importance of this substituent (compare compounds <b>1</b> and <b>3</b> discussed above). Opposing trends in the enzymatic and cellular assays were observed for the series methyl (<b>7</b>), ethyl (<b>15</b>), and cyclopropyl (<b>16</b>), perhaps reflecting improved permeability of the more lipophilic analogues. The increased cellular potency of <b>15</b> and <b>16</b> was negated by increased lipophilicity as the LLE was unchanged compared to <b>7</b>. Thus, the methyl group was retained at this position throughout the rest of the optimization.</div><div class="NLM_p">The only unsubstituted carbon atom of the core scaffold offered a vector toward the solvent front and the selectivity-modulating residue Glu 966, and this position was targeted next. A hydroxymethyl substituent (<b>17</b>) was tolerated: no major difference in cellular and enzymatic potency compared to <b>7</b> was observed, and LLE and solubility were improved. Interestingly, <b>17</b> exhibited a twofold improvement in selectivity over JAK2 compared to <b>7</b>, suggesting a productive interaction with Glu 966 of JAK1 or a disruption of the water network connecting the ligand to Asp 939 in JAK2. Thus, we noted that a hydroxymethyl substituent might be useful later in the optimization campaign, should we need to solve issues resulting from high log <i>D</i>, e.g., low solubility or poor metabolic stability. Hydroxyethyl (<b>18</b>) and cyano (<b>19</b>) analogues were less potent and were not considered further.</div><div class="NLM_p">Having optimized the lipophilic substituents of the core, we proceeded to grow the prototypical analogue <b>7</b> toward the P-loop. In the spirit of fragment-based drug design—start small and make every added atom count—small substituents with balanced polarity were added to the cyclohexyl analogue <b>7</b> (see <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). To direct the substituent toward the P-loop while avoiding the complication of fluctuation between two axial/equatorial chair conformers, only trans-configured substituents at the 4-position of the cyclohexyl ring were considered. With the bioactive tautomer and binding mode known, docking could now be leveraged to inform the design of analogues. One example is shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. Here, the published X-ray crystal structure of the JAK inhibitor tofacitinib (<b>20</b>)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> overlaid on the X-ray structure of <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) suggested that an acetonitrile appended to compound <b>7</b> might overlay with the acetonitrile moiety of tofacitinib. Indeed, docking this hypothetical compound <b>21</b> into the tofacitinib X-ray structure indicated a fairly close overlay of the nitriles in the two compounds (see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The reported SAR of tofacitinib (<b>20</b>) indicates that its nitrile moiety contributes significantly to the binding affinity.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Thus, we synthesized and tested compound <b>21</b>, and it afforded a 3-fold improvement in cellular potency relative to <b>7</b> with a concomitant increase in LLE from 2.6 to 4.4 (see <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Because the nitrile of <b>21</b> appears to be slightly further from the P-loop than the corresponding nitrile in <b>20</b> (see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), a one-carbon homologue, <b>22</b>, was prepared to try to reach closer toward the P-loop, but potency was essentially unchanged. On the other hand, contracting the nitrile back to the cyclohexane caused a large drop in activity because this compound (<b>23</b>) cannot reach the P-loop and the nitrile does not add other interactions with the kinase. The desolvation penalty of the nitrile may explain the 6-fold drop in potency relative to the unsubstituted cyclohexane <b>7</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Addition of Polar Substituents Projecting toward the P-loop<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0024.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0025.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">STAT IC<sub>50</sub> values were determined in a cellular reporter gene assay, and JAK IC<sub>50</sub> values were determined in a TR-FRET biochemical assay for kinase inhibition with [ATP] = <i>K</i><sub>m</sub>. All values represent the geometric mean of at least two independent experiments unless otherwise noted; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a> for details. Log <i>D</i><sub>7.4</sub> was determined using a shake flask assay and aqueous solubility was determined using an HPLC assay from DMSO stock solutions of test compounds diluted in phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Only one determination was made.</p></div></div><div></div></div><div class="NLM_p">To better understand the postulated interaction between the nitrile of <b>21</b> and the P-loop of the kinase, an X-ray crystal structure of <b>21</b> in complex with the JAK1 kinase domain was solved (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The core scaffold and cyclohexane moieties in the crystal structure overlaid perfectly with the predicted binding mode from docking (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). However, the nitrile functional group was not defined by the electron density suggesting that it adopts several conformations. Thus, it is unlikely that it engages the P-loop like the nitrile in tofacitinib (<b>20</b>), which has a clearly defined electron density (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG">3EYG</a>). With this result in hand, we set out to investigate other options for reaching the P-loop and forming productive interactions with it. To this end, compounds with amide, ester, and sulfonamide linkers connecting the cyclohexane moiety with small cycloalkyl and fluorocycloalkyl moieties were synthesized (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The cyclohexyl carboxamide <b>24</b> possessed modest JAK1 potency, slightly lower than that for <b>7</b>, while the potency of reversed amide <b>25</b> was much lower. Increasing the steric bulk of <b>24</b> to cyclopentane <b>26</b> only afforded a twofold improvement. Thus, <b>26</b> was no better than <b>7</b> with respect to JAK1 potency. Gratifyingly, the introduction of a <i>gem</i>-difluoro motif to <b>24</b> greatly improved JAK1 potency, particularly in the <i>S</i> enantiomer <b>27</b>, but the less active <i>R</i> enantiomer <b>28</b> also showed a slight improvement relative to <b>24</b>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0004.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of compound <b>21</b> (cyan) in complex with JAK1 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPE">6TPE</a>, 2.9 Å resolution). The ligand electron density is shown in blue mesh. Hydrogen bonds are shown as green dotted lines. The nitrile functional group is modeled in an arbitrary rotameric state because no electron density was observed for it.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unfortunately, the high potency of <b>27</b> in the enzymatic assay did not translate to the cellular STAT6 assay. For the compounds discussed up to this point, on average, an <i>ca</i>. 30-fold drop in potency was observed going from enzymatic to cellular assays, largely consistent with the different ATP concentrations in these assays, as discussed above. However, for compound <b>27</b>, the drop was close to 3000-fold, suggesting a permeability limitation for this analogue. We suspected that the polar nature of the scaffold core together with the additional hydrogen-bond donor of <b>27</b> might be responsible for the putative permeability limitation. To remove one hydrogen-bond donor, the ester analogue <b>29</b> was prepared and tested. This compound retained most of the potency in the JAK1 assay and showed a potency in the STAT6 assay consistent with the expected 30-fold drop discussed above. However, this compound had poor solubility and was extremely rapidly degraded in human liver microsomes, presumably due to ester hydrolysis. Replacing the amide linker with a sulfonamide was briefly investigated (compounds <b>30</b> and <b>31</b>) but did not result in an improvement in potency or lower drop in activity from biochemical to cellular assays. For completeness, we tested the building blocks <b>32</b> and <b>33</b> used to prepare compounds <b>24</b> and <b>26</b>–<b>31</b>, but they were much less potent than <b>7</b>. Very large desolvation penalties of the hydroxy and amino groups of these compounds in the absence of productive interactions with the protein may explain this result.</div><div class="NLM_p">To confirm the binding mode of <b>27</b> and understand the details of its interaction with the JAK1 kinase domain, an X-ray crystal structure of this compound in complex with JAK1 was solved (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The pyrazolopyridone core makes the same interactions with the hinge loop residues as do compounds <b>6</b> and <b>21</b>. The higher resolution of this X-ray structure allows the water network to be observed. A water-mediated contact with Arg 879 and Pro 960 is observed, but no interaction with Glu 966 is seen. Moreover, the two protein molecules in the crystallographic unit cell show different side-chain conformations for this residue. In contrast, the Arg 879 side chain has a very similar conformation in both protein molecules. This suggests that the JAK1 selectivity of the scaffold derives from the interaction with Arg 879. This residue is Gln in JAK2, Ser in JAK3, and Arg in TYK2. However, the combination of Phe 958 (Tyr in JAK2, JAK3, and TYK2) and Arg 879 is unique to JAK1. Comparing the binding modes of <b>6</b> in JAK2 and <b>27</b> in JAK1 may give a clue to the reason for the JAK1 selectivity of the scaffold: The carbonyl oxygen of <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) makes a water-mediated contact with the JAK2 Tyr 931 hydroxyl while <b>27</b> makes a very similar contact with the JAK1 Arg 879 side chain. If the latter interaction is more favorable, it would explain the preference of the scaffold for JAK1 binding.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0005.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of compound <b>27</b> in complex with JAK1 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPF">6TPF</a>, 2.3 Å resolution). The ligand <b>27</b> is colored green, the hinge loop is colored purple, the P-loop is colored orange, and the DFG loop is colored blue. Hydrogen bonds are shown as green dotted lines. Side-chain conformations from the second protein molecule in the crystallographic unit cell are shown in cyan for Arg 879 and Glu 966.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Other strategies for achieving high selectivity for JAK1 have been pursued in the literature, and a large body of work by many groups has been reviewed.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> In particular, targeting Glu 966 in JAK1 has been shown to be a viable approach, although other amino acid differences between the JAK family subtype enzymes have also been exploited. For a comprehensive discussion of these approaches, see ref <a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a>. Alternatively, it has been suggested that the P-loop is more flexible in JAK1 than in JAK2. Extending the ligand toward the P-loop thus causes a clash with this moiety in JAK2, thus rendering compounds JAK1-selective.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Although, as noted above, interaction with Glu 966 seems unlikely to contribute to the selectivity of the series reported herein, a contribution from the differential P-loop flexibility may well augment the inherent JAK1 bias of compound <b>27</b>.</div><div class="NLM_p">The <i>gem</i>-difluoro moiety of <b>27</b> does contact the P-loop; however, the reason for the 34-fold increase in potency observed when adding these two fluorine atoms to <b>24</b> is not obvious from the visual inspection of the X-ray structure. A hydrogen-bonding interaction between the amide NH and the backbone carbonyl of the Asp 1021 residue of the DFG loop is present, but it probably contributes little to the binding affinity, considering that the ester analogue <b>29</b> is almost as potent. Thus, to improve permeability by removing one hydrogen-bond donor, the amide NH of <b>27</b> was replaced by CH<sub>2</sub> and tertiary amide nitrogen was introduced on the other side of the carbonyl (see <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). With this change, the direct analogue of <b>27</b> would be an aziridine amide, which would be expected to have poor chemical stability. Thus, we targeted azetidine, pyrrolidine, and piperidine amides instead.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Tertiary Amides Projecting toward the P-loop<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0026.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0027.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">STAT IC<sub>50</sub> values were determined in a cellular reporter gene assay, and JAK IC<sub>50</sub> values were determined in a TR-FRET biochemical assay for kinase inhibition with [ATP] = <i>K</i><sub>m</sub>. All values represent the geometric mean of at least two independent experiments; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a> for details. Log <i>D</i><sub>7.4</sub> was determined using a shake flask assay, and aqueous solubility was determined using an HPLC assay from DMSO stock solutions of test compounds diluted in phosphate buffer at pH 7.4. Human liver microsome (HLM) Cl<sub>app</sub> is the intrinsic clearance in human liver microsomes.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Only one determination was made.</p></div></div><div></div></div><div class="NLM_p">To maintain lipophilicity under control, the nitrile functional group was reintroduced as a P-loop interaction moiety. Both azetidine <b>34</b> and pyrrolidine <b>35</b> showed respectable levels of JAK1 potency, but unfortunately cellular potency was not achieved. It is worth noting that <b>35</b> is racemic, and the pure enantiomers were not prepared because of the lack of sufficient cellular activity. Both compounds possessed good aqueous solubility and were stable toward human liver microsomes. To improve cellular potency at the expense of increasing log <i>D</i>, the nitrile was replaced by more lipophilic substituents, e.g., benzyl (<b>36</b>), phenyl (<b>37</b>), and <i>gem</i>-dimethyl (<b>38</b>). Although these compounds showed excellent JAK1 potency and cellular potency in the STAT6 assay, consistent with the expected 30-fold drop, solubility and, in particular, metabolic stability were very poor. Clearly, the polar nature of the core scaffold limits the amount of additional polarity that can be tolerated in the compounds without losing cellular potency. On the other hand, compounds with sufficient lipophilicity to achieve cellular activity showed poor solubility and metabolic stability.</div><div class="NLM_p">To overcome these issues, we set out to transfer the best P-loop-targeting substituents discovered above back to the norbornane scaffold (compounds <b>11</b> and <b>12</b>). Thus, we hoped to significantly improve the potency of compound <b>21</b> without compromising solubility and metabolic stability. Although no difference in potency between the unsubstituted <i>exo</i> (<b>11</b>) and <i>endo</i> (<b>12</b>) norbornanes was observed, once a second substituent is appended to the norbornane, this must be directed toward the P-loop to achieve the desired potency boost. Although docking could not conclusively direct our efforts toward a single regio- and stereoisomer, it appeared unlikely that the core hinge binder could occupy an <i>endo</i> vector. To closely mimic the arrangement of the core and nitrile of <b>21</b>, the four stereoisomers <b>39</b>–<b>42</b> were targeted for synthesis (see <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The compounds were prepared as racemates and the enantiomers were separated by chiral chromatography. The absolute configurations of these compounds were not determined. Gratifyingly, one enantiomer of the <i>exo</i>,<i>exo</i> diastereomer, compound <b>40</b>, afforded high enzymatic and cellular potency combined with high metabolic stability in human liver microsomes and good solubility. Importantly, <b>40</b> showed excellent selectivity for JAK1 over JAK2 in both assay formats: In the enzymatic assays with ATP at <i>K</i><sub>m</sub>, a 12-fold selectivity was found, and in the STAT cellular assays, a 36-fold selectivity was observed. The enantiomer of <b>40</b>, i.e., compound <b>39</b>, and the enantiomeric pair of <i>endo</i>,<i>exo</i> diastereomers <b>41</b> and <b>42</b> all showed much lower potency.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Norbornane Nitriles Compared to Benchmark Pan-JAK and Selective JAK1 Inhibitors<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0028.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Compounds <b>39</b> and <b>40</b> are enantiomers of unknown absolute configurations, as are compounds <b>41</b> and <b>42</b>. STAT IC<sub>50</sub> values were determined in a cellular reporter gene assay, and JAK IC<sub>50</sub> values were determined in a TR-FRET biochemical assay for kinase inhibition with [ATP] = <i>K</i><sub>m</sub>. All values represent the geometric mean of at least two independent experiments; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a> for details. Log <i>D</i><sub>7.4</sub> was determined using a shake flask assay, and aqueous solubility was determined using an HPLC assay from DMSO stock solutions of test compounds diluted in phosphate buffer at pH 7.4. HLM Cl<sub>app</sub> is the intrinsic clearance in human liver microsomes.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Only one determination was made.</p></div></div><div></div></div><div class="NLM_p">To benchmark the selectivity profile of compound <b>40</b>, we assayed the pan-JAK inhibitor tofacitinib (<b>20</b>)<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and the selective JAK1 inhibitor abrocitinib<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> that recently completed phase III clinical trials in atopic dermatitis.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> As expected, tofacitinib (<b>20</b>) showed no selectivity for JAK1 over JAK2, nor did it show any selectivity in the cellular STAT reporter gene assays. Abrocitinib on the other hand showed a 7-fold selectivity for JAK1 over JAK2 and an 8-fold selectivity in the cellular STAT reporter gene assays.</div><div class="NLM_p">Compound <b>40</b> was selected for further profiling to assess its potential as a lead compound. In a panel of 50 kinases broadly covering the kinome, it only inhibited one kinase more than 30% (FGFR1: 32%) when tested at 1 μM. All assays in the panel were conducted with 1 mM ATP; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a> for details. Compound <b>40</b> did not inhibit the cytochrome P450 enzymes Cyp1A2, 2C9, 2C19, 2D6, or 3A4 up to 25 μM and showed no effect in an hERG binding assay at 30 μM. Good <i>in vitro</i> metabolic stability was found in rat liver microsomes (Cl<sub>app</sub> < 15 mL/min/kg) and rat hepatocytes (Cl<sub>app</sub> = 25 mL/min/kg), and rat plasma protein binding was moderate (<i>f</i><sub>u</sub> = 22%). A low permeability (<i>P</i><sub>app</sub> = 0.7 × 10<sup>–6</sup> cm/s) and a high efflux ratio of 40 were observed in the Caco-2 assay, suggesting a potential permeability limitation for oral absorption from the gut. Thus, compound <b>40</b> was tested in an early discovery rat pharmacokinetic (PK) study (only one animal for each route of administration, see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) and was found to exhibit high clearance, short half-life, and fairly low oral bioavailability (<i>F</i> = 14%). Assuming no elimination in the gut, the fraction of dose absorbed (<i>F</i><sub>abs</sub>) was calculated to be approximately 41%. This confirms that <b>40</b> has a permeability-limited absorption, as suggested by the Caco-2 data. The <i>in vitro</i> to <i>in vivo</i> extrapolation using the well-stirred model adjusted for protein binding was poor: The predicted <i>in vivo</i> unbound clearance based on rat microsomal or hepatocyte intrinsic clearance was <2.0 and 10 mL/min/kg, respectively, indicating extrahepatic clearance mechanisms.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0006.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat PK study with compound <b>40</b>. <i>T</i><sub>1/2</sub> = 0.3 h, Cl = 53 mL/min/kg, <i>V</i><sub>β</sub> = 1.2 L/kg, <i>F</i> = 14%. Inset: Blood concentration on a logarithmic scale vs time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56121" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56121" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A fragment screening hit <b>1</b> was developed into lead compound <b>40</b> using a structure-guided fragment growing approach. Throughout the lead generation campaign, a strict focus was kept on adding the minimum amount of molecular weight and lipophilicity at every step. During the progression from <b>1</b> to <b>40</b>, the molecular weight increased from 199 to 282, the number of nonhydrogen atoms increased from 14 to 21, and JAK1 potency increased 16 000-fold (4.2 log units). The resulting lead compound <b>40</b> displayed potency in the cellular STAT6 assay below 100 nM, 36-fold selectivity over JAK2 signaling as measured in the cellular STAT assays, and physicochemical properties that satisfied our lead compound criteria.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To support the fragment-based lead generation campaign reported above, a flexible and convenient synthetic route to the 2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one scaffold was needed. Synthetic routes to this scaffold have been reviewed,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and our initial attempt at resynthesis of compound <b>1</b> was based on the condensation between 3-amino-5-methylpyrazole (<b>43c</b>) and ethyl difluoroacetoacetate (<b>49</b>) in acetic acid (see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Based on the reported regiochemical outcome of reactions of 3-aminopyrazoles (<b>43a</b> and <b>43b</b>) and ethyl trifluoroacetoacetate (<b>44</b>) that yielded <b>45</b> and <b>46</b>, respectively,<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> we expected to obtain <b>1</b>. However, the product of this reaction was not identical to the commercial sample of <b>1</b> and was inactive in the JAK1 assay. Based on <sup>1</sup>H-<sup>13</sup>C HMBC NMR and predicted <sup>13</sup>C chemical shifts, we assigned structure <b>50</b> to the product; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a> for details. This result is contrary to the reported result that only when the 4-position was blocked, this regiochemistry was observed, e.g., pyrazole <b>47</b> was reported to give <b>48</b> when reacted with <b>44</b>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> To avoid the formation of <b>50</b>, the pyrazole NH position was protected with a <i>t</i>-Bu group.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Reaction of the protected pyrazole <b>51</b> with <b>49</b> afforded <b>55</b>, which upon deprotection with trifluoroacetic acid (TFA) yielded <b>1</b> identical to the commercial sample and with the same JAK1 potency. Compounds <b>3</b>, <b>6</b>, and <b>14</b> were similarly prepared starting from the appropriate pyrazoles (<b>51</b> and <b>52</b>) and β-ketoesters (<b>49</b>, <b>53</b>, and <b>54</b>).</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. First Route to the Pyrazolopyridone Scaffold<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AcOH, reflux, 76–82%; (b) AcOH, reflux, 88%; (c) AcOH, 135 °C (microwave heating), 23%; (d) AcOH, 110 °C, 12–98%; (e) TFA, 70 °C, 16–68%.</p></p></figure><div class="NLM_p">Although a regiochemically unambiguous route was now available, the harsh conditions needed for both the cyclocondensation and the deprotection steps, and the necessity of constructing β-keto ester starting materials lead us to explore alternatives. A three-component reaction between an aminopyrazole (<b>43</b>), an aldehyde (<b>59</b>), and Meldrum’s acid (<b>60</b>) to afford intermediate <b>61</b><a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> appeared attractive (see <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). When aromatic α-keto aldehydes were employed, air oxidation of <b>61</b> in either acidic or basic media furnished the desired 2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-ones.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> We found that air oxidation of <b>61</b> was inefficient with aliphatic R<sup>2</sup> groups, but oxidation with DDQ readily afforded the desired products under mild conditions. This method allowed access to the target compounds in two steps from readily available starting materials and was used to prepare all final compounds reported herein except <b>1</b>–<b>6</b>, <b>14</b>, and <b>19</b>. In many cases, we observed the formation of a byproduct (<b>61p</b>) in the three-component reaction. Compound <b>61p</b> is presumably formed from in situ generated acetone deriving from Meldrum’s acid (<b>60</b>). The formation of <b>61p</b> from <b>43a</b>, <b>60</b>, and acetone in refluxing methanol has been reported in the literature.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In some cases, <b>61p</b> was the only product formed when the reaction was carried out in ethanol. Switching solvent to pyridine with 10 mol % piperidine for the condensation of aldehyde <b>59</b> with Meldrum’s acid <b>60</b> followed by the addition of pyrazole <b>43c</b> and ethanol allowed the formation of the desired product in those problematic cases (<b>61c</b> and <b>61n</b>).</div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Three-Component Reaction Route to the Pyrazolopyridone Scaffold<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH, 60–70 °C or reflux, 23–86%; (b) DDQ, 1,4-dioxane, 100 °C, 12–87%; (c) 4 M HCl in 1,4-dioxane, room temperature (rt), 86%; (d) 1 M tetra-<i>n</i>-butylammonium fluoride (TBAF) in THF, dichloromethane (DCM), 40 °C, 40%; (e) H<sub>2</sub>, Pt/C, MeOH, rt.</p></p></figure><div class="NLM_p">To access compounds <b>17</b>–<b>19</b> functionalized with the carbonyl α-carbon, two methods were used. Compounds <b>17</b> and <b>18</b> were prepared from intermediate <b>61a</b> by simultaneous chlorination of the amide functionality and the Vilsmeier–Haack formylation of the α-carbon, as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The resulting chloride <b>62</b> was converted to the corresponding methoxide <b>63</b>, which was reduced to alcohol <b>64</b> without isolation and demethylated to yield <b>17</b>. Alternatively, methoxide <b>63</b> was subjected to a Wittig reaction yielding alkene <b>65</b>. Hydroboration–oxidation then afforded alcohol <b>66</b>, which was demethylated to give <b>18</b>. To prepare compound <b>19</b>, a cyclocondensation between aminopyrazole <b>43c</b> and malononitrile <b>67</b> was employed to yield intermediate <b>68</b> (see <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Oxidation by bromination followed by elimination of HBr afforded compound <b>19</b>.</div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0013.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>17</b> and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) POCl<sub>3</sub>, <i>N</i>,<i>N</i>-dimethylformamide (DMF), 100 °C, then MnO<sub>2</sub>, MeCN, rt, 15%; (b) 4.4 M NaOMe in MeOH, 120 °C, microwave heating, then NaBH<sub>4</sub>, MeOH, rt, 81%; (c) 5 M HBr in AcOH, 40 °C, 23%; (d) 4.4 M NaOMe in MeOH, 120 °C, microwave heating, 99%; (e) PPh<sub>3</sub>MeBr, 2.5 M <i>n</i>-BuLi, THF, 0 °C to rt, 91%; (f) 0.5 M 9-BBN, THF, then H<sub>2</sub>O<sub>2</sub>, NaOH, rt, 47%; (g) Pyridine hydrochloride, neat, 90 °C, 4.4%.</p></p></figure><figure id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0014.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MeOH, 60 °C, 47%; (b) NBS, DBU, MeCN, rt, 9.1%.</p></p></figure><div class="NLM_p">Nitrile <b>22</b> was prepared by homologation of the nitrile intermediate <b>61j</b> (see <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Protection of the NH protons with 4-methoxybenzyl chloride gave <b>69</b>, which appeared to be a single regioisomer according to the <sup>1</sup>H NMR spectrum. The regiochemistry of the PMB groups was not investigated. Structure <b>69</b> and the following structures show one plausible regioisomer, but no attempt to determine if this is the correct one was made. Oxidation of <b>69</b> with DDQ gave <b>70</b>, which upon reduction with DIBAL-H yielded aldehyde <b>71</b>. This was further reduced to the alcohol <b>72</b>, mesylated to yield <b>73</b>, and treated with NaCN to afford the homologated nitrile <b>74</b>. Deprotection in refluxing TFA finally yielded compound <b>22</b>.</div><figure id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0015.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, PMBCl, DMF, rt, 53%; (b) DDQ, 1,4-dioxane, 100 °C, 50%; (c) 1.0 M DIBAL-H, toluene, 0 °C, 82%; (d) NaBH<sub>4</sub>, THF, rt, 71%; (e) MsCl, Et<sub>3</sub>N, DCM, rt, 69%; (f) NaCN, DMF, 90 °C, 66%; (g) TFA, reflux, 25%.</p></p></figure><div class="NLM_p">The syntheses of amides <b>24</b> and <b>26</b>–<b>28</b>, sulfonamides <b>30</b> and <b>31</b>, and ester <b>29</b> are outlined in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. The amides were prepared by 1-[<i>bis</i>(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate (HATU) coupling of amine <b>32</b> with the respective acids, and the sulfonamides were prepared by reacting <b>32</b> with the respective sulfonyl chlorides. The ester <b>29</b> was prepared by HATU/4-dimethylaminopyridine (DMAP) coupling of alcohol <b>33</b> with (1<i>S</i>)-2,2-difluorocyclopropanecarboxylic acid. To prepare the inverted amide <b>25</b>, the route in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a> was used. Protection of the ester intermediate <b>61n</b> afforded <b>75</b>, which was oxidized with DDQ to afford <b>76</b>, which appeared to be a single regioisomer according to the <sup>1</sup>H NMR spectrum (see the discussion of <b>69</b> above). Hydrolysis of the methyl ester yielded acid <b>77</b> and amide coupling with HATU followed by deprotection gave compound <b>25</b>. Amides <b>34</b>–<b>38</b> were prepared in a library format from acid intermediate <b>78</b> and the respective amines (see <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).</div><figure id="sch6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0016.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>24</b> and <b>26-31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) RCO<sub>2</sub>H, HATU, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMF, rt, library format; (b) RSO<sub>2</sub>Cl, DIPEA, DMSO, rt, library format; (c) (1<i>S</i>)-2,2-difluorocyclopropanecarboxylic acid, HATU, DMAP, DMF, rt, 13%.</p></p></figure><figure id="sch7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0017.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compound <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, PMBCl, DMF, rt, 92%; (b) DDQ, 1,4-dioxane, 100 °C, 87%; (c) LiOH·H<sub>2</sub>O, THF, 40 °C, 50%; (d) cyclopropylamine, HATU, DIPEA, DMF, rt, then TFA, 90 °C, 9%.</p></p></figure><figure id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0018.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>34</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) conc. HCl, 1,4-dioxane, 100 °C, 83%; (b) amine, HATU, DIPEA, DMF, rt, library format.</p></p></figure><div class="NLM_p">The acetonitrile norbornanes <b>39</b>–<b>42</b> were prepared from the common intermediate <b>39a</b> (see <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). Compound <b>39a</b> is a mixture of four stereoisomers: it consists of enantiomeric pairs of the (<i>Z</i>)-olefin/<i>exo</i>-norbornane and (<i>E</i>)-olefin/<i>exo</i>-norbornane diastereomers in an ca. 1:1 diastereomeric ratio. Hydrogenation of the olefin thus afforded a ca. 1:1 mixture of racemic <i>exo</i>,<i>exo</i>-norbornane and <i>endo</i>,<i>exo</i>-norbornane diastereomers. This mixture was subjected to chiral SFC separation to afford four stereoisomers <b>39</b>–<b>42</b> individually. Relative stereochemistry was assigned from <sup>1</sup>H NMR NOE (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a> for details), but no attempt to assign absolute configuration was made. Thus, although <b>39</b> and <b>40</b> are enantiomers, the assignment of absolute configuration shown in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a> is arbitrary. This also holds for <b>41</b> and <b>42</b>.</div><figure id="sch9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0019.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Compounds <b>39</b>–<b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) H<sub>2</sub>, Pt/C, MeOH, rt, then chiral SFC separation of stereoisomers. Compound <b>39a</b> is a mixture of <i>E</i> and <i>Z</i> isomers, and the <i>E</i> and <i>Z</i> isomers are racemic. Compounds <b>39</b> and <b>40</b> are enantiomers of unknown absolute configurations, as are compounds <b>41</b> and <b>42</b>.</p></p></figure><div class="NLM_p">Although most of the aldehydes <b>59</b> (see <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) required to prepare the final compounds were commercially available, <b>59d</b>–<b>f</b>, <b>59j</b>, and <b>59o</b> needed to be synthesized. The routes used to access these intermediates are shown in <a class="ref internalNav" href="#sch10" aria-label="Schemes 10">Schemes 10</a>–<a class="ref internalNav" href="#sch13" aria-label="13">13</a>. Starting from the known ester <b>79</b>,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> the racemic aldehyde <b>59d</b> was prepared by LiAlH<sub>4</sub> reduction to furnish alcohol <b>80</b>, which was oxidized with Dess–Martin periodinane (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>). The norbornanecarbaldehydes <b>59e</b> and <b>59f</b> were prepared from commercially available norbornene carboxylic acid <b>81</b> (<i>exo</i>/<i>endo</i> mixture, predominantly <i>endo</i>), as shown in <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> After esterification with isopropanol, the <i>exo</i> and <i>endo</i> esters <b>82</b> and <b>83</b> could be separated by silica gel column chromatography. The two isomers were separately treated with LiAlH<sub>4</sub> to afford alcohols <b>84</b> and <b>86</b>, which were hydrogenated to afford norbornane methanols <b>85</b> and <b>87</b>. Swern oxidation furnished the required aldehyde building blocks <b>59e</b> and <b>59f</b>. To synthesize building block <b>59j</b>, the route in <a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a> was employed. Mesylation of alcohol <b>88</b> afforded intermediate <b>89</b>, which was treated with KCN to yield nitrile <b>90</b>. Chemoselective reduction of the ester moiety with LiBH<sub>4</sub> gave alcohol <b>91</b>, which upon Swern oxidation furnished aldehyde <b>59j</b>. The route to aldehyde <b>59o</b> is outlined in <a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>. Analogous to the preparation of esters <b>82</b> and <b>83</b> (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>), the corresponding benzyl esters <b>92</b> and <b>93</b> were prepared from norbornene carboxylic acid <b>81</b> and separated using silica gel column chromatography. The <i>exo</i> isomer <b>93</b> was subjected to hydroboration/oxidation to afford a separable mixture of regioisomers <b>94</b> and <b>95</b>.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The Dess–Martin periodinane oxidation of the desired regioisomer <b>94</b> afforded ketone <b>96</b>, which was converted to alkene <b>97</b> by means of an HWE olefination. Chemoselective reduction of the ester moiety with LiBH<sub>4</sub> gave alcohol <b>98</b>, which upon Swern oxidation furnished aldehyde <b>59o</b>.</div><figure id="sch10" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Aldehyde Building Block <b>59d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiAlH<sub>4</sub>, THF, −30 °C, 83%; (b) Dess–Martin periodinane, NaHCO<sub>3</sub>, DCM, rt, 30%.</p></p></figure><figure id="sch11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Aldehyde Building Blocks <b>59e</b> and <b>59f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-propanol, EDCI, DMAP, 1,2-dichloroethane, rt, 14% (<b>82</b>), 55% (<b>83</b>); (b) LiAlH<sub>4</sub>, THF, 40 °C; (c) H<sub>2</sub>, Pd/C, EtOAc, rt, 96%; (d) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, DCM, −78 °C, 68%.</p></p></figure><figure id="sch12" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Aldehyde Building Block <b>59j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MsCl, Et<sub>3</sub>N, DCM, 0 °C, 99%; (b) KCN, DMSO, rt, 81%; (c) LiBH<sub>4</sub>, THF, 40 °C, 84%; (d) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, DCM, −78 °C, 75%.</p></p></figure><figure id="sch13" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Aldehyde Building Block <b>59o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Benzyl alcohol, DCC, DMAP, DCM, rt, 26% (<b>92</b>), 10% (<b>93</b>); (b) BH<sub>3</sub>. THF, THF, −5 °C, then KH<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>O<sub>2</sub>, −5 °C, 25% (<b>94</b>), 25% (<b>95</b>); (c) Dess–Martin periodinane, DCM, rt, 54%; (d) NCCH<sub>2</sub>PO(OEt)<sub>2</sub>, <i>t</i>-BuOK, THF, rt, 68%; (e) LiBH<sub>4</sub>, THF, rt, 87%; (f) Dess–Martin periodinane, DCM, rt, 94%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17628" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17628" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">General biological experimental procedures are detailed in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a>. Most of the IC<sub>50</sub> values reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> are geometric means of at least three independent experiments. The corresponding pIC<sub>50</sub> values, their standard errors of the mean (SEM), and the number of experiments (N) are provided in the molecular formula strings of the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_002.csv" class="ext-link">Supporting Information</a>.</div><div class="NLM_p">The housing and husbandry of animals was undertaken in compliance with the European Committee Directive 2010/63/EU and performed under permit 2015-15-0201-00595 from the Danish authorities. Our animal welfare body inspects all experiments in our animal facility on a regular basis to secure the implementation of the 3Rs in all experimental procedures.</div><div class="NLM_p">Reagents and solvents were commercially available and used without purification unless otherwise noted. Chromatographic purification was performed using a Grace REVELERIS system or a Teledyne ISCO Combi<i>Flash</i> Rf system with prepacked silica gel cartridges or manually using silica gel 60. Mass spectra of intermediates were recorded using a Shimadzu LCMS2020 system equipped with an LCMS2020 mass spectrometer operating in positive electrospray ionization mode. A Chromolith SpeedROD RP-18e column (50 mm × 4.6 mm, 2 μm particle size) at 40 °C was used (mobile phase: A = CH<sub>3</sub>CN/H<sub>2</sub>O/HCO<sub>2</sub>H = 10/90/0.05 and B = CH<sub>3</sub>CN/H<sub>2</sub>O/ HCO<sub>2</sub>H = 90/10/0.05; flow rate: 3.0 mL/min; gradient: 0.8 min @ 10% B, 2.7 min gradient (10–95% B), then 0.8 min @ 95% B). Alternatively, ultraperformance liquid chromatography–mass spectrometry (UPLC-MS) analyses of intermediates were performed using a Waters Acquity UPLC system with a 2.1 mm × 50 mm Acquity UPLC HSS T3 1.8 μm column and an Acquity SQ Detector operating in positive ionization electrospray mode. The mobile phase consisted of 0.1% formic acid in an aqueous 10 mM ammonium acetate solution for buffer A and 0.1% formic acid in acetonitrile for buffer B. A binary gradient (A:B 95:5 → 5:95) over 1.4 min was used with a flow rate of 1.2 mL/min, and the column temperature was 60 °C. Purities and high-resolution mass spectra of all compounds tested in biological assays were determined using a Waters Acquity UPLC system with a 2.1 mm × 50 mm Acquity UPLC HSS T3 1.8 μm column, a Waters PDA detector, and a Waters XEVO G2-XS QTof or a Waters LCT Premier XE mass spectrometer. The same buffers A and B as above were used, but with a slower gradient (A:B 99:1 → 1:99 over 4.8 min; 0.7 mL/min; column temp.: 30 °C). All compounds tested in biological assays were ≥95% pure by integration of peaks in the UV total absorbance chromatogram trace (240–400 nm) except compounds <b>17</b>, <b>37</b>, and <b>41</b> that were 94% pure, and compound <b>34</b> that was 81% pure. <sup>1</sup>H NMR spectra were recorded on a Bruker instrument at 300, 400, or 600 MHz with tetramethylsilane as reference.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Attempted Synthesis of 4-(Difluoromethyl)-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>1</b>)<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a></h3><div class="NLM_p last">A solution of ethyl 4,4-difluoro-3-oxo-butanoate (171 mg, 1.03 mmol) and 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (100 mg, 1.03 mmol) in acetic acid (1 mL) was heated in a microwave synthesizer at 135 °C for 30 min. The reaction mixture partially solidified. Volatiles were evaporated, and the residue was diluted with water (5 mL). The solid was collected by filtration and washed with water. It was then dried <i>in vacuo</i> overnight and recrystallized from methanol to afford 7-(difluoromethyl)-2-methyl-4<i>H</i>-pyrazolo[1,5-<i>a</i>]pyrimidin-5-one <b>50</b> (48 mg, 23%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.94 (br s, 1H), 7.03 (t, <i>J</i> = 53.5 Hz, 1H), 6.10 (s, 1H), 6.00 (s, 1H), 2.32 (s, 3H).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-(Difluoromethyl)-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>1</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">To a solution of 2-<i>tert</i>-butyl-5-methyl-pyrazol-3-amine <b>51</b> (153 mg, 1.00 mmol) in acetic acid (1 mL) was added ethyl 4,4-difluoro-3-oxo-butanoate <b>49</b> (332 mg, 2.00 mmol) under argon. The resulting pale yellow solution was stirred at 110 °C for 17 h, cooled to rt, and volatiles were evaporated. To the residue was added sat. NaHCO<sub>3</sub> solution, and the mixture was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The yellow solid residue was dried under high vacuum to afford 1-<i>tert</i>-butyl-4-(difluoromethyl)-3-methyl-7<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-6-one <b>55</b> (263 mg, 98%) that was used without purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.81 (br s, 1H), 6.74 (t, <i>J</i> = 55.0 Hz, 1H), 6.51 (s, 1H), 2.48 (s, 3H), 1.73 (s, 9H).</div><div class="NLM_p last">A solution of 1-<i>tert</i>-butyl-4-(difluoromethyl)-3-methyl-7<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-6-one <b>55</b> (200 mg, 0.744 mmol) in TFA (2 mL) was heated at 70 °C for 19 h. After cooling, volatiles were evaporated and sat. NaHCO<sub>3</sub> solution was added to the residue. The mixture was extracted with EtOAc (2 × 30 mL), and the combined organic layers were washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. Upon concentration to a volume of ∼3 mL, a white solid precipitated. This was collected by filtration, washed with a small amount of EtOAc, and dried to afford 4-(difluoromethyl)-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>1</b> (55.3 mg, 35%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.05 (br s, 1H), 11.88 (br s, 1H), 7.11 (t, <i>J</i> = 54.2 Hz, 1H), 6.31 (s, 1H), 2.43 (s, 3H). UPLC <i>t</i><sub>R</sub> = 1.65 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>8</sub>H<sub>8</sub>F<sub>2</sub>N<sub>3</sub>O 200.0630; found 200.0638.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-(Difluoromethyl)-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>3</b>)</h3><div class="NLM_p last">Obtained as a white solid (86% in step 1, 16% in step 2) from 2-<i>tert</i>-butylpyrazol-3-amine <b>52</b> (400 mg, 2.9 mmol) and ethyl 4,4-difluoro-3-oxo-butanoate <b>49</b> (760 mg, 4.6 mmol) following the experimental procedure described for <b>1</b>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.34 (br s, 1H), 12.01 (br s, 1H), 8.11 (s, 1H), 7.07 (t, <i>J</i> = 54.6 Hz, 1H), 6.34 (s, 1H). UPLC <i>t</i><sub>R</sub> = 1.53 min, purity UV<sub>254</sub> = 98%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>7</sub>H<sub>6</sub>F<sub>2</sub>N<sub>3</sub>O 186.0479; found 186.0461.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 3-Methyl-4-phenyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>6</b>)</h3><div class="NLM_p last">Obtained as a white solid (47% in step 1, 68% in step 2) from 2-<i>tert</i>-butyl-5-methyl-pyrazol-3-amine <b>51</b> (400 mg, 2.61 mmol) and methyl 3-oxo-3-phenyl-propanoate <b>53</b> (1.01 g, 5.25 mmol) following the experimental procedure described for <b>1</b>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.87 (br s, 1H), 11.59 (br s, 1H), 7.52–7.45 (m, 5H), 5.86 (s, 1H), 2.00 (s, 3H). UPLC <i>t</i><sub>R</sub> = 1.83 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>12</sub>N<sub>3</sub>O 226.0975; found 226.0961.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4-Cyclohexyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>14</b>)</h3><div class="NLM_p last">Obtained as a white solid (12% in step 1, 18% in step 2) from 2-<i>tert</i>-butylpyrazol-3-amine <b>52</b> (305 mg, 2.19 mmol) and 3-cyclohexyl-3-oxo-propanoate <b>54</b> (645 mg, 3.50 mmol) following the experimental procedure described for <b>1</b>. The product was purified by HPLC. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.03 (br s, 1H), 11.42 (br s, 1H), 8.19 (s, 1H), 5.86 (s, 1H), 2.68–2.58 (m, 1H), 1.88–1.76 (m, 4H), 1.74–1.68 (m, 1H), 1.49–1.36 (m, 4H), 1.33–1.22 (m, 1H). UPLC <i>t</i><sub>R</sub> = 1.89 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>16</sub>N<sub>3</sub>O 218.1288; found 218.1287.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-Cyclohexyl-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>7</b>)</h3><div class="NLM_p">A 25 mL round-bottom flask was charged with Meldrum’s acid <b>60</b> (144 mg, 1.00 mmol) and ethanol (3 mL) under argon. To the white suspension was added cyclohexanecarbaldehyde <b>59a</b> (0.121 mL, 1.00 mmol). The resulting suspension was stirred for 5 min at rt, 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (97.1 mg, 1.00 mmol) was added, and the mixture was heated to reflux. Initially, a pale yellow solution formed. After 2.5 h at reflux, the resulting pale yellow suspension was cooled to rt. The solid was collected by filtration and washed with ethanol (2 × 0.4 mL). The filter cake was dried under high vacuum (freeze dryer) overnight to afford 4-cyclohexyl-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61a</b> (147 mg, 63%) as a white solid.</div><div class="NLM_p last">To a suspension of 4-cyclohexyl-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61a</b> (35.0 mg, 0.150 mmol) and 1,4-dioxane (0.35 mL) was added DDQ (51.1 mg, 0.225 mmol). The mixture was heated at 100 °C for 2 h and then cooled to rt over 2 h. Volatiles were removed by evaporation. To the residue was added sat. aq. NaHCO<sub>3</sub> solution (2 mL), and the mixture was extracted with DCM/MeOH 9:1 (5 × 3 mL). Because some solid remained in the water phase, the mixture was filtered. The organic phases from the extraction and the filter cake were combined, diluted with DCM/MeOH 7:3 (50 mL), and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration and evaporation afforded a crude product, which was suspended in ethanol (0.5 mL). The solid was collected by filtration, and the filter cake was washed with ethanol (4 × 0.15 mL). The filter cake was then dried under high vacuum (freeze dryer) overnight to afford 4-cyclohexyl-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>7</b> (20.9 mg, 57%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.72 (br s, 1H), 11.36 (br s, 1H), 5.79 (s, 1H), 2.82–2.67 (m, 1H), 2.46 (s, 3H), 1.93–1.77 (m, 4H), 1.73 (d, <i>J</i> = 13.0 Hz, 1H), 1.48–1.16 (m, 5H). UPLC <i>t</i><sub>R</sub> = 1.95 min, purity UV<sub>254</sub> = 96%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>18</sub>N<sub>3</sub>O 232.1444; found 232.1469.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 4-Cyclopentyl-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>8</b>)</h3><div class="NLM_p">To a solution of cyclopentanecarbaldehyde <b>59b</b> (150 mg, 1.53 mmol) in ethanol (2 mL) was added Meldrum’s acid <b>60</b> (220 mg, 1.53 mmol), and the mixture was stirred for 15 min at rt. Another portion of ethanol (3 mL) was added, and the mixture was stirred for a further 10 min at rt. To the reaction mixture was added 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (148 mg, 1.53 mmol), and the mixture was heated at 70 °C for 1.5 h, during which time a precipitate formed. The mixture was cooled to rt, and the solid was collected by filtration and dried under high vacuum (freeze dryer) to afford 4-cyclopentyl-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61b</b> (239 mg, 71%) as a white solid.</div><div class="NLM_p last">To a suspension of 4-cyclopentyl-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61b</b> (25 mg, 0.11 mmol) in 1,4-dioxane (2 mL) was added DDQ (44 mg, 0.19 mmol), and the mixture was heated at 100 °C for 25 min. After cooling to rt, the formed precipitate was collected by filtration, dissolved in DMSO, and purified by HPLC (acidic method) to afford 4-cyclopentyl-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>8</b> (7.8 mg, 32%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.69 (br s, 1H), 11.35 (br s, 1H), 5.84 (s, 1H), 3.28 (p, <i>J</i> = 7.7 Hz, 1H), 2.49 (s, 3H), 2.03–1.92 (m, 2H), 1.78–1.53 (m, 6H). UPLC <i>t</i><sub>R</sub> = 1.87 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>16</sub>N<sub>3</sub>O 218.1288; found 218.1347.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 4-(Cyclobutylmethyl)-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>9</b>)</h3><div class="NLM_p">To a solution of cyclobutaneacetaldehyde <b>59c</b> (49 mg, 0.50 mmol) in pyridine (1 mL) was added piperidine (4.9 μL, 0.050 mmol) and Meldrum’s acid <b>60</b> (72 mg, 0.50 mmol). The mixture was stirred at rt for 30 min. To the reaction mixture was added ethanol (1 mL) and 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (48 mg, 0.50 mmol), and the mixture was heated at 70 °C for 1 h. Volatiles were evaporated, and the residue was purified by chromatography (ISCO CombiFlash, 12 g silica gel column, heptane/EtOAc 100:0 → 0:100) to afford 4-(cyclobutylmethyl)-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61c</b> (25 mg, 23%) as a solid.</div><div class="NLM_p last">To a suspension of 4-(cyclobutylmethyl)-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61c</b> (25 mg, 0.11 mmol) in 1,4-dioxane (1 mL) was added DDQ (44 mg, 0.19 mmol), and the mixture was heated at 100 °C for 20 min. After cooling to rt, the precipitated solid was collected by filtration, dissolved in DMSO, and purified by HPLC to afford 4-(cyclobutylmethyl)-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>9</b> (3.0 mg, 12%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.70 (br s, 1H), 11.30 (br s, 1H), 5.72 (s, 1H), 2.77 (d, <i>J</i> = 7.3 Hz, 2H), 2.64–2.55 (m, 1H), 2.45 (s, 3H), 2.09–2.01 (m, 2H), 1.89–1.79 (m, 2H), 1.76–1.68 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.89 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>16</sub>N<sub>3</sub>O 218.1288; found 218.1308.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-Methyl-4-[(1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexyl]-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>10</b>)</h3><div class="NLM_p">To a solution of (1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexanecarbaldehyde <b>59d</b> (0.600 g, 4.75 mmol) in ethanol (10 mL) was added Meldrum’s acid <b>60</b> (0.685 g, 4.75 mmol). The reaction mixture was stirred at rt for 15 min followed by the addition of 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (0.369 g, 3.80 mmol), and the resulting mixture was stirred at 80 °C for 3 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was washed with diethyl ether. The solid thus obtained was dried under vacuum to afford 3-methyl-4-[(1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexyl]-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61d</b> (0.250 g, 27%) as an off-white solid (mixture of diastereomers). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.69 (s, 1H), 10.06 (s, 1H), 2.54 (m, 1H), 2.25 (m, 2H), 2.05 (s, 3H) 1.75–1.45 (m, 6H), 1.45–1.20 (m, 2H), 0.9 (m, 3H).</div><div class="NLM_p last">To a solution of 3-methyl-4-[(1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexyl]-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61d</b> (0.250 g, 1.01 mmol) in 1,4-dioxane (10 mL) was added DDQ (0.456 g, 1.52 mmol). The reaction mixture was stirred at 100 °C for 3h. After cooling, the mixture was concentrated under reduced pressure. The residue was purified by HPLC to afford 3-methyl-4-[(1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexyl]-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>10</b> (0.040 g, 16%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.72 (br s, 1H), 11.30 (br s, 1H), 5.65 (s, 1H), 3.01 (br d, <i>J</i> = 11.5 Hz, 1H), 2.15–2.04 (m, 1H), 1.87–1.56 (m, 4H), 1.54–1.31 (m, 4H), 0.72 (d, <i>J</i> = 7.1 Hz, 3H). UPLC <i>t</i><sub>R</sub> = 2.02 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>19</sub>N<sub>3</sub>O 246.1601; found 246.1622.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 3-Methyl-4-[(1<i>R</i>*,2<i>R</i>*,4<i>S</i>*)-norbornan-2-yl]-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>11</b>)</h3><div class="NLM_p">To a solution of norbornane-2-<i>exo</i>-carbaldehyde <b>59e</b> (137 mg, 1.10 mmol) in ethanol (2 mL) was added Meldrum’s acid <b>60</b> (159 mg, 1.10 mmol). The reaction mixture was stirred at rt for 5 min followed by the addition of 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (107 mg, 1.10 mmol), and the resulting mixture was stirred at reflux for 4 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was stirred with EtOAc (3 mL) for 30 min. The solid thus obtained was collected by filtration, washed with EtOAc (2 × 0.5 mL), and dried under vacuum to afford 3-methyl-4-[(1<i>R</i>*,2<i>R</i>*,4<i>S</i>*)-norbornan-2-yl]-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61e</b> (180 mg, 60%) as a white solid (mixture of diastereomers).</div><div class="NLM_p last">To a suspension of 3-methyl-4-[(1<i>R</i>*,2<i>R</i>*,4<i>S</i>*)-norbornan-2-yl]-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61e</b> (180 mg, 0.66 mmol) in 1,4-dioxane (3 mL) was added DDQ (255 mg, 1.12 mmol), and the mixture was heated at 100 °C for 2 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was suspended in sat. NaHCO<sub>3</sub> solution (20 mL), and the mixture was extracted with DCM/MeOH 9:1 (3 × 40 mL). The combined organic phases were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and volatiles were evaporated. The residue was purified by column chromatography (silica gel column, DCM/MeOH 96:4 → 94:6) to afford 3-methyl-4-[(1<i>R</i>*,2<i>R</i>*,4<i>S</i>*)-norbornan-2-yl]-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>11</b> (39.2 mg, 22%) as a yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.71 (br s, 1H), 11.30 (br s, 1H), 5.76 (br s, 1H), 2.92 (br s, 1H), 2.49 (s, 3H), 2.32 (br s, 1H), 2.29 (br d, <i>J</i> = 4.1 Hz, 1H), 1.67–1.50 (m, 4H), 1.45–1.37 (m, 2H), 1.32–1.26 (m, 1H), 1.20–1.14 (m, 1H). UPLC <i>t</i><sub>R</sub> = 1.97 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>18</sub>N<sub>3</sub>O 244.1444; found 244.1427.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 3-Methyl-4-[(1<i>R</i>*,2<i>S</i>*,4<i>S</i>*)-norbornan-2-yl]-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>12</b>)</h3><div class="NLM_p">To a solution of norbornane-2-<i>endo</i>-carbaldehyde <b>59f</b> (107 mg, 0862 mmol) in ethanol (1.5 mL) was added Meldrum’s acid <b>60</b> (124 mg, 0.862 mmol). The reaction mixture was stirred at rt for 5 min followed by the addition of 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (83.7 mg, 0.862 mmol), and the resulting mixture was stirred at reflux for 4 h. The resulting pale yellow suspension was cooled in an ice bath. The solid was collected by filtration and washed with ice-cold ethanol (3 × 0.2 mL). Drying under high vacuum afforded [(1<i>R</i>*,2<i>S</i>*,4<i>S</i>*)-norbornan-2-yl]-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61f</b> (88.5 mg, 35%) as a white solid (mixture of diastereomers).</div><div class="NLM_p last">To a suspension of 3-methyl-4-[(1<i>R</i>*,2<i>S</i>*,4<i>S</i>*)-norbornan-2-yl]-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61f</b> (84.3 mg, 0.344 mmol) in 1,4-dioxane (1.4 mL) was added DDQ (117 mg, 0.515 mmol), and the mixture was heated at 100 °C for 2 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was suspended in sat. NaHCO<sub>3</sub> solution (10 mL), and the mixture was extracted with DCM/MeOH 9:1 (3 × 20 mL). The combined organic phases were washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and volatiles were evaporated. The residue was purified by column chromatography (silica gel column, DCM/MeOH 96:4 → 95:5) to afford 3-methyl-4-[(1<i>R</i>*,2<i>S</i>*,4<i>S</i>*)-norbornan-2-yl]-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>12</b> (29.8 mg, 34%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.69 (br s, 1H), 11.34 (br s, 1H), 5.89 (s, 1H), 3.53–3.40 (m, 1H), 2.50 (s, 3H), 2.40–2.24 (m, 2H), 1.82–1.69 (m, 1H), 1.69–1.60 (m, 1H), 1.58–1.36 (m, 3H), 1.33–1.15 (m, 3H). UPLC <i>t</i><sub>R</sub> = 1.95 min, purity UV<sub>254</sub> = 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>18</sub>N<sub>3</sub>O 244.1444; found 244.1438.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-(2-Bicyclo[2.2.2]octanyl)-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>13</b>)</h3><div class="NLM_p">To a solution of bicyclo[2.2.2]octane-2-carbaldehyde <b>59g</b> (74.3 mg, 0.473 mmol) in ethanol (1.4 mL) was added Meldrum’s acid <b>60</b> (68.2 mg, 0.473 mmol). The reaction mixture was stirred at rt for 5 min followed by the addition of 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (45.9 mg, 0.473 mmol), and the resulting mixture was stirred at reflux for 4 h. The resulting pale yellow suspension was cooled in an ice bath. The solid was collected by filtration and washed with ice-cold ethanol (2 × 0.3 mL). Drying under high vacuum afforded 4-(2-bicyclo[2.2.2]octanyl)-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61g</b> (63.3 mg, 49%) as a white solid (mixture of diastereomers).</div><div class="NLM_p last">To a suspension of 4-(2-bicyclo[2.2.2]octanyl)-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61g</b> (59.0 mg, 0.227 mmol) in 1,4-dioxane (1.0 mL) was added DDQ (77.5 mg, 0.341 mmol), and the mixture was heated at 100 °C for 1.5 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was dissolved in DCM/MeOH 95:5 (8 mL), washed with sat. NaHCO<sub>3</sub> solution (10 mL), and the aqueous layer was extracted with DCM/MeOH 95:5 (4 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, and volatiles were evaporated. The residue was purified by column chromatography (silica gel column, DCM/MeOH 96:4 → 94:6) to afford 4-(2-bicyclo[2.2.2]octanyl)-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one <b>13</b> (25.8 mg, 42%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.63 (br s, 1H), 11.37 (br s, 1H), 5.97 (s, 1H), 3.30–3.19 (m, 1H), 2.45 (s, 3H), 1.88–1.39 (m, 11H), 1.37–1.22 (m, 1H). UPLC <i>t</i><sub>R</sub> = 2.03 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O 258.1601; found 258.1567.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-Cyclohexyl-3-ethyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>15</b>)</h3><div class="NLM_p">To a solution of cyclohexanecarbaldehyde <b>59a</b> (63 mg, 0.56 mmol) in ethanol (2.7 mL) was added Meldrum’s acid <b>60</b> (81 mg, 0.56 mmol). The reaction mixture was stirred at rt for 5 min followed by the addition of 3-ethyl-1<i>H</i>-pyrazol-5-amine <b>43d</b> (62 mg, 0.56 mmol), and the resulting mixture was stirred at 60 °C overnight. The reaction mixture was cooled, concentrated to half its volume, and ether (2 mL) was added to afford a white precipitate. The white solid was collected by filtration and washed with ether. Drying under high vacuum afforded 4-cyclohexyl-3-ethyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61h</b> (120 mg, 86%) as a white solid.</div><div class="NLM_p last">To a suspension of 4-cyclohexyl-3-ethyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61h</b> (20 mg, 0.081 mmol) in 1,4-dioxane (1.0 mL) was added DDQ (128 mg, 0.562 mmol), and the mixture was heated at 100 °C for 15 min. After cooling to rt, the resulting white precipitate was collected by filtration and washed with methanol. The crude product was purified by HPLC (acidic method) to afford 4-cyclohexyl-3-ethyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>15</b> (4.1 mg, 21%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (br s, 1H), 11.33 (br s, 1H), 5.82 (s, 1H), 2.85 (q, <i>J</i> = 7.6 Hz, 2H), 2.72 (s, 1H), 1.89–1.77 (m, 4H), 1.76–1.69 (m, 1H), 1.47–1.32 (m, 4H), 1.27 (t, <i>J</i> = 7.6 Hz, 3H), 1.26–1.21 (m, 1H). UPLC <i>t</i><sub>R</sub> = 2.02 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>20</sub>N<sub>3</sub>O 246.1601; found 246.1614.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 4-Cyclohexyl-3-cyclopropyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>16</b>)</h3><div class="NLM_p">To a solution of cyclohexanecarbaldehyde <b>59a</b> (100 mg, 0.892 mmol) in ethanol (2.7 mL) was added Meldrum’s acid <b>60</b> (129 mg, 0.892 mmol). The reaction mixture was stirred at rt for 5 min followed by the addition of 3-cyclopropyl-1<i>H</i>-pyrazol-5-amine <b>43e</b> (110 mg, 0.892 mmol), and the resulting mixture was stirred at 60 °C overnight. The reaction mixture was cooled, concentrated to half its volume, and ether (5 mL) was added to afford a white precipitate. The white solid was collected by filtration and washed with ether. Drying under high vacuum afforded 4-cyclohexyl-3-cyclopropyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61i</b> (144 mg, 62%) as a white solid.</div><div class="NLM_p last">To a suspension of 4-cyclohexyl-3-cyclopropyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61i</b> (20 mg, 0.077 mmol) in 1,4-dioxane (1.0 mL) was added DDQ (202 mg, 0.892 mmol), and the mixture was heated at 100 °C for 15 min. After cooling to rt, the resulting white precipitate was collected by filtration and washed with methanol. Vacuum drying afforded 4-cyclohexyl-3-cyclopropyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>16</b> (4.4 mg, 22%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.47 (br s, 1H), 11.36 (br s, 1H), 5.83 (s, 1H), 3.04 (br t, 1H), 2.15–2.07 (m, 1H), 1.98–1.90 (m, 2H), 1.86–1.78 (m, 2H), 1.76–1.69 (m, 1H), 1.46–1.31 (m, 4H), 1.30–1.21 (m, 1H), 1.02–0.95 (m, 2H), 0.93–0.88 (m, 2H). UPLC <i>t</i><sub>R</sub> = 2.05 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O 258.1601; found 258.1624.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 4-Cyclohexyl-5-(hydroxymethyl)-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>17</b>)</h3><div class="NLM_p">A mixture of 6-chloro-4-cyclohexyl-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-5-carbaldehyde <b>62</b> (0.15 g, 0.54 mmol) and 4.4 M NaOMe in MeOH (1.0 mL, 4.4 mmol) in MeOH (2 mL) was heated in microwave at 120 °C for 40 min. After cooling to rt, NaBH<sub>4</sub> (10 mg, 0.27 mmol) was added and stirred until the yellow color disappeared and a clear solution was obtained (ca. 30 min). The reaction was quenched by adding AcOH, volatiles were evaporated, the residue was triturated with water, and the solid was collected by filtration and dried <i>in vacuo</i> to afford (4-cyclohexyl-6-methoxy-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)methanol <b>64</b> (120 mg, 81%) as an off-white solid that was used directly in the following step.</div><div class="NLM_p last">A mixture of (4-cyclohexyl-6-methoxy-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)methanol <b>64</b> (22.0 mg, 0.0799 mmol) and 5 M HBr in AcOH (0.50 mL, 2.5 mmol) was stirred at 40 °C for 30 min. After cooling to rt, water (0.50 mL) was added, the mixture was purified by HPLC, and pure fractions were combined and freeze-dried to afford 4-cyclohexyl-5-(hydroxymethyl)-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>17</b> (4.9 mg, 23%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.70 (br s, 1H), 11.46 (br s, 1H), 4.49 (s, 2H), 3.08 (br s, 1H), 2.55 (br s, 3H), 1.91–1.56 (m, 7H), 1.47–1.21 (m, 3H). Very broad peaks, probably due to the slow interconversion of tautomers. UPLC <i>t</i><sub>R</sub> = 1.86 min, purity UV<sub>254</sub> = 94%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub> 262.1550; found 262.1529.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-Cyclohexyl-5-(2-hydroxyethyl)-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>18</b>)</h3><div class="NLM_p">A mixture of 6-chloro-4-cyclohexyl-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-5-carbaldehyde <b>62</b> (0.30 g, 1.1 mmol), 4.4 M NaOMe solution in MeOH (2.0 mL, 8.8 mmol), and MeOH (10 mL) was heated in the microwave at 120 °C for 40 min. After cooling to rt, the reaction was quenched with AcOH (1 mL) and volatiles were evaporated. The residue was dissolved in ether (25 mL) and washed with brine (10 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness to afford 4-cyclohexyl-6-methoxy-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-5-carbaldehyde <b>63</b> (298 mg, 99%) which was used without further purification.</div><div class="NLM_p">A 2.5 M solution of <i>n</i>-BuLi in heptanes (0.29 mL, 0.73 mmol) was added slowly to a suspension of methyl(triphenyl)phosphonium bromide (261 mg, 0.732 mmol) in dry THF (10 mL) at 0 °C under argon. The resulting orange solution was stirred for 30 min at 0 °C. A solution of 4-cyclohexyl-6-methoxy-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-5-carbaldehyde <b>63</b> (100 mg, 0.366 mmol) in dry THF (5 mL) was added, and the mixture was stirred for 6 h at rt. The reaction was quenched with AcOH (0.5 mL), diluted with water (10 mL), and extracted with DCM (2 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by chromatography (ISCO CombiFlash, silica gel column, heptane/EtOAc) to afford 4-cyclohexyl-6-methoxy-3-methyl-5-vinyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine <b>65</b> (90 mg, 91%) as a clear oil.</div><div class="NLM_p">A 0.50 M solution of 9-BBN in THF (1.3 mL, 0.65 mmol) was added to a solution of 4-cyclohexyl-6-methoxy-3-methyl-5-vinyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine <b>65</b> (90.0 mg, 0.332 mmol) in dry THF (4 mL), and the mixture was stirred at rt for 3 h. A solution of 50% H<sub>2</sub>O<sub>2</sub> (0.123 mL, 1.99 mmol) in 4 M NaOH (1 mL) was added carefully, and the resulting mixture was evaporated. The residue was purified by HPLC to afford 2-(4-cyclohexyl-6-methoxy-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)ethanol <b>66</b> (45 mg, 47%) as a clear oil.</div><div class="NLM_p last">A mixture of pyridine hydrochloride (500 mg) and 2-(4-cyclohexyl-6-methoxy-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)ethanol <b>66</b> (45 mg, 0.16 mmol) was stirred at 90 °C for 45 min. Water (0.5 mL) was added, the mixture was purified by HPLC, and pure fractions were combined and freeze-dried to afford 4-cyclohexyl-5-(2-hydroxyethyl)-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>18</b> (1.9 mg, 4.4%) as a white solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.84 (br s, 1H), 11.73 (br d, 1H), 5.62 (br s, 0.4H), 5.44 (d, <i>J</i> = 10.5 Hz, 0.6H), 5.26 (br s, 0.4H), 5.05 (br s, 0.6H), 3.50 (br s, 0.4H), 3.07 (br s, 0.6H), 2.66 (br s, 1H), 2.53 (br s, 2H), 1.92–1.23 (m, 13H). Two sets of broad peaks, <i>ca</i>. 4:6, probably due to two slowly interconverting tautomers. UPLC <i>t</i><sub>R</sub> = 1.97 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub> 276.1706; found 276.1700.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-Cyclohexyl-3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridine-5-carbonitrile (<b>19</b>)</h3><div class="NLM_p">A mixture of 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (1.18 g, 12.2 mmol) and methyl (<i>Z</i>)-2-cyano-3-cyclohexyl-prop-2-enoate <b>67</b> (2.35 g, 12.2 mmol) in MeOH (15 mL) was stirred at 60 °C for 18 h. Volatiles were evaporated, and the residue was purified by column chromatography (ISCO CombiFlash, silica gel column, DCM/MeOH) to afford 4-cyclohexyl-3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridine-5-carbonitrile <b>68</b> (1.47 g, 47%) as a pale orange solid (mixture of diastereomers).</div><div class="NLM_p last">To a solution of 4-cyclohexyl-3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridine-5-carbonitrile <b>68</b> (62.0 mg, 0.240 mmol) in MeCN (5 mL) was added NBS (42.7 mg, 0.240 mmol) at rt. The mixture was stirred for 30 min at rt, after which DBU (72 μL, 0.48 mmol) was added and stirring was continued for an additional 10 min at rt. Volatiles were evaporated, and the residue was purified by HPLC to afford 4-cyclohexyl-3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridine-5-carbonitrile <b>19</b> (5.6 mg, 9.1%) as a white solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.08 (br s, 1H), 12.51 (br s, 1H), 3.13 (br t, <i>J</i> = 12.6 Hz, 1H), 2.57 (s, 3H), 2.14–1.95 (m, 2H), 1.91–1.69 (m, 5H), 1.45–1.34 (m, 2H), 1.32–1.18 (m, 1H). UPLC <i>t</i><sub>R</sub> = 1.98 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>17</sub>N<sub>4</sub>O 257.1397; found 257.1392.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 2-[<i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]acetonitrile (<b>21</b>)</h3><div class="NLM_p">To a solution of 2-(<i>trans</i>-4-formylcyclohexyl)acetonitrile <b>59j</b> (500 mg, 3.31 mmol) in ethanol (16.5 mL) was added Meldrum’s acid <b>60</b> (477 mg, 3.31 mmol). The reaction mixture was stirred at rt for 5 min followed by the addition of 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (321 mg, 3.31 mmol), and the resulting mixture was stirred at 60 °C overnight. After cooling to rt, the mixture was concentrated to half its volume under reduced pressure and ether (5 mL) was added. The solid thus obtained was collected by filtration, washed with ether, and dried under vacuum to afford 2-[4-(3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexyl]acetonitrile <b>61j</b> (764 mg, 85%), which was used without purification.</div><div class="NLM_p last">To a suspension of 2-[4-(3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexyl]acetonitrile <b>61j</b> (100 mg, 0.367 mmol) in 1,4-dioxane (8 mL) was added DDQ (83.4 mg, 0.367 mmol), and the mixture was heated at 100 °C for 30 min. After cooling to rt, the resulting white precipitate was collected by filtration and washed with 1,4-dioxane. The crude solid was purified using HPLC (acidic method) to afford 2-[<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexyl]acetonitrile <b>21</b> (57 mg, 57%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (br s, 1H), 11.32 (br s, 1H), 5.81 (br s, 1H), 2.81–2.66 (m, 1H), 2.50 (d, <i>J</i> = 6.5 Hz, 2H), 2.47 (s, 3H), 1.94–1.84 (m, 4H), 1.76–1.65 (m, 1H), 1.49–1.38 (m, 2H), 1.32–1.19 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.80 min, purity UV<sub>254</sub> = 97%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>N<sub>4</sub>O 271.1553; found 271.1574.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 3-[<i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]propanenitrile (<b>22</b>)</h3><div class="NLM_p last">A solution of 3-[4-[1,7-bis[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]propanenitrile <b>74</b> (50 mg, 0.09 mmol) in TFA (4 mL) was prepared at 0 °C and then refluxed for 6 h. On completion, the reaction mixture was concentrated under reduced pressure. The crude product was diluted with MeOH and basified with Amberlyst A21 free base. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, and the crude product was purified by HPLC to afford 3-[<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]propanenitrile <b>22</b> (6.9 mg, 25%) as an off-white solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (br s, 1H), 11.29 (br s, 1H), 5.78 (br s, 1H), 2.76–2.66 (br m, 1H), 2.54 (s, 2H), 2.46 (s, 3H), 1.92–1.82 (m, 4H), 1.53 (q, J = 7.2 Hz, 2H), 1.44–1.33 (m, 3H), 1.17–1.06 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.88 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>N<sub>4</sub>O 285.1710; found 285.1729.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexanecarbonitrile (<b>23</b>)</h3><div class="NLM_p">To a solution of <i>trans</i>-4-formylcyclohexanecarbonitrile <b>59k</b><a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (212 mg, 1.55 mmol) in ethanol (8 mL) was added Meldrum’s acid <b>60</b> (223 mg, 1.55 mmol). The reaction mixture was stirred at rt for 5 min followed by the addition of 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (150 mg, 1.55 mmol), and the resulting mixture was stirred at 60 °C for 2 h. After cooling to rt, the mixture was concentrated to half its volume under reduced pressure, and ether (10 mL) was added. The solid thus obtained was collected by filtration, washed with ether, and dried to afford 4-(3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexanecarbonitrile <b>61k</b> (341 mg, 85%), which was used without purification.</div><div class="NLM_p last">To a suspension of 4-(3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexanecarbonitrile <b>61k</b> (341 mg, 1.32 mmol) in 1,4-dioxane (10 mL) was added DDQ (300 mg, 1.32 mmol), and the mixture was heated at 100 °C for 15 min. After cooling to rt, the resulting white precipitate was collected by filtration and washed with 1,4-dioxane. It was triturated with MeOH to afford <i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexanecarbonitrile as a light brown solid <b>23</b> (79 mg, 23%). A sample (7 mg) was further purified using HPLC (acidic method) to afford an analytically pure sample. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.80 (br s, 1H), 11.40 (br s, 1H), 5.75 (s, 1H), 2.87–2.78 (m, 1H), 2.77 (tt, <i>J</i> = 12.3, 3.7 Hz, 1H), 2.47 (s, 3H), 2.16–2.09 (m, 2H), 1.91–1.83 (m, 2H), 1.76–1.66 (m, 2H), 1.47–1.36 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.75 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>17</sub>N<sub>4</sub>O 257.1397; found 257.1414.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> General Procedure for Amide Formation in Library Format: One Amine, Multiple Acids</h3><div class="NLM_p last">A stock solution of 4-(4-<i>trans</i>-aminocyclohexyl)-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>32</b> (45 mg, 0.18 mmol) in DMF (3.6 mL) was prepared, and HATU (69 mg, 0.18 mmol) and DIPEA (94 μL, 0.54 mmol) were added. To each acid (20 μmol) in the library was added an aliquot of the stock solution (0.40 mL), and the resulting mixture was shaken at rt for 15 min. The reaction mixtures were purified by HPLC (acidic method) without prior workup to afford the corresponding amides.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-[<i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]cyclopropanecarboxamide (<b>24</b>)</h3><div class="NLM_p last">Prepared using the general procedure. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.75 (br s, 1H), 11.31 (br s, 1H), 7.95 (d, <i>J</i> = 7.8 Hz, 1H), 5.80 (br s, 1H), 3.66–3.55 (m, 1H), 2.78–2.66 (br m, 1H), 2.48 (s, 3H), 1.96–1.83 (m, 4H), 1.55–1.40 (m, 3H), 1.40–1.30 (m, 2H), 0.69–0.58 (m, 4H). UPLC <i>t</i><sub>R</sub> = 1.72 min, purity UV<sub>254</sub> = 98%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> 315.1816; found 315.1820.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-[<i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]cyclopentanecarboxamide (<b>26</b>)</h3><div class="NLM_p last">Prepared using the general procedure. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.74 (br s, 1H), 11.31 (br s, 1H), 7.62 (d, <i>J</i> = 7.8 Hz, 1H), 5.80 (br s, 1H), 3.58 (tdt, <i>J</i> = 11.7, 8.0, 4.0 Hz, 1H), 2.80–2.63 (br m, 1H), 2.53–2.50 (m, 1H), 2.47 (s, 3H), 1.94–1.83 (m, 4H), 1.76–1.67 (m, 2H), 1.65–1.55 (m, 4H), 1.54–1.41 (m, 4H), 1.38–1.29 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.86 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> 343.2129; found 343.2133.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (1<i>S</i>)-2,2-Difluoro-<i>N</i>-[<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]cyclopropanecarboxamide (<b>27</b>)</h3><div class="NLM_p last">Prepared using the general procedure. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.75 (br s, 1H), 11.31 (br s, 1H), 8.23 (d, <i>J</i> = 7.6 Hz, 1H), 5.81 (br s, 1H), 3.64 (tdt, <i>J</i> = 11.6, 7.9, 3.7 Hz, 1H), 2.79–2.67 (m, 1H), 2.55–2.51 (m, 1H), 2.48 (s, 3H), 1.98–1.92 (m, 2H), 1.92–1.85 (m, 3H), 1.85–1.77 (m, 1H), 1.55–1.43 (m, 2H), 1.42–1.31 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.78 min, purity UV<sub>254</sub> = 97%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> 351.1627; found 351.1639.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (1<i>R</i>)-2,2-Difluoro-<i>N</i>-[<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]cyclopropanecarboxamide (<b>28</b>)</h3><div class="NLM_p last">Prepared using the general procedure. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.74 (br s, 1H), 11.32 (br s, 1H), 8.23 (d, <i>J</i> = 7.7 Hz, 1H), 5.82 (br s, 1H), 3.64 (tdt, <i>J</i> = 11.6, 7.9, 4.1 Hz, 1H), 2.82–2.68 (br m, 1H), 2.55–2.51 (m, 1H), 2.48 (s, 3H), 2.00–1.92 (m, 2H), 1.92–1.85 (m, 3H), 1.85–1.77 (m, 1H), 1.54–1.43 (m, 2H), 1.42–1.31 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.78 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> 351.1627; found 351.1632.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-Cyclopropyl-<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexanecarboxamide (<b>25</b>)</h3><div class="NLM_p last">To a solution of 4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexanecarboxylic acid <b>77</b> (40 mg, 0.078 mmol) in DMF (1 mL) were added HATU (38 mg, 0.10 mmol), cyclopropylamine (6.6 mg, 0.12 mmol), and DIPEA (40.5 μL, 0.233 mmol). The reaction was stirred at room temperature for 5 min. It was poured into 1 N HCl (10 mL), and the product was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with sat. NaHCO<sub>3</sub> (10 mL), brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and evaporated to afford 4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]-<i>N</i>-cyclopropyl-cyclohexanecarboxamide (41 mg, 90%) as a solid. A portion of this material (27 mg, 0.049 mmol) was dissolved in TFA (1 mL), and the solution was heated in a microwave synthesizer at 80 °C for 1.5 h. The reaction mixture was purified by HPLC (acidic method) to afford <i>N</i>-cyclopropyl-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexanecarboxamide <b>25</b> (2.3 mg, 9.4%) as the pure trans isomer. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.74 (br s, 1H), 11.32 (br s, 1H), 7.80 (br d, <i>J</i> = 4.3 Hz, 1H), 5.78 (br s, 1H), 2.81–2.68 (br m, 1H), 2.64–2.58 (m, 1H), 2.47 (s, 3H), 2.11 (tt, <i>J</i> = 12.0, 3.7 Hz, 1H), 1.93–1.85 (m, 2H), 1.84–1.77 (m, 2H), 1.60–1.49 (m, 2H), 1.42–1.31 (m, 2H), 0.61–0.56 (m, 2H), 0.39–0.35 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.68 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> 315.1816; found 315.1823.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> [<i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl] (1<i>S</i>)-2,2-difluorocyclopropanecarboxylate (<b>29</b>)</h3><div class="NLM_p last">A mixture of 4-(4-<i>trans</i>-hydroxycyclohexyl)-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>33</b> (100 mg, 0.404 mmol), (1<i>S</i>)-2,2-difluorocyclopropanecarboxylic acid, HATU (154 mg, 0.404 mmol), and DMAP (74 mg, 0.607 mmol) in DMF (2 mL) was stirred at rt for 15 h. The mixture was purified without workup by HPLC to afford [<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexyl] (1<i>S</i>)-2,2-difluorocyclopropanecarboxylate <b>29</b> (18 mg, 13%) as a white solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.75 (br s, 1H), 11.33 (br s, 1H), 5.80 (br s, 1H), 4.83–4.75 (m, 1H), 3.39–3.36 (m, 1H), 2.83–2.74 (m, 1H), 2.48 (s, 3H), 2.09–1.95 (m, 4H), 1.93–1.87 (m, 2H), 1.63–1.48 (m, 4H). UPLC <i>t</i><sub>R</sub> = 1.98 min, purity UV<sub>254</sub> = 95%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>20</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub> 352.1467; found 352.1482.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> General Procedure for Sulfonamide Formation in Library Format</h3><div class="NLM_p last">A stock solution of 4-(4-<i>trans</i>-aminocyclohexyl)-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>32</b> (80 mg, 0.32 mmol) in DMSO (4.0 mL) was prepared, and DIPEA (288 μL, 1.65 mmol) was added. To each sulfonyl chloride (0.12 mmol) in the library was added an aliquot of the stock solution (0.50 mL), and the resulting mixture was shaken at rt for 15 min. The reaction mixtures were purified by HPLC (acidic method) without prior workup to afford the corresponding sulfonamides.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-[<i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]cyclopropanesulfonamide (<b>30</b>)</h3><div class="NLM_p last">Prepared using the general procedure. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.30 (br s, 1H), 11.78 (br s, 1H), 7.09 (br s, 1H), 5.82 (br s, 1H), 3.22 (tt, <i>J</i> = 11.0, 4.1 Hz, 1H), 2.75–2.67 (m, 1H), 2.60–2.54 (m, 1H), 2.47 (s, 3H), 2.09–2.02 (m, 2H), 1.91–1.84 (m, 2H), 1.54–1.37 (m, 4H), 0.98–0.90 (m, 4H). UPLC <i>t</i><sub>R</sub> = 1.73 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>S 351.1485; found 351.1513.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 1-Cyclobutyl-<i>N</i>-[<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]methanesulfonamide (<b>31</b>)</h3><div class="NLM_p last">Prepared using the general procedure. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.75 (s, 1H), 11.31 (s, 1H), 7.01 (d, <i>J</i> = 7.4 Hz, 1H), 5.78 (s, 1H), 3.19–3.13 (m, 1H), 3.12 (d, <i>J</i> = 7.2 Hz, 2H), 2.73–2.63 (m, 2H), 2.46 (s, 3H), 2.15–2.06 (m, 2H), 2.03–1.96 (m, 2H), 1.91–1.74 (m, 6H), 1.52–1.34 (m, 4H). UPLC <i>t</i><sub>R</sub> = 1.89 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>27</sub>N<sub>4</sub>O<sub>3</sub>S 379.1798; found 379.1825.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 4-(4-<i>trans</i>-Aminocyclohexyl)-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>32</b>)</h3><div class="NLM_p">To a solution of <i>tert</i>-butyl <i>N</i>-(4-formylcyclohexyl)carbamate <b>59l</b> (1.17 g, 5.15 mmol) in ethanol (13 mL) was added Meldrum’s acid <b>60</b> (371 mg, 2.57 mmol). The reaction mixture was stirred at rt for 5 min followed by the addition of 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (250 mg, 2.57 mmol), and the resulting mixture was stirred at 60 °C overnight. After cooling to rt, the reaction mixture was reduced to half its initial volume by evaporation, and ether (10 mL) was added. The resulting white precipitate was collected by filtration and washed with ether to afford <i>tert</i>-butyl <i>N</i>-[4-(3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexyl]carbamate <b>61l</b> (502 mg, 56%) as a white solid that was used without purification. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.71 (s, 1H), 10.05 (s, 1H), 6.63 (d, <i>J</i> = 8.0 Hz, 1H), 3.11–3.01 (m, 1H), 2.61 (t, <i>J</i> = 6.5 Hz, 1H), 2.53–2.49 (m, 1H), 2.35 (d, <i>J</i> = 16.8 Hz, 1H), 2.11 (s, 3H), 1.80–1.69 (m, 2H), 1.68–1.62 (m, 1H), 1.55–1.47 (m, 1H), 1.35 (s, 9H), 1.22–1.14 (m, 1H), 1.11–1.00 (m, 2H), 1.00–0.90 (m, 2H).</div><div class="NLM_p">To a suspension of <i>tert</i>-butyl <i>N</i>-[4-(3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexyl]carbamate <b>61l</b> (502 mg, 1.44 mmol) in 1,4-dioxane (8 mL) was added DDQ (327 mg, 1.44 mmol), and the mixture was heated at 100 °C for 30 min. After cooling to rt, the precipitated solid was collected by filtration and washed with ether to afford <i>tert</i>-butyl <i>N</i>-[4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]carbamate <b>32a</b> (498 mg, 99%) as a white solid that was used without purification. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.74 (s, 1H), 11.31 (s, 1H), 6.77 (d, <i>J</i> = 7.9 Hz, 1H), 5.81 (s, 1H), 2.75–2.59 (m, 1H), 2.52–2.49 (m, 1H), 2.46 (s, 3H), 1.96–1.81 (m, 4H), 1.51–1.40 (m, 2H), 1.39 (s, 9H), 1.36–1.27 (m, 2H).</div><div class="NLM_p last">The intermediate <i>tert</i>-butyl <i>N</i>-[4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]carbamate <b>32a</b> (498 mg, 1.44 mmol) was dissolved in 4 M HCl in 1,4-dioxane, and the mixture was stirred at rt for 15 min. Evaporation to dryness afforded 4-(4-<i>trans</i>-aminocyclohexyl)-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>32</b> as the hydrochloride salt (350 mg, 86%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.11 (br s, 3H), 5.86 (s, 1H), 3.13–3.01 (m, 1H), 2.80–2.71 (m, 1H), 2.48 (s, 3H), 2.14–2.03 (m, 2H), 1.97–1.86 (m, 2H), 1.57–1.44 (m, 4H). Not all exchangeable protons are visible. UPLC <i>t</i><sub>R</sub> = 0.87 min, purity UV<sub>254</sub> = 95%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>19</sub>N<sub>4</sub>O 247.1553; found 247.1576.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 4-(4-<i>trans</i>-Hydroxycyclohexyl)-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>33</b>)</h3><div class="NLM_p">To solution of <i>trans</i>-4-[<i>tert</i>-butyl(dimethyl)silyl]oxycyclohexanecarbaldehyde <b>59m</b><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (20 g, 83 mmol) in ethanol (1.4 L) was added Meldrum’s acid <b>60</b> (5.6 g, 58 mmol). The resulting mixture was stirred at rt for 15 min followed by the addition of 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (8.3 g, 58 mmol), and the resulting mixture was stirred at 90 °C for 3 h. After cooling to rt, the mixture was concentrated under reduced pressure, and the solid thus obtained was collected by filtration, washed with water and diethyl ether, and dried under vacuum to afford 4-[4-[<i>tert</i>-butyl(dimethyl)silyl]oxycyclohexyl]-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61m</b> (10 g, 45%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.71 (s, 1H), 10.05 (s, 1H), 3.50–3.42 (m, 1H), 3.40–3.34 (m, 1H), 2.68–2.57 (m, 1H), 2.56–2.51 (m, 1H), 2.11 (s, 3H), 1.82–1.73 (m, 2H), 1.67–1.47 (m, 2H), 1.28–1.21 (m, 1H), 1.16–1.07 (m, 2H), 1.02–0.92 (m, 2H), 0.86 (s, 9H), 0.02 (s, 6H).</div><div class="NLM_p">To a solution of 4-[4-[<i>tert</i>-butyl(dimethyl)silyl]oxycyclohexyl]-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61m</b> (170 mg, 0.468 mmol) in 1,4-dioxane (5 mL) was added DDQ (106 mg, 0.468 mmol), and the mixture was stirred at 100 °C for 30 min. After cooling to rt, the precipitate was collected by filtration, washed with 1,4-dioxane, and dried under vacuum to afford 4-[4-[<i>tert</i>-butyl(dimethyl)silyl]oxycyclohexyl]-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>33a</b> (100 mg, 59%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.85 (s, 1H), 11.40 (s, 1H), 5.78 (br s, 1H), 3.75–3.65 (m, 1H), 2.47 (s, 3H), 1.93–1.91 (m, 2H), 1.87–1.81 (m, 2H), 1.50–1.39 (m, 4H), 0.87 (s, 9H), 0.06 (s, 6H).</div><div class="NLM_p last">To a solution of 4-[4-[<i>tert</i>-butyl(dimethyl)silyl]oxycyclohexyl]-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>33a</b> (100 mg, 0.275 mmol) in DCM (5 mL) at 0 °C was added 1 M TBAF in THF (0.55 mL, 0.55 mmol) at 0 °C. The resulting reaction mass was stirred at 40 °C for 16 h. Volatiles were evaporated, and the residue was triturated with saturated NaHCO<sub>3</sub> solution to give a solid. The solid was filtered, washed with ether, and dried under vacuum to afford 4-(4-<i>trans</i>-hydroxycyclohexyl)-3-methyl-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>33</b> (56 mg, 40%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 11.31 (s, 1H), 5.78 (s, 1H), 4.61 (d, <i>J</i> = 4.4 Hz, 1H), 3.51–3.41 (m, 1H), 2.77–2.62 (m, 1H), 2.47 (s, 3H), 1.98–1.89 (m, 2H), 1.87–1.77 (m, 2H), 1.48–1.21 (m, 4H). UPLC <i>t</i><sub>R</sub> = 1.54 min, purity UV<sub>254</sub> = 98%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>18</sub>N<sub>3</sub>O<sub>2</sub> 248.1394; found 248.1382.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> General Procedure for Amide Formation in Library Format: One Acid, Multiple Amines</h3><div class="NLM_p last">A stock solution of 2-[<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexyl]acetic acid <b>78</b> (95.0 mg, 0.328 mmol) in DMF (4.75 mL) was prepared, and an aliquot (0.25 mL, 0.017 mmol) was added to each amine (0.0346 mmol) in the library. A stock solution of HATU (124 mg, 0.326 mmol) in DMF (4.75 mL) was prepared, and an aliquot (0.25 mL, 0.017 mmol) was added to each of the reaction mixtures. Finally, DIPEA (9.0 μL, 0.052 mmol) was added to each of the reaction mixtures, which were then shaken at rt for 15 min. The reaction mixtures were purified by HPLC without prior workup to afford the corresponding amides.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 1-[2-[<i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]acetyl]azetidine-3-carbonitrile (<b>34</b>)</h3><div class="NLM_p last">Prepared using the general procedure. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.72 (br s, 1H), 11.29 (br s, 1H), 5.78 (br s, 1H), 4.40 (t, <i>J</i> = 8.8 Hz, 1H), 4.32 (dd, <i>J</i> = 8.4, 6.0 Hz, 1H), 4.13 (t, <i>J</i> = 9.3 Hz, 1H), 3.98 (dd, <i>J</i> = 9.4, 6.1 Hz, 1H), 3.76 (tt, <i>J</i> = 9.1, 6.0 Hz, 1H), 2.75–2.64 (m, 1H), 2.45 (s, 3H), 2.03–1.93 (m, 2H), 1.90–1.79 (m, 4H), 1.78–1.68 (m, 1H), 1.46–1.32 (m, 2H), 1.21–1.08 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.72 min, purity UV<sub>254</sub> = 81%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub> 354.1925; found 354.1943.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 1-[2-[<i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]acetyl]pyrrolidine-3-carbonitrile (<b>35</b>)</h3><div class="NLM_p last">Prepared using the general procedure. Two rotamers around the amide bond are visible in the NMR spectrum. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (br s, 1H), 11.29 (br s, 1H), 5.78 (br s, 1H), 3.78 (dd, <i>J</i> = 10.3, 7.2 Hz, 0.5H), 3.67 (dd, <i>J</i> = 10.3, 6.0 Hz, 0.5H), 3.62 (dd, <i>J</i> = 11.8, 7.4 Hz, 0.5H), 3.59–3.35 (m, 3.5H), 2.75–2.64 (br m, 1H), 2.46 (s, 3H), 2.33–2.26 (m, 0.5H), 2.24–2.14 (m, 3H), 2.11–2.03 (m, 0.5H), 1.90–1.74 (m, 5H), 1.47–1.33 (m, 2H), 1.23–1.10 (m, 2H). UPLC <i>t</i><sub>R</sub> = 1.76 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub> 368.2081; found 368.2093.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 4-[<i>trans</i>-4-[2-(3-Benzylazetidin-1-yl)-2-oxo-ethyl]cyclohexyl]-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>36</b>)</h3><div class="NLM_p last">Prepared using the general procedure. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.72 (br s, 1H), 11.32 (br s, 1H), 7.33–7.26 (m, 2H), 7.24–7.17 (m, 3H), 5.80 (br s, 1H), 4.15 (t, <i>J</i> = 7.9 Hz, 1H), 3.88 (t, <i>J</i> = 8.6 Hz, 1H), 3.81 (dd, <i>J</i> = 8.3, 4.6 Hz, 1H), 3.55 (dd, <i>J</i> = 9.5, 4.8 Hz, 1H), 2.89–2.81 (m, 3H), 2.75–2.67 (m, 1H), 2.46 (s, 3H), 1.95 (d, <i>J</i> = 6.9 Hz, 2H), 1.88–1.77 (m, 4H), 1.76–1.67 (m, 1H), 1.44–1.34 (m, 2H), 1.18–1.09 (m, 2H). UPLC <i>t</i><sub>R</sub> = 2.04 min, purity UV<sub>254</sub> = 97%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>N<sub>4</sub>O<sub>2</sub> 419.2442; found 419.2459.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 3-Methyl-4-[<i>trans</i>-4-[2-oxo-2-(3-phenylpyrrolidin-1-yl)ethyl]cyclohexyl]-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>37</b>)</h3><div class="NLM_p last">Prepared using the general procedure. Two rotamers around the amide bond are visible in the NMR spectrum. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (br s, 1H), 11.30 (br s, 1H), 7.38–7.28 (m, 4H), 7.26–7.20 (m, 1H), 5.79 (br s, 1H), 3.93 (dd, <i>J</i> = 9.4, 7.1 Hz, 0.5H), 3.84 (dd, <i>J</i> = 11.5, 7.6 Hz, 0.5H), 3.70–3.64 (m, 0.5H), 3.64–3.58 (m, 0.5H), 3.52 (td, <i>J</i> = 9.8, 6.8 Hz, 0.5H), 3.46–3.40 (m, 0.5H), 3.40–3.34 (m, 0.5H), 3.20 (dd, <i>J</i> = 11.4, 9.3 Hz, 0.5H), 2.78–2.64 (m, 1H), 2.47 (s, 1.5H), 2.45 (s, 1.5H), 2.33–2.26 (m, 0.5H), 2.24–2.17 (m, 3H), 2.06–1.97 (m, 0.5H), 1.96–1.77 (m, 6H), 1.47–1.33 (m, 2H), 1.26–1.10 (m, 2H). UPLC <i>t</i><sub>R</sub> = 2.00 min, purity UV<sub>254</sub> = 94%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>N<sub>4</sub>O<sub>2</sub> 419.2442; found 419.2460.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 4-[<i>trans</i>-4-[2-(4,4-Dimethyl-1-piperidyl)-2-oxo-ethyl]cyclohexyl]-3-methyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one (<b>38</b>)</h3><div class="NLM_p last">Prepared using the general procedure. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (br s, 1H), 11.29 (br s, 1H), 5.78 (br s, 1H), 3.47–3.38 (m, 4H), 2.76–2.63 (m, 1H), 2.46 (s, 3H), 2.23 (d, <i>J</i> = 6.9 Hz, 2H), 1.89–1.80 (m, 4H), 1.79–1.70 (m, 1H), 1.45–1.33 (m, 2H), 1.32–1.27 (m, 2H), 1.24–1.19 (m, 2H), 1.19–1.10 (m, 2H), 0.94 (s, 6H). UPLC <i>t</i><sub>R</sub> = 2.04 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>33</sub>N<sub>4</sub>O<sub>2</sub> 385.2598; found 385.2609.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Norbornane Acetonitriles <b>39–42</b></h3><div class="NLM_p">To a solution of 2-[(1<i>S*</i>,4<i>S*</i>,5<i>R*</i>)-5-formylnorbornan-2-ylidene]acetonitrile <b>59o</b> (0.750 g, 4.61 mmol) in ethanol (30 mL) was added Meldrum’s acid <b>60</b> (0.670 g, 4.6 mmol), the mixture was stirred at rt for 15 min, and 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (0.450 g, 4.6 mmol) was added. The resulting mixture was stirred at 80 °C for 3 h. After cooling to rt, the mixture was concentrated under reduced pressure and the residue was washed with ether. The solid thus obtained was dried under vacuum to afford 2-[(1<i>S*</i>,4<i>S*</i>,5<i>R*</i>)-5-(6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)norbornan-2-ylidene]acetonitrile <b>61o</b> (0.7 g, 53%) as an off-white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.77–11.52 (m, 1H), 10.25–9.98 (m, 1H), 5.34–5.20 (m, 1H), 3.17 (s, 1H), 2.66–2.53 (m, 2H), 2.26 (br s, 3H), 2.17 (d, <i>J</i> = 4.4 Hz, 3H), 2.00 (br d, <i>J</i> = 17.6 Hz, 1H), 1.56–1.18 (m, 3H), 1.20–1.08 (m, 2H).</div><div class="NLM_p">To a solution of 2-[(1<i>S*</i>,4<i>S*</i>,5<i>R*</i>)-5-(6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)norbornan-2-ylidene]acetonitrile <b>61o</b> (0.700 g, 2.48 mmol) in 1,4-dioxane (20 mL) was added DDQ (0.845 g, 3.73 mmol). The resulting mixture was stirred at 100 °C for 3 h. After cooling to rt, the mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel column, DCM/MeOH 95:5) to afford 2-[(1<i>S*</i>,4<i>S*</i>,5<i>R*</i>)-5-(6-oxo-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)norbornan-2-ylidene]acetonitrile <b>39a</b> (0.500 g, 71%) as an off-white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.03–12.61 (m, 1H), 11.39 (br d, <i>J</i> = 9.2 Hz, 1H), 5.97–5.77 (m, 1H), 5.49–5.23 (m, 1H), 3.23 (br d, <i>J</i> = 3.7 Hz, 1H), 3.07 (br d, <i>J</i> = 4.0 Hz, 1H), 2.54–2.39 (m, 3H), 2.18–1.77 (m, 2H), 1.72–1.41 (m, 4H), 1.31–1.10 (m, 1H).</div><div class="NLM_p last">A suspension of 2-[(1<i>S*</i>,4<i>S*</i>,5<i>R*</i>)-5-(6-oxo-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)norbornan-2-ylidene]acetonitrile <b>39a</b> (0.500 g, 2.14 mmol) and 5% Pt/C (0.500 g, 50% of moisture) in methanol (30 mL) was stirred under H<sub>2</sub> (1 atm) at rt for 16 h. The reaction mixture was filtered through a celite pad, and the pad was washed with methanol. The filtrate was concentrated under reduced pressure, and the residue was subjected to chiral SFC purification (Column: Chiralpak AD-H 30 mm × 250 mm, 5 μm; CO<sub>2</sub>/MeOH 35:65 wt/wt; total flow: 90.0 g/min; back pressure: 100 bar; detection: UV 296 nm; stack time: 12.5 min; load per injection: 12.5 mg dissolved in 1.25 mL MeOH; number of injections: 45). Compounds <b>41</b> and <b>42</b> were isolated as the pure enantiomers, but compounds <b>39</b> and <b>40</b> were obtained as a mixture. The enantiomeric purities of <b>41</b> and <b>42</b> were determined by analytical chiral SFC (Column: Chiralpak AD-H 4.6 mm × 250 mm, 5 μm; CO<sub>2</sub>/MeOH 60:40 wt/wt, column temperature: 25 °C, total flow: 4 g/min). The mixture of compounds <b>39</b> and <b>40</b> was subjected to a second round of chiral SFC purification (Column: Chiralpak IC 30 mm × 250 mm, 5 μm; CO<sub>2</sub>/co-solvent 60:40 wt/wt, where the co-solvent is 0.5% DEA in MeOH; total flow: 90.0 g/min; back pressure: 100 bar; detection: UV 214 nm; stack time: 16.5 min; load per injection: 5.04 mg dissolved in MeCN + MeOH; number of injections: 20), which afforded compounds <b>39</b> and <b>40</b> as the pure enantiomers. The enantiomeric purities of <b>39</b> and <b>40</b> were determined by analytical chiral SFC (Column: Chiralpak IC 4.6 mm × 250 mm, 5 μm; CO<sub>2</sub>/co-solvent 60:40 wt/wt, where the co-solvent is 0.5% DEA in MeOH, column temperature: 30 °C, total flow: 4 g/min). The relative stereochemistry of compounds <b>39</b> to <b>42</b> was assigned from <sup>1</sup>H NMR NOE experiments; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">Supporting Information</a> for details. Absolute configurations were not determined.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> [(1<i>S</i>,2<i>S</i>,4<i>S</i>,5<i>R</i>)-5-(3-Methyl-6-oxo-1,2,7-triaza-2,7-dihydroinden-4-yl)-2-norbornanyl]acetonitrile (<b>39</b>)</h3><div class="NLM_p last">Yield 30 mg, 6.0%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.05 (br s, 2H), 5.78 (br s, 1H), 2.93 (br t, <i>J</i> = 7.3 Hz, 1H), 2.53–2.49 (m, 1H), 2.48 (s, 3H), 2.43 (dd, <i>J</i> = 16.9, 7.7 Hz, 1H), 2.31 (br d, <i>J</i> = 4.0 Hz, 1H), 2.16 (br s, 1H), 1.95–1.89 (m, 1H), 1.79–1.73 (m, 1H), 1.72–1.62 (m, 2H), 1.44–1.40 (m, 1H), 1.35–1.30 (m, 1H), 1.22 (dt, <i>J</i> = 12.5, 4.5 Hz, 1H). Chiral SFC <i>t</i><sub>R</sub> = 14.28 min, 94% ee. UPLC <i>t</i><sub>R</sub> = 1.82 min, purity UV<sub>254</sub> = 95%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>4</sub>O 283.1553; found 283.1566.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> [(1<i>R</i>,2<i>R</i>,4<i>R</i>,5<i>S</i>)-5-(3-Methyl-6-oxo-1,2,7-triaza-2,7-dihydroinden-4-yl)-2-norbornanyl]acetonitrile (<b>40</b>)</h3><div class="NLM_p last">Yield 11 mg, 2.2%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.72 (br s, 1H), 11.30 (br s, 1H), 5.78 (br s, 1H), 2.92 (br s, 1H), 2.53–2.49 (m, 1H), 2.48 (s, 3H), 2.43 (dd, <i>J</i> = 17.0, 7.7 Hz, 1H), 2.31 (br d, <i>J</i> = 3.6 Hz, 1H), 2.16 (br d, <i>J</i> = 2.7 Hz, 1H), 1.95–1.89 (m, 1H), 1.79–1.73 (m, 1H), 1.72–1.62 (m, 2H), 1.44–1.40 (m, 1H), 1.35–1.30 (m, 1H), 1.22 (dt, <i>J</i> = 12.5, 4.5 Hz, 1H). Chiral SFC <i>t</i><sub>R</sub> = 10.28 min, >99% ee. UPLC <i>t</i><sub>R</sub> = 1.81 min, purity UV<sub>254</sub> = 96%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>4</sub>O 283.1553; found 283.1556.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> [(1<i>S</i>,2<i>R</i>,4<i>S</i>,5<i>R</i>)-5-(3-Methyl-6-oxo-1,2,7-triaza-2,7-dihydroinden-4-yl)-2-norbornanyl]acetonitrile (<b>41</b>)</h3><div class="NLM_p last">Yield 80 mg, 16%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.70 (br s, 1H), 11.29 (br s, 1H), 5.77 (br s, 1H), 2.94 (br s, 1H), 2.67 (dd, <i>J</i> = 16.8, 8.1 Hz, 1H), 2.56 (dd, <i>J</i> = 16.9, 8.0 Hz, 1H), 2.50 (s, 3H), 2.32 (br s, 1H), 2.28–2.15 (m, 2H), 2.01–1.91 (m, 1H), 1.90–1.82 (m, 1H), 1.62–1.53 (m, 1H), 1.52–1.45 (m, 1H), 1.38–1.31 (m, 1H), 1.05–0.96 (m, 1H). Chiral SFC <i>t</i><sub>R</sub> = 4.38 min, >99% ee. UPLC <i>t</i><sub>R</sub> = 1.81 min, purity UV<sub>254</sub> = 94%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>4</sub>O 283.1553; found 283.1567.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> [(1<i>R</i>,2<i>S</i>,4<i>R</i>,5<i>S</i>)-5-(3-Methyl-6-oxo-1,2,7-triaza-2,7-dihydroinden-4-yl)-2-norbornanyl]acetonitrile (<b>42</b>)</h3><div class="NLM_p last">Yield 80 mg, 16%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.96 (br s, 2H), 5.79 (br s, 1H), 2.96 (br t, <i>J</i> = 7.2 Hz, 1H), 2.67 (dd, <i>J</i> = 16.9, 8.0 Hz, 1H), 2.56 (dd, <i>J</i> = 16.8, 8.0 Hz, 1H), 2.50 (s, 3H), 2.32 (br s, 1H), 2.28–2.15 (m, 2H), 2.01–1.91 (m, 1H), 1.90–1.82 (m, 1H), 1.62–1.53 (m, 1H), 1.52–1.45 (m, 1H), 1.38–1.31 (m, 1H), 1.05–0.96 (m, 1H). Chiral SFC <i>t</i><sub>R</sub> = 3.65 min, >99% ee. UPLC <i>t</i><sub>R</sub> = 1.82 min, purity UV<sub>254</sub> > 99%. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>4</sub>O 283.1553; found 283.1555.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Methyl 4-(3-Methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-b]pyridin-4-yl)cyclohexanecarboxylate (<b>61n</b>)</h3><div class="NLM_p last">Meldrum’s acid <b>60</b> (423 mg, 2.94 mmol) and methyl <i>trans</i>-4-formylcyclohexanecarboxylate <b>59n</b> (500 mg, 2.94 mmol) were mixed in pyridine (5 mL). Piperidine (29 μL, 0.29 mmol) was added, and the reaction mixture was stirred at room temperature for 3 h. To the reaction mixture were added ethanol (10 mL) and 3-methyl-1<i>H</i>-pyrazol-5-amine <b>43c</b> (285 mg, 2.94 mmol). The reaction mixture was heated at 70 °C for 1 h. After cooling to rt, volatiles were evaporated and the residue was purified by chromatography (ISCO CombiFlash, 40 g silica gel column, EtOAc/MeOH 100:0 → 90:10) to give methyl 4-(3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexanecarboxylate <b>61n</b> (200 mg, 23%) as a yellow solid (mixture of isomers, cis/trans ca. 20:80). <sup>1</sup>H NMR for the trans isomer (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.71 (s, 1H), 10.05 (s, 1H), 3.56 (s, 3H), 2.68–2.59 (m, 1H), 2.54–2.51 (m, 1H), 2.38–2.31 (m, 1H), 2.21–2.14 (m, 1H), 2.11 (s, 3H), 1.93–1.83 (m, 2H), 1.74–1.65 (m, 1H), 1.60–1.54 (m, 1H), 1.32–1.18 (m, 3H), 1.03–0.92 (m, 2H).</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 6-Chloro-4-cyclohexyl-3-methyl-1<i>H</i>-pyrazolo[3,4-b]pyridine-5-carbaldehyde (<b>62</b>)</h3><div class="NLM_p last">To a suspension of 4-cyclohexyl-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-6-one <b>61a</b> (854 mg, 3.66 mmol) in DMF (7 mL) was slowly added POCl<sub>3</sub> (0.716 mL, 7.69 mmol) at rt (exothermic) in a closed microwave vial. The mixture became yellow and homogeneous. It was stirred at 100 °C for 3 h to produce a dark red solution. After cooling to rt, volatiles were evaporated and the residual thick syrup was stirred in water (20 mL) overnight. The resulting yellow precipitate was filtered off and dried. The so-obtained crude intermediate was suspended in MeCN (50 mL), and MnO<sub>2</sub> (3 g) was added. The mixture was stirred at rt for 2 h, filtered, and evaporated. The residue was purified by chromatography (ISCO CombiFlash, silica gel column, heptane/EtOAc) to afford 6-chloro-4-cyclohexyl-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-5-carbaldehyde <b>62</b> (150 mg, 15%) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.93 (br s, 1H), 10.65 (s, 1H), 3.62 (br t, <i>J</i> = 12.5 Hz, 1H), 2.79 (s, 3H), 2.09–1.87 (m, 4H), 1.87–1.72 (m, 3H), 1.52–1.31 (m, 3H).</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 2-[4-[1,7-bis[(4-Methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-b]pyridin-4-yl]cyclohexyl]acetonitrile (<b>70</b>)</h3><div class="NLM_p">To a solution of 2-[4-(3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexyl]acetonitrile <b>61j</b> (4.00 g, 14.7 mmol) in DMF (20 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (14.4 g, 44.1 mmol) followed by 4-methoxybenzyl chloride (4.3 mL, 32 mmol). The resulting reaction mixture was stirred at rt for 16 h. The mixture was then diluted with water and extracted with EtOAc (2 × 100 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 2-[4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-4,5-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]acetonitrile <b>69</b> (4.0 g, 53%), which was used without purification.</div><div class="NLM_p last">To a solution of 2-[4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-4,5-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]acetonitrile <b>69</b> (4.0 g, 7.8 mmol) in 1,4-dioxane (30 mL) was added DDQ (1.8 g, 7.8 mmol). The resulting mixture was stirred at 100 °C for 16 h. The mixture was concentrated under reduced pressure, and the residue was dissolved in 1,4-dioxane and filtered. The filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel column, hexane/EtOAc 100:0 → 50:50) to afford 2-[4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]acetonitrile <b>70</b> (2.0 g, 50%) as a brown solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.29 (d, <i>J</i> = 8.7 Hz, 2H), 7.16 (d, <i>J</i> = 8.9 Hz, 2H), 6.94–6.86 (m, 2 H) 6.83–6.78 (m, 2H), 5.96 (s, 1H), 5.32 (s, 2H), 5.09 (s, 2H), 3.72 (s, 3H), 3.71–3.68 (m, 3H), 2.77 (br t, <i>J</i> = 11.8 Hz, 1H), 2.52 (s, 3H), 2.50 (s, 2H), 1.86 (br d, <i>J</i> = 11.0 Hz, 4H), 1.68 (ddd, <i>J</i> = 8.8, 5.7, 3.1 Hz, 1H), 1.49–1.38 (m, 2H), 1.30–1.22 (m, 2H).</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 4-[4-(2-Hydroxyethyl)cyclohexyl]-1,7-bis[(4-methoxyphenyl)methyl]-3-methyl-pyrazolo[3,4-b]pyridin-6-one (<b>72</b>)</h3><div class="NLM_p">A solution of 2-[4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]acetonitrile <b>70</b> (600 mg, 1.18 mmol) in toluene (10 mL) was cooled to 0 °C, 1.0 M DIBAL-H in hexane (2.35 mL, 2.35 mmol) was added <i>via</i> a syringe, and the mixture was stirred for 2 h at 0 °C. The reaction was quenched with sat. potassium tartrate and extracted with EtOAc (2 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 2-[4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]acetaldehyde <b>71</b> (500 mg, 82%) as a colorless oil that was used without purification.</div><div class="NLM_p last">To a solution of 2-[4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]acetaldehyde <b>71</b> (3.5 g, 6.8 mmol) in THF (70 mL) was added NaBH<sub>4</sub> (1.89 g, 50.0 mmol) slowly at 0 °C. The resulting mixture was stirred at rt for 2 h. The reaction was quenched with sat. NH<sub>4</sub>Cl at 0 °C and extracted with EtOAc (2 × 100 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel column, petroleum ether/EtOAc 80:20) to afford 4-[4-(2-hydroxyethyl)cyclohexyl]-1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-pyrazolo[3,4-<i>b</i>]pyridin-6-one <b>72</b> (2.5 g, 71%) as a light yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.29 (d, <i>J</i> = 8.8 Hz, 2H), 7.15 (d, <i>J</i> = 8.7 Hz, 2H), 6.89 (s, 2H), 6.81 (d, <i>J</i> = 8.8 Hz, 2H), 5.94 (s, 1H), 5.31 (s, 2H), 5.09 (s, 2H), 3.72 (s, 3H), 3.70 (s, 3H) 3.48–3.45 (m, 1H), 2.80–2.71 (m, 1H), 2.55 (s, 3H), 2.43–2.41 (m, 2H), 1.83–1.82 (m, 4H), 1.40–1.33 (m, 4H), 1.14–1.05 (m, 3H).</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 2-[4-[1,7-bis[(4-Methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-b]pyridin-4-yl]cyclohexyl]ethyl methanesulfonate (<b>73</b>)</h3><div class="NLM_p last">To a solution of 4-[4-(2-hydroxyethyl)cyclohexyl]-1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-pyrazolo[3,4-<i>b</i>]pyridin-6-one <b>72</b> (150 mg, 0.29 mmol) in DCM (10 mL) was added triethylamine (0.13 mL, 0.87 mmol) at 0 °C. After 5 min, methanesulfonyl chloride (33 μL, 0.43 mmol) was added. The resulting mixture was stirred at rt for 30 min. The reaction was quenched with sat. NaHCO<sub>3</sub> and extracted with DCM (2 × 50 mL). The combined organic layers were washed with water (30 mL), brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel column, DCM/MeOH 100:0 → 98:2) to afford 2-[4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]ethyl methanesulfonate <b>73</b> (120 mg, 69%) as a pale yellow viscous oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.52 (d, <i>J</i> = 8.8 Hz, 2H), 7.09 (d, <i>J</i> = 8.8 Hz, 2H), 6.84 (d, <i>J</i> = 8.41 Hz, 2H), 6.79 (d, <i>J</i> = 8.8 Hz, 2H), 6.18 (s, 1H), 5.27 (d, <i>J</i> = 4.8 Hz, 4H), 4.29 (t, <i>J</i> = 6.8 Hz, 2H), 3.79 (s, 3H), 3.76 (s, 3H), 3.01 (s, 3H), 2.65 (br t, <i>J</i> = 12.1 Hz, 1H), 2.42 (s, 3H), 1.92 (br d, <i>J</i> = 11.3 Hz, 4H), 1.71 (q, <i>J</i> = 6.6 Hz, 2H), 1.43 (br d, <i>J</i> = 10.6 Hz, 3H), 1.18–1.02 (m, 2H).</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 3-[4-[1,7-bis[(4-Methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-b]pyridin-4-yl]cyclohexyl]propanenitrile (<b>74</b>)</h3><div class="NLM_p last">To a solution of 2-[4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]ethyl methanesulfonate <b>73</b> (120 mg, 0.202 mmol) in DMF (10 mL) was added NaCN (11.8 mg, 0.241 mmol) at rt. The resulting reaction mixture was stirred at 90 °C for 16 h. The mixture was cooled to rt, diluted with water, and extracted with EtOAc (2 × 30 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel column, DCM/MeOH 100:0 → 98:2) to afford 3-[4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexyl]propanenitrile <b>74</b> (70 mg, 66%) as a pale yellow viscous oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.52 (d, <i>J</i> = 8.8 Hz, 2H), 7.09 (d, <i>J</i> = 8.8 Hz, 2H), 6.84 (d, <i>J</i> = 8.8 Hz, 2H), 6.79 (d, <i>J</i> = 8.8 Hz, 2H), 6.14 (s, 1H), 5.27 (d, <i>J</i> = 4.4 Hz, 4H), 3.79 (s, 3H), 3.76 (s, 3H), 2.65 (br t, <i>J</i> = 12.1 Hz, 1H), 2.42 (s, 3H), 2.37 (t, <i>J</i> = 7.3 Hz, 2H), 1.93 (d, <i>J</i> = 11.0 Hz, 4H), 1.68–1.59 (m, 2H), 1.52–1.41 (m, 3H), 1.15–1.03 (m, 2H).</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Methyl 4-[1,7-bis[(4-Methoxyphenyl)methyl]-3-methyl-6-oxo-4,5-dihydropyrazolo[3,4-b]pyridin-4-yl]cyclohexanecarboxylate (<b>75</b>)</h3><div class="NLM_p last">To a solution of 4-(3-methyl-6-oxo-2,4,5,7-tetrahydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexanecarboxylate <b>61n</b> (540 mg, 1.85 mmol) in DMF (25 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (1.51 g, 4.63 mmol) followed by 4-methoxybenzyl chloride (578 μL, 4.26 mmol). The reaction was stirred at rt for 3 h. A second portion of 4-methoxybenzyl chloride (58 mg, 0.37 mmol) was added, and the reaction was stirred overnight at rt. Water (40 mL) was added, and the product was extracted with EtOAc (4 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by chromatography (ISCO CombiFlash, 40 g silica gel column, heptane/EtOAc 100:0 → 0:100) to afford methyl 4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-4,5-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexanecarboxylate <b>75</b> (903 mg, 92%) as a mixture of isomers, cis/trans ca. 20:80. <sup>1</sup>H NMR for the trans isomer (600 MHz, CDCl<sub>3</sub>) δ 7.42–7.37 (m, 2H), 7.03–6.99 (m, 2H), 6.86–6.81 (m, 2H), 6.80–6.73 (m, 2H), 5.12–5.05 (m, 3H), 4.90–4.84 (m, 1H), 3.80 (s, 3H), 3.77 (s, 3H), 3.63 (s, 3H), 2.73–2.65 (m, 2H), 2.59–2.55 (m, 1H), 2.11–2.02 (m, 4H), 1.90–1.80 (m, 2H), 1.65–1.59 (m, 1H), 1.54–1.47 (m, 1H), 1.34–1.17 (m, 3H), 0.95–0.77 (m, 2H).</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Methyl 4-[1,7-bis[(4-Methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-b]pyridin-4-yl]cyclohexanecarboxylate (<b>76</b>)</h3><div class="NLM_p last">To a solution of methyl 4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-4,5-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexanecarboxylate <b>75</b> (794 mg, 1.49 mmol) in 1,4-dioxane (50 mL) was added DDQ (576 mg, 2.54 mmol), and the reaction mixture was heated at 100 °C for 1 h. After cooling to rt, volatiles were removed by rotary evaporation and the residue was purified by chromatography (ISCO CombiFlash, 40 g silica gel column, heptane/EtOAc 100:0 → 0:100) to afford methyl 4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexanecarboxylate <b>76</b> (810 mg, 87%) as a semisolid. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.53–7.48 (m, 2H), 7.11–7.06 (m, 2H), 6.86–6.82 (m, 2H), 6.80–6.76 (m, 2H), 6.17 (s, 1H), 5.29 (s, 2H), 5.27 (s, 2H), 3.79 (s, 3H), 3.76 (s, 3H), 3.68 (s, 3H), 2.75–2.67 (m, 1H), 2.44 (s, 3H), 2.38 (tt, <i>J</i> = 12.2, 3.7 Hz, 1H), 2.16–2.09 (m, 2H), 2.00–1.93 (m, 2H), 1.62–1.51 (m, 2H), 1.50–1.39 (m, 2H).</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 4-[1,7-bis[(4-Methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-b]pyridin-4-yl]cyclohexanecarboxylic acid (<b>77</b>)</h3><div class="NLM_p last">A solution of LiOH·H<sub>2</sub>O (29.7 mg, 0.709 mmol) in water (1 mL) was added to a solution of methyl 4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexanecarboxylate <b>76</b> (289 mg, 0.545 mmol) in THF (5 mL). The reaction mixture was stirred overnight at rt and then at 40 °C for 3 days. The reaction mixture was poured into water (20 mL), and the aqueous phase was washed with EtOAc (3 × 10 mL). The aqueous phase was then acidified with 4 M HCl (pH = 3), and the product was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and evaporated to afford 4-[1,7-<i>bis</i>[(4-methoxyphenyl)methyl]-3-methyl-6-oxo-pyrazolo[3,4-<i>b</i>]pyridin-4-yl]cyclohexanecarboxylic acid <b>77</b> (142 mg, 50%), which was used without purification in the next step. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.06 (br s, 1H), 7.31–7.27 (m, 2H), 7.17–7.13 (m, 2H), 6.90–6.86 (m, 2H), 6.83–6.79 (m, 2H), 5.95 (s, 1H), 5.32 (s, 2H), 5.09 (s, 2H), 3.72 (s, 3H), 3.70 (s, 3H), 2.83–2.76 (m, 1H), 2.52 (s, 3H), 2.27 (tt, <i>J</i> = 12.0, 3.6 Hz, 1H), 2.02–1.95 (m, 2H), 1.90–1.83 (m, 2H), 1.55–1.37 (m, 4H).</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 2-[<i>trans</i>-4-(3-Methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]acetic acid (<b>78</b>)</h3><div class="NLM_p last">To a stirred solution of 2-[<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-<i>b</i>]pyridin-4-yl)cyclohexyl]acetonitrile <b>21</b> (450 mg, 1.66 mmol) in 1,4-dioxane (4.5 mL) was added conc. HCl (1 mL). The resulting reaction mixture was stirred at 100 °C for 24 h. The mixture was concentrated under reduced pressure. The residue was diluted with water (5 mL), and the resulting precipitate was filtered, washed with water, and dried under vacuum to afford 2-[<i>trans</i>-4-(3-methyl-6-oxo-2,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]acetic acid <b>78</b> (400 mg, 83%) as a pale brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.00 (br s, 3H), 5.80 (s, 1H), 2.71 (t, <i>J</i> =11.6 Hz, 1H), 2.45 (s, 3H), 2.15 (d, <i>J</i> = 6.8 Hz, 2H), 1.85 (d, <i>J</i> = 10.4 Hz, 4H), 1.75–1.73 (m, 1H), 1.40 (q, <i>J</i> = 12.8 Hz, 2H), 1.16 (q, <i>J</i> = 11.2 Hz, 2H).</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> [(1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexyl]methanol (<b>80</b>)</h3><div class="NLM_p last">To a solution of methyl (1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexanecarboxylate <b>79</b> [1] (3.00 g, 19.2 mmol) in THF (30 mL) was added 1 M LiAlH<sub>4</sub> in THF (38.4 mL, 38.4 mmol) slowly at −30 °C. The resulting mixture was stirred at −30 °C for 2 h and then warmed to 0 °C. The reaction was quenched with NH<sub>4</sub>Cl (sat), and the mixture was extracted with diethyl ether (2 × 100 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel column, DCM) to afford [(1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexyl]methanol <b>80</b> (2.04 g, 83%) as a light yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.56–3.44 (m, 2H), 2.39–2.37 (m, 3H), 1.95 (m, 1H), 1.65 (m, 2H), 1.46–1.36 (m, 6H), 0.80 (m, 3H).</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexanecarbaldehyde (<b>59d</b>)</h3><div class="NLM_p last">To a solution of [(1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexyl]methanol <b>80</b> (2.04 g, 15.9 mmol) in DCM (60 mL) was added NaHCO<sub>3</sub> (1.31 g, 15.9 mmol) followed by Dess–Martin periodinane (9.94 g, 23.4 mmol) slowly at 0 °C. The resulting mixture was stirred at rt for 3 h. On completion, the reaction mixture was diluted with DCM (100 mL) and filtered through celite. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel column, petroleum ether/EtOAc 90:10) to afford (1<i>S</i>*,2<i>R</i>*)-2-methylcyclohexanecarbaldehyde <b>59d</b> (0.600 g, 30%) as a light yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.85 (s, 1H), 2.40 (m, 1H), 2.21 (m, 1H), 1.85 (m, 1H), 1.79–1.45 (m, 6H), 1.35 (m, 1H), 0.90 (m, 3H).</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Isopropyl 5-Norbornene-2-exo-carboxylate (<b>82</b>) and isopropyl 5-norbornene-2-endo-carboxylate (<b>83</b>)</h3><div class="NLM_p">Adapted from Ricks et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> To a solution of 5-norbornene-2-carboxylic acid <b>81</b> (commercial grade, <i>endo</i>/<i>exo</i> mixture, 1.38 g, 10.0 mmol) in 1,2-dichloroethane (10 mL) were added DMAP (367 mg, 3.00 mmol), 2-propanol (0.91 mL, 12 mmol), and EDCI (2.30 g, 12.0 mmol). The resulting white suspension was stirred at rt (slightly exothermic) for 2 h, at which point a clear solution was obtained and thin-layer chromatography (TLC) showed complete consumption of the starting material. The solution was poured into water/sat. NaHCO<sub>3</sub> solution 1:1 (70 mL), and the mixture was extracted with DCM (2 × 80 mL). The combined organic phases were washed with brine (70 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and volatiles were evaporated to afford a turbid, pale yellow oil. The <i>endo</i> and <i>exo</i> isomers were separated by chromatography in two stages. First, the crude product was purified using a Grace Reveleris system (silica gel column, heptane/EtOAc 100:0 → 90:10) to afford one fraction containing a ∼4:1 <i>endo</i>/<i>exo</i> mixture (1.38 g, colorless liquid) followed by a second fraction containing the pure <i>endo</i> isomer <b>83</b> (311 mg). The first fraction was then purified again by column chromatography (silica gel column, heptane:diisopropyl ether: 98:2) to afford one fraction containing the pure <i>exo</i> isomer <b>82</b> (353 mg, 14%, colorless liquid, contains ∼25% heptane), followed by a second fraction containing the pure <i>endo</i> isomer <b>83</b> (878 mg). This was combined with the pure <i>endo</i> fraction from the first chromatographic separation to afford the pure <i>endo</i> isomer <b>83</b> (1.05 g, 55%).</div><div class="NLM_p">Isopropyl 5-norbornene-2-<i>exo</i>-carboxylate <b>82</b>: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.16–6.07 (m, 2H), 5.01 (hept, <i>J</i> = 6.3 Hz, 1H), 3.02 (br s, 1H), 2.91 (br s, 1H), 2.22–2.14 (m, 1H), 1.96–1.86 (m, 1H), 1.56–1.49 (m, 1H), 1.42–1.29 (m, 2H), 1.24 (dd, <i>J</i> = 6.3, 1.0 Hz, 6H).</div><div class="NLM_p last">Isopropyl 5-norbornene-2-<i>endo</i>-carboxylate <b>83</b>: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.18 (dd, <i>J</i> = 5.7, 3.0 Hz, 1H), 5.92 (dd, <i>J</i> = 5.7, 2.8 Hz, 1H), 4.94 (hept, <i>J</i> = 6.3 Hz, 1H), 3.20 (s, 1H), 2.96–2.84 (m, 2H), 1.94–1.81 (m, 1H), 1.48–1.37 (m, 2H), 1.34–1.23 (m, 2H), 1.20 (dd, <i>J</i> = 6.3, 1.8 Hz, 6H).</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 5-Norbornene-2-endo-methanol (<b>84</b>)</h3><div class="NLM_p last">Adapted from Ricks et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> To a solution of isopropyl 5-norbornene-2-<i>endo</i>-carboxylate (500 mg, 2.77 mmol) in THF (6 mL) was added 1 M LiAlH<sub>4</sub> solution in THF (1.75 mL, 1.75 mmol) over 2 min at rt. The resulting pale yellow solution was stirred for 1 h at 40 °C and then cooled to rt. The reaction was quenched by the sequential addition of water (70 μL), 15% aq. NaOH (70 μL), and water (210 μL). The solid precipitate formed was removed by filtration, and the filter cake was washed with diethyl ether (30 mL). The filtrate was washed with brine (30 mL), and the aqueous layer was extracted with diethyl ether (30 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, and volatiles were evaporated to afford 5-norbornene-2-<i>endo</i>-methanol <b>84</b> as a colorless oil (408 mg) that was used without purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.15 (dd, <i>J</i> = 5.8, 3.0 Hz, 1H), 5.96 (dd, <i>J</i> = 5.8, 2.9 Hz, 1H), 3.40 (dd, <i>J</i> = 10.3, 6.5 Hz, 1H), 3.26 (dd, <i>J</i> = 10.5, 8.8 Hz, 1H), 2.93 (br s, 1H), 2.81 (br s, 1H), 2.37–2.22 (m, 1H), 1.82 (ddd, <i>J</i> = 11.6, 9.2, 3.8 Hz, 1H), 1.50–1.41 (m, 1H), 1.30–1.22 (m, 1H), 0.53 (ddd, <i>J</i> = 11.6, 4.5, 2.6 Hz, 1H).</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Norbornane-2-endo-methanol (<b>85</b>)</h3><div class="NLM_p last">To a solution 5-norbornene-2-<i>endo</i>-methanol <b>84</b> (∼90% purity, 185 mg, 1.34 mmol) in EtOAc (4.6 mL) was added 10% Pd/C (18.5 mg, 0.0174 mmol). The reaction was hydrogenated for 4 h 10 min at rt and ambient pressure (complete conversion by TLC). The catalyst was removed by filtration, and the filtrate was evaporated to afford norbornane-2-<i>endo</i>-methanol <b>85</b> (∼90% purity, 181 mg, 96%) as a colorless oil that was used without purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.70–3.43 (m, 2H), 2.27 (br s, 1H), 2.20 (br s, 1H), 2.14–1.98 (m, 1H), 1.72 (ddd, <i>J</i> = 12.0, 4.7, 2.9 Hz, 1H), 1.61–1.44 (m, 2H), 1.41–1.24 (m, 3H), 1.14–1.01 (m, 1H), 0.63 (ddd, <i>J</i> = 12.2, 5.2, 2.2 Hz, 1H).</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Norbornane-2-endo-carbaldehyde (<b>59f</b>)</h3><div class="NLM_p last">To a solution of oxalyl chloride (0.16 mL, 1.9 mmol) in DCM (8.5 mL) at −75 °C was added a solution of DMSO (0.183 mL, 2.58 mmol) in DCM (0.45 mL) via a syringe over 4 min while maintaining the temperature between −75 and −70 °C. The resulting colorless solution was stirred for 10 min at −75 °C. Then, a solution of norbornane-2-<i>endo</i>-methanol <b>85</b> (163 mg, 1.29 mmol) in DCM (1.5 mL) was added via a syringe over 3 min while maintaining the temperature between −75 and −70 °C. After 30 min at −75 °C, triethylamine (0.600 mL, 4.30 mmol) was added via syringe over 3 min at −75 to −68 °C. The viscous colorless solution was stirred for a further 20 min at −75 °C. The cooling bath was then removed, and the mixture was warmed to rt over 30 min. After a further 30 min at rt, the resulting white turbid mixture was washed with water (30 mL). The aqueous phase was extracted with DCM (30 mL), and the combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under evaporation at maximum 30 °C/50 mbar to afford a yellow turbid oil. The crude product was purified by column chromatography (silica gel column, petroleum ether/TBME 99:1 → 98:2) to afford norbornane-2-<i>endo</i>-carbaldehyde (115 mg, 68%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.77 (<i>d</i>, <i>J</i> = 1.1 Hz, 1H), 2.77–2.66 (m, 2H), 2.31 (br t, 1H), 1.73–1.47 (m, 3H), 1.47–1.33 (m, 2H), 1.32–1.18 (m, 2H), 0.93–0.80 (m, 1H).</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Norbornane-2-exo-carbaldehyde (<b>59e</b>)</h3><div class="NLM_p last">Prepared using the method described above for the <i>endo</i> isomer <b>59f</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.63 (d, <i>J</i> = 1.5 Hz, 1H), 2.61–2.53 (m, 1H), 2.38–2.27 (m, 2H), 1.95–1.84 (m, 1H), 1.69–1.47 (m, 3H), 1.40–1.19 (m, 3H), 0.94–0.78 (m, 1H).</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Methyl <i>trans</i>-4-(Methylsulfonyloxymethyl)cyclohexanecarboxylate (<b>89</b>)</h3><div class="NLM_p last">To a solution of methyl <i>trans</i>-4-(hydroxymethyl)cyclohexanecarboxylate <b>88</b> (836 mg, 4.85 mmol) in DCM (10 mL) was added Et<sub>3</sub>N (1.01 mL, 7.28 mmol). The solution was cooled in an ice bath, and MsCl (451 μL, 5.83 mmol) was added dropwise over 5 min. The mixture was stirred at 0 °C for 20 min, after which the reaction was quenched by the addition of water (20 mL), 4 N HCl (1.8 mL, 7.3 mmol), and DCM (20 mL). The layers were separated, the organic layer was washed with sat. NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered, and evaporated to afford methyl <i>trans</i>-4-(methylsulfonyloxymethyl)cyclohexanecarboxylate <b>89</b> (1.21 g, 99%), which was used without purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.01 (d, <i>J</i> = 6.2 Hz, 2H), 3.59 (s, 3H), 3.15 (s, 3H), 2.25 (tt, <i>J</i> = 12.2, 3.6 Hz, 1H), 2.00–1.87 (m, 2H), 1.85–1.72 (m, 2H), 1.72–1.56 (m, 1H), 1.43–1.25 (m, 2H), 1.21–0.95 (m, 2H).</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Methyl <i>trans</i>-4-(cyanomethyl)cyclohexanecarboxylate (<b>90</b>)</h3><div class="NLM_p last">A solution of methyl <i>trans</i>-4-(methylsulfonyloxymethyl)cyclohexanecarboxylate <b>89</b> (1.22 g, 4.87 mmol) in DMSO (2 mL) was added to a suspension of KCN (635 mg, 9.75 mmol) in DMSO (2 mL), and the mixture was stirred at rt for 30 min. The mixture was diluted with water (20 mL) and sat. NaHCO<sub>3</sub> (3 mL). It was extracted with ether (3 × 20 mL), and the combined extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered, and evaporated to dryness to afford methyl <i>trans</i>-4-(cyanomethyl)cyclohexanecarboxylate <b>90</b> (720 mg, 81%), which was used without purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.58 (s, 3H), 2.44 (d, <i>J</i> = 6.5 Hz, 2H), 2.24 (tt, <i>J</i> = 12.2, 3.6 Hz, 1H), 1.98–1.85 (m, 2H), 1.84–1.71 (m, 2H), 1.69–1.49 (m, 1H), 1.44–1.25 (m, 2H), 1.17–0.97 (m, 2H).</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 2-[<i>trans</i>-4-(Hydroxymethyl)cyclohexyl]acetonitrile (<b>91</b>)</h3><div class="NLM_p last">To a solution of methyl <i>trans</i>-4-(cyanomethyl)cyclohexanecarboxylate <b>90</b> (720 mg, 3.97 mmol) in dry THF (20 mL) was added 2.0 M LiBH<sub>4</sub> solution in THF (4.0 mL, 8.0 mmol), and the resulting colorless solution was stirred at rt for 2 h and then at 40 °C overnight. The reaction was quenched by the addition of brine (30 mL) and extracted with EtOAc (3 × 30 mL). The organic phase was dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford 2-[<i>trans</i>-4-(hydroxymethyl)cyclohexyl]acetonitrile <b>91</b> (571 mg, 84%) as a clear oil, which was used without purification. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.36 (t, <i>J</i> = 5.3 Hz, 1H), 3.22–3.17 (m, 2H), 2.42 (d, <i>J</i> = 6.5 Hz, 2H), 1.81–1.70 (m, 4H), 1.57–1.47 (m, 1H), 1.32–1.22 (m, 1H), 1.06–0.97 (m, 2H), 0.94–0.82 (m, 2H).</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 2-(<i>trans</i>-4-Formylcyclohexyl)acetonitrile (<b>59j</b>)</h3><div class="NLM_p last">A solution of oxalyl chloride (0.47 mL, 5.6 mmol) in DCM (25 mL) under Ar was cooled to −70 °C. A solution of DMSO (529 μL, 7.45 mmol) in DCM (2 mL) was added slowly over 5 min such that the temperature was kept between −65 and −70 °C. The reaction mixture was stirred at −70 °C for 15 min. A solution of 2-[<i>trans</i>-4-(hydroxymethyl)cyclohexyl]acetonitrile <b>91</b> (571 mg, 3.73 mmol) in DCM (5 mL) was added slowly such that the temperature was kept between −75 and −70 °C. The reaction mixture was stirred at −75 °C for 30 min, after which Et<sub>3</sub>N (1.73 mL, 12.4 mmol) was added dropwise such that the temperature was kept between −74 and −68 °C. The resulting solution was stirred at −75 °C for 30 min. The cooling bath was removed, and the temperature was raised to room temperature over 30 min. After a further 5 min at room temperature, the clear yellow solution was quenched with 150 mL of water. The phases were separated, and the aqueous phase was extracted with DCM (2 × 100 mL). The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated by evaporation to afford 2-(<i>trans</i>-4-formylcyclohexyl)acetonitrile <b>59j</b> (500 mg, 75%) as a clear oil, which was used without purification.</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Benzyl 5-Norbornene-2-carboxylate (<b>92</b> and <b>93</b>)</h3><div class="NLM_p">Adapted from Ricks et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> To a solution of 5-norbornene-2-carboxylic acid <b>81</b> (commercial grade, <i>endo</i>/<i>exo</i> mixture, 20 g, 50.0 mmol) in DCM (600 mL) were added benzyl alcohol (18 mL, 28.5 mmol), DCC (31.6 g, 53.0 mmol), and DMAP (17.6 g, 50.0 mmol), and the resulting mixture was stirred at rt for 16 h. The reaction mixture was washed with 1 N NaOH followed by 1 N HCl. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel column, petroleum ether/EtOAc 98:2) to afford benzyl 5-norbornene-2-<i>endo</i>-carboxylate <b>92</b> (10 g, 26%) and benzyl 5-norbornene-2-<i>exo</i>-carboxylate <b>93</b> (2 g, 10%) as light yellow oils.</div><div class="NLM_p">Benzyl 5-norbornene-2-<i>endo</i>-carboxylate <b>92</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.30 (m, 5H), 6.16 (d, <i>J</i> = 4.0 Hz, 1H), 5.82 (d, <i>J</i> = 4.0 Hz, 1H), 5.04 (s, 2H), 3.32 (s, 1H), 3.14–3.06 (m, 2H), 2.86 (s, 1H), 1.90–1.89 (m, 1H), 1.31–1.27 (m, 2H).</div><div class="NLM_p last">Benzyl 5-norbornene-2-<i>exo</i>-carboxylate <b>93</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.30 (m, 5H), 6.18–6.15 (m, 2H), 5.04 (s, 2H), 3.15 (s, 1H), 2.90 (m, 2H), 2.15 (m, 1H), 1.95 (m, 1H), 1.56 (m, 1H), 1.45 (m, 1H).</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Benzyl (1<i>S</i>*,2<i>R</i>*,4<i>S</i>*,5<i>R</i>*)-5-hydroxynorbornane-2-carboxylate (<b>94</b>) and benzyl (1<i>R</i>*,2<i>R</i>*,4<i>S</i>*,6<i>S</i>*)-6-hydroxynorbornane-2-carboxylate (<b>95</b>)</h3><div class="NLM_p">Adapted from Chen et al.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> To a solution of benzyl 5-norbornene-2-<i>exo</i>-carboxylate <b>93</b> (15 g, 65.7 mmol) in THF (150 mL) was added 1 M BH<sub>3</sub>. THF (263 mL, 263 mmol) slowly at −5 °C under argon. The mixture was stirred at −5 °C for 1 h, after which 1 M KH<sub>2</sub>PO<sub>4</sub> (200 mL) and 30% H<sub>2</sub>O<sub>2</sub> (300 mL) were added sequentially. The resulting mixture was stirred at −5 °C for 2 h. The reaction mixture was diluted with brine and extracted with EtOAc (2 × 500 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel column; petroleum ether/EtOAc, 70:30) to afford benzyl (1<i>S*</i>,2<i>R*</i>,4<i>S*</i>,5<i>R*</i>)-5-hydroxynorbornane-2-carboxylate <b>94</b> (4 g, 25%) and benzyl (1<i>R*</i>,2<i>R*</i>,4<i>S*</i>,6<i>S*</i>)-6-hydroxynorbornane-2-carboxylate <b>95</b> (4 g, 25%) as light yellow oils.</div><div class="NLM_p">Benzyl (1<i>S*</i>,2<i>R*</i>,4<i>S*</i>,5<i>R*</i>)-5-hydroxynorbornane-2-carboxylate <b>94:</b><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.40–7.27 (m, 5H), 5.10 (s, 2H), 3.85–3.76 (m, 1H), 2.60–2.55 (m, 1H), 2.32–2.20 (m, 2H), 1.95–1.84 (m, 1H), 1.81–1.66 (m, 1H), 1.63–1.53 (m, 1H) 1.51–1.16 (m, 3H).</div><div class="NLM_p last">Benzyl (1<i>R*</i>,2<i>R*</i>,4<i>S*</i>,6<i>S*</i>)-6-hydroxynorbornane-2-carboxylate <b>95:</b><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.35 (s, 5H), 5.11 (d, <i>J</i> = 1.5 Hz, 2H), 3.83 (br d, <i>J</i> = 6.9 Hz, 1H), 2.45 (s, 1 H), 2.34 (br s, 1H), 2.22 (dd, <i>J</i> = 9.0, 5.7 Hz, 1H) 1.85–1.76 (m, 1H), 1.72–1.63 (m, 1H), 1.60–1.53 (m, 1H), 1.42–1.24 (m, 3H).</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Benzyl (1<i>S</i>*,2<i>R</i>*,4<i>S</i>*)-5-Oxonorbornane-2-carboxylate (<b>96</b>)</h3><div class="NLM_p last">To a solution of benzyl (1<i>S*</i>,2<i>R*</i>,4<i>S*</i>,5<i>R*</i>)-5-hydroxynorbornane-2-carboxylate <b>94</b> (3.8 g, 15.4 mmol) in DCM (80 mL) was added Dess–Martin periodinane (6.54 g, 15.4 mmol) at 0 °C, and the mixture was stirred at rt for 3 h. The reaction mixture was diluted with DCM (100 mL), filtered through a celite pad, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel column, petroleum ether/EtOAc 80:20) to afford benzyl (1<i>S*</i>,2<i>R*</i>,4<i>S*</i>)-5-oxonorbornane-2-carboxylate <b>96</b> (2 g, 54%) as a light yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.40–7.32 (m, 5H), 5.15 (s, 2H), 2.97–2.91 (m, 1H), 2.70–2.59 (m, 2H), 2.29–2.09 (m, 2H), 1.98–1.81 (m, 2H), 1.76–1.65 (m, 2H).</div></div><div id="sec4_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Benzyl (1<i>S</i>*,2<i>R</i>*,4<i>S</i>*)-5-(Cyanomethylene)norbornane-2-carboxylate (<b>97</b>)</h3><div class="NLM_p last">To a solution of potassium <i>tert</i>-butoxide (1.37 g, 12.3 mmol) in THF was added diethyl cyanomethylphosphonate (1.98 g, 12.3 mmol) at 0 °C. The resulting solution was stirred at rt for 1 h, after which benzyl (1<i>S*</i>,2<i>R*</i>,4<i>S*</i>)-5-oxonorbornane-2-carboxylate <b>96</b> (2 g, 8.19 mmol) was added, and stirring was continued for 3 h at rt. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel column, petroleum ether/EtOAc 70:30) to afford benzyl (1<i>S*</i>,2<i>R*</i>,4<i>S*</i>)-5-(cyanomethylene)norbornane-2-carboxylate <b>97</b> (1.5 g, 68%) as a viscous oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.36 (s, 5H), 5.13 (s, 2H), 5.35–5.05 (m, 1H), 3.35 (br s, 0.5H), 2.97 (br d, <i>J</i> = 2.9 Hz, 0.5H), 2.87–2.73 (m, 1H), 2.47 (br dd, <i>J</i> = 13.9, 4.8 Hz, 1H), 2.17 (br s, 2H), 1.75–1.56 (m, 2H), 1.45 (br d, <i>J</i> = 10.2 Hz, 2H).</div></div><div id="sec4_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 2-[(1<i>S</i>*,4<i>S</i>*,5<i>R</i>*)-5-(Hydroxymethyl)norbornan-2-ylidene]acetonitrile (<b>98</b>)</h3><div class="NLM_p last">To a solution of benzyl (1<i>S*</i>,2<i>R*</i>,4<i>S*</i>)-5-(cyanomethylene)norbornane-2-carboxylate <b>97</b> (1.5 g, 5.61 mmol) in THF (30 mL) was added LiBH<sub>4</sub> (0.353 g, 16.85 mmol) at 0 °C, and the resulting mixture was stirred at rt for 16 h. The reaction was quenched with sat. NH<sub>4</sub>Cl at 0 °C and extracted with EtOAc (2 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel column, petroleum ether/EtOAc 60:40) to afford 2-[(1<i>S*</i>,4<i>S*</i>,5<i>R*</i>)-5-(hydroxymethyl)norbornan-2-ylidene]acetonitrile <b>98</b> (0.8 g, 87%) as a light yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.37–5.20 (m, 1H), 3.72–3.42 (m, 2H), 3.31–3.26 (m, 0.5H), 2.90 (br d, <i>J</i> = 3.9 Hz, 0.5H), 2.54–2.46 (m, 2H), 2.29–2.21 (m, 1H), 2.15–2.05 (m, 1H), 1.82–1.71 (m, 1H), 1.60–1.45 (m, 1H), 1.40 (br dd, <i>J</i> = 10.3, 1.5 Hz, 1H), 1.35–1.26 (m, 1H).</div></div><div id="sec4_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 2-[(1<i>S</i>*,4<i>S</i>*,5<i>R</i>*)-5-Formylnorbornan-2-ylidene]acetonitrile (<b>59o</b>)</h3><div class="NLM_p last">To a solution of 2-[(1<i>S*</i>,4<i>S*</i>,5<i>R*</i>)-5-(hydroxymethyl)norbornan-2-ylidene]acetonitrile <b>98</b> (0.800 g, 4.90 mmol) in DCM (30 mL) was added Dess–Martin periodinane (3.12 g, 7.36 mmol) at 0 °C, and the mixture was stirred at rt for 3 h. The reaction mixture was diluted with DCM (100 mL), filtered through a celite pad, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel column, petroleum ether/EtOAc 90:10) to afford 2-[(1<i>S*</i>,4<i>S*</i>,5<i>R*</i>)-5-formylnorbornan-2-ylidene]acetonitrile <b>59o</b> (0.750 g, 94%) as a light yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.72 (d, <i>J</i> = 6.9 Hz, 1H), 5.08 (s, 1H), 3.40 (br d, <i>J</i> = 3.9 Hz, 1H), 3.09–2.95 (m, 1H), 2.87 (br dd, <i>J</i> = 15.9, 3.7 Hz, 2H), 2.61–2.30 (m, 2H), 2.27–2.13 (m, 1H), 1.65–1.50 (m, 2H).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00359" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00359?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00359</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">General biological experimental procedures; NMR spectra for the structure elucidation of compound <b>50</b> and determination of the relative stereochemistry of compounds <b>39</b>–<b>42</b>; UPLC chromatograms of compounds <b>21</b>, <b>27</b>, and <b>40</b>; and details of the kinase panel screen (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf">jm0c00359_si_001.pdf (602.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_002.csv">jm0c00359_si_002.csv (7.88 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPD">6TPD</a> for <b>6</b>; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPE">6TPE</a> for <b>21</b>; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPF">6TPF</a> for <b>27</b>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00359" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Ritzén</span> - <span class="hlFld-Affiliation affiliation">MedChem
II, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3313-3753" title="Orcid link">http://orcid.org/0000-0002-3313-3753</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0e6a687c6a654e626b61237e666f7c636f206d6163"><span class="__cf_email__" data-cfemail="a3c7c5d1c7c8e3cfc6cc8ed3cbc2d1cec28dc0ccce">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bettina Borreschmidt Hansen</span> - <span class="hlFld-Affiliation affiliation">MedChem
II, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tue Heesgaard Jepsen</span> - <span class="hlFld-Affiliation affiliation">MedChem
II, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mogens Larsen</span> - <span class="hlFld-Affiliation affiliation">MedChem
II, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rikke Sindet</span> - <span class="hlFld-Affiliation affiliation">MedChem
II, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Vifian</span> - <span class="hlFld-Affiliation affiliation">MedChem
II, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mia Nørreskov Burhardt</span> - <span class="hlFld-Affiliation affiliation">MedChem
II, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jens Larsen</span> - <span class="hlFld-Affiliation affiliation">MedChem
II, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jimmi Gerner Seitzberg</span> - <span class="hlFld-Affiliation affiliation">MedChem
II, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin A. Carnerup</span> - <span class="hlFld-Affiliation affiliation">DMPK, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Jerre</span> - <span class="hlFld-Affiliation affiliation">Skin Research, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span>; 
    <span>Present Address:
                        SenzaGen AB, Medicon Village, Building 401, Scheelevägen 2, 223 81 Lund, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christina Mølck</span> - <span class="hlFld-Affiliation affiliation">Skin Research, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paola Lovato</span> - <span class="hlFld-Affiliation affiliation">Skin Research, , and , LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sanjay Rai</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, GVK Biosciences Private Limited, 28 A, IDA Nacharam, Hyderabad 500076, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Venkatarathnam Reddy Nasipireddy</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, GVK Biosciences Private Limited, 28 A, IDA Nacharam, Hyderabad 500076, India</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>T.H.J., M.L., M.N.B., J.L., J.G.S., and A.R. contributed to the design of compounds, computer modeling, and interpretation of results. B.B.H., T.H.J., M.L., R.S., T.V., S.R., and V.R.N. designed the synthetic routes and synthesized compounds. M.A.C. performed the pharmacokinetic studies. A.J. and C.M. performed the enzymatic and cell-based JAK assays. A.R. and P.L. wrote the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>All funding for the work was provided by LEO Pharma A/S.</p></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d7e7682-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i101">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Anja Jestel, Alfred Lammens, Andreas Griessner, and Michael Blaesse from Proteros Biostructures GmbH for X-ray structure determination of human JAK1 in complex with compounds <b>21</b> and <b>27</b> (PDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPE">6TPE</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPF">6TPF</a>). They also thank Jhansi Athava, Kammari Rammurthy, Kumar Ravivalasa, Vennam Sruthi, Ruili Yuan, and Shubao Zhou for performing syntheses of compounds.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Aq. sol.</td><td class="NLM_def"><p class="first last">aqueous solubility</p></td></tr><tr><td class="NLM_term"><i>c</i>-Pr</td><td class="NLM_def"><p class="first last">cyclopropyl</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DFT</td><td class="NLM_def"><p class="first last">density functional theory</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[<i>bis</i>(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand lipophilic efficiency</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved Förster resonance energy transfer</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">UPLC</td><td class="NLM_def"><p class="first last">ultraperformance liquid chromatography</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0liv4Q2ZWlCNcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">B. Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lj1TYlMAUGScg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DB.%2BLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R.</span></span> <span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0lj1TYlMAUGScg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span> <span> </span><span class="NLM_article-title">Case History: Xeljanz (tofacitinib citrate), a first-in-class janus kinase inhibitor for the treatment of rheumatoid arthritis</span>. <i>Annu. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-800167-7.00025-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2FB978-0-12-800167-7.00025-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOqtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2014&pages=399-416&author=M.+E.+Flanaganauthor=M.+F.+Brownauthor=C.+Subramanyamauthor=M.+J.+Munchhof&title=Case+History%3A+Xeljanz+%28tofacitinib+citrate%29%2C+a+first-in-class+janus+kinase+inhibitor+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2FB978-0-12-800167-7.00025-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Case history: Xeljanz (Tofacitinib citrate), a first-in-class janus kinase inhibitor for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Flanagan, Mark E.; Brown, Matthew F.; Subramanyam, Chakrapani; Munchhof, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">399-416, 3 plates</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Xeljanz is a first-in-class janus kinase inhibitor for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVulYxfr7x07Vg90H21EOLACvtfcHk0lhO9F0Z6TCDoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOqtLzN&md5=c91e0e9e6f918dcb01cd861bbd8358ee</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-800167-7.00025-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-800167-7.00025-0%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26atitle%3DCase%2520History%253A%2520Xeljanz%2520%2528tofacitinib%2520citrate%2529%252C%2520a%2520first-in-class%2520janus%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2014%26volume%3D49%26spage%3D399%26epage%3D416%26doi%3D10.1016%2FB978-0-12-800167-7.00025-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting cytokine signaling in autoimmunity: back to the future and beyond</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.coi.2016.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2Fj.coi.2016.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=27821272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWht7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=89-97&author=K.+Hiraharaauthor=D.+Schwartzauthor=M.+Gadinaauthor=Y.+Kannoauthor=J.+J.+O%E2%80%99Shea&title=Targeting+cytokine+signaling+in+autoimmunity%3A+back+to+the+future+and+beyond&doi=10.1016%2Fj.coi.2016.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cytokine signaling in autoimmunity: back to the future and beyond</span></div><div class="casAuthors">Hirahara, Kiyoshi; Schwartz, Daniella; Gadina, Massimo; Kanno, Yuka; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-97</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cytokines represent structurally diverse sol. factors with crit. roles in normal immune function and the pathogenesis of autoimmunity.  The emergence of many successful biol. therapies targeting cytokines and cytokine receptors exemplifies the importance of cytokines in driving human autoimmune disease; unsurprisingly, there is no paucity of reviews on this subject.  Nonetheless, many patients with autoimmune disease do not respond to biologicals, and cure remains an unmet goal.  Thus, targeting the intracellular pathways employed by cytokines provides new therapeutic opportunities.  A subset of cytokines utilizes the Janus kinase-signal transducer of activators of transcription (JAK-STAT) pathway as a mode of signal transduction.  First generation JAK inhibitors (jakinibs) are used to treat rheumatol. disease, and second-generation jakinibs are being developed.  Simultaneously, rapid advances are being made in our understanding of the genomic and epigenomic impact of cytokines.  In this review, we will briefly review the role of JAK-STAT-dependent cytokines in immune-mediated disease, the current status of Jakinibs, and future possibilities for therapeutic intervention using genomic insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoU3YQbIRsnLVg90H21EOLACvtfcHk0lhO9F0Z6TCDoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWht7zF&md5=7330f7c6a749cebfa90305e771d63d66</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2016.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2016.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DSchwartz%26aufirst%3DD.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520cytokine%2520signaling%2520in%2520autoimmunity%253A%2520back%2520to%2520the%2520future%2520and%2520beyond%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2016%26volume%3D43%26spage%3D89%26epage%3D97%26doi%3D10.1016%2Fj.coi.2016.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craiglow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B.</span></span> <span> </span><span class="NLM_article-title">Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">2988</span>– <span class="NLM_lpage">2990</span>, <span class="refDoi"> DOI: 10.1038/jid.2014.260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1038%2Fjid.2014.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=24940651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOjsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=2988-2990&author=B.+Craiglowauthor=B.+King&title=Killing+two+birds+with+one+stone%3A+oral+tofacitinib+reverses+alopecia+universalis+in+a+patient+with+plaque+psoriasis&doi=10.1038%2Fjid.2014.260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis</span></div><div class="casAuthors">Craiglow, Brittany G.; King, Brett A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2988-2990</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TO THE EDITOR The patient is a 25-yr-old male who presented for evaluation and management of plaque psoriasis, which had begun 5 years earlier.  Treatment with topical corticosteroids had not been particularly helpful, and, because of the involvement of psoriasis over an increasing body surface area, systemic therapy with adalimumab had been initiated 1 yr before.  Although clearing of psoriasis was experienced early in the course of adalimumab, the improvement faded.  In addn. to psoriasis, the patient reported a history of alopecia areata (AA) beginning at around age 2 years, which progressed to alopecia universalis (AU) by age 18 years.  Treatment of the alopecia with topical corticosteroids had not been effective, and he had received no other therapy for it.  He had no family history of either psoriasis or AA, and his past medical history was otherwise unremarkable.  On examn., the patient demonstrated numerous well-marginated pink-red scaly plaques on the scalp, torso, and elbows.  He had no eyebrows, eyelashes (Figure 1a), or facial hair, and no hair on his arms, legs, torso, axillae, or groin.  Notably, the only prominent hair growth on the scalp was within areas of psoriasis (Figure 2a), reminiscent of hair growth that occurs in areas of irritant contact dermatitis generated by topical anthralin (Schmoeckel et al., 1979).  As treatment options for the patient were considered, we sought a therapeutic agent that could potentially target both psoriasis and AU simultaneously.  We identified tofacitinib as a promising agent and began treatment.  Tofacitinib citrate (Xeljanz), formerly CP-690550 and tasocitinib, is a novel small-mol. selective Janus kinase 1/3 (JAK 1/3) inhibitor that was FDA-approved in late 2012 for the treatment of moderate-to-severe rheumatoid arthritis (RA).  JAK inhibition has myriad effects on T-lymphocytes, and therefore it is not surprising that this medication may be useful in the treatment of many inflammatory diseases (Pesu et al., 2005).  Indeed, both oral and topical formulations of tofacitinib have been demonstrated to be safe and effective for the treatment of plaque psoriasis (Boy et al., 2009; Papp et al., 2012; Mamolo et al., 2013; Ports et al., 2013; Strober et al., 2013), with addnl. clin. trials for psoriasis and other inflammatory disorders now underway (clinicaltrials.gov).  In the case of psoriasis, increased interleukin-15 (IL-15) expression is obsd. in lesional skin and may lead to epidermal hyperproliferation via keratinocyte apoptotic resistance (Ruckert et al., 2000).  Tofacitinib, which abrogates IL-15 signaling (Johnston et al., 1995), might therefore be effective in psoriasis by normalizing keratinocyte apoptosis (Ruckert et al., 2000).  In a murine model of AA, a type I cytotoxic pathway has been demonstrated to be responsible for the disease state, with NKG2D-expressing CD8+ cytolytic T-lymphocytes identified as both necessary and sufficient for induction of disease.  Upregulation of IL-15 in the outer root sheath of the hair follicle activates cytolytic T-lymphocytes, which in turn produce IFNγ, leading to activation of the hair follicle and upregulation of IL-15, NKG2D ligands, and MHC mols., all of which target the hair follicle for attack (Jabbari et al., 2013).  The same group has demonstrated that systemic treatment with the JAK inhibitors tofacitinib and ruxolitinib (a JAK 1/2 inhibitor) prevents the onset of AA in grafted AA mice (Dai et al., 2012; Jabbari et al., 2012) and that topical treatment reverses AA in these mice (Jabbari et al., 2013).  JAK 1/3 signaling mediates IL-15 activation of T-lymphocytes (Ghoreschi et al., 2011), explaining the success of these therapies.  After 2 mo of tofacitinib at 5 mg twice daily (the approved RA dose), there was some improvement in psoriasis with partial hair regrowth on the scalp (Figure 2b) and face.  Given that higher doses of tofacitinib (up to 15 mg twice daily) have been shown to be more effective in psoriasis (Papp et al., 2012), the dose was increased to 10 mg in the morning and 5 mg at night.  After 3 more months of therapy, there was complete regrowth of the scalp hair (Figure 2c) along with significant regrowth of eyebrows, eyelashes, and facial hair along with axillary and pubic hair.  After 8 mo of therapy, there was full regrowth of hair at all body sites (Figures 1b and 2d), except for the arms and legs, locations where the patient reports never having more than sparse hair growth prior to the onset of AU.  Improvement of psoriasis has lagged behind reversal of alopecia, which is likely dose-related (Papp et al., 2012).  Although we considered increasing the dose of tofacitinib, the patient is so pleased with the regrowth of his hair (and is not particularly bothered by the remaining psoriasis) that he has chosen to continue at the present dose.  The patient has tolerated tofacitinib without subjective complaints.  Lab. monitoring has revealed no abnormalities in serum creatinine, electrolytes, glucose, complete blood count, hepatic function, or lipids.  To our knowledge, this is the first report of effective pathogenesis-based therapy for a patient with alopecia universalis.  Although the results in this patient are provocative, a clin. trial would more fully and systematically address the safety and efficacy of tofacitinib and other JAK inhibitors in the treatment of AA and its variants.  Aptly, an open-label pilot study evaluating the efficacy of ruxolitinib in moderate-to-severe AA is currently underway (Mackay-Wiggan, 2014).  Given the potential for serious adverse effects from oral JAK inhibitors, it would be particularly useful to explore the use of topical formulations for these disorders.  The era of biol. therapy has greatly enhanced the ability to make nuanced therapeutic decisions.  With every new agent, more thoughtful treatment algorithms become possible, permitting better treatment of complex patients with multiple comorbidities.  As in the case presented herein, seemingly disparate diseases with different pathomechanisms may be affected pos. by a single agent.  This case highlights the interplay between advances in basic science and therapeutics and provides a compelling example of the ways in which an increasingly complex understanding of medicine and ingenuity in treatment benefit patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLel5_J-hmObVg90H21EOLACvtfcHk0lhvnkqad-r_hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOjsbrM&md5=352a8f2a4fdeee0d338a961099886866</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fjid.2014.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2014.260%26sid%3Dliteratum%253Aachs%26aulast%3DCraiglow%26aufirst%3DB.%26aulast%3DKing%26aufirst%3DB.%26atitle%3DKilling%2520two%2520birds%2520with%2520one%2520stone%253A%2520oral%2520tofacitinib%2520reverses%2520alopecia%2520universalis%2520in%2520a%2520patient%2520with%2520plaque%2520psoriasis%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2014%26volume%3D134%26spage%3D2988%26epage%3D2990%26doi%3D10.1038%2Fjid.2014.260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachelez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kerkhof, P. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ubanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakusevich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papacharalambous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawadrous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)62113-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2FS0140-6736%2814%2962113-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=26051365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=552-561&author=H.+Bachelezauthor=P.+C.+M.+van+de+Kerkhofauthor=R.+Strohalauthor=A.+ubanovauthor=F.+Valenzuelaauthor=J.-H.+Leeauthor=V.+Yakusevichauthor=S.+Chimentiauthor=J.+Papacharalambousauthor=J.+Proulxauthor=P.+Guptaauthor=H.+Tanauthor=M.+Tawadrousauthor=H.+Valdezauthor=R.+Wolk&title=Tofacitinib+versus+etanercept+or+placebo+in+moderate-to-severe+chronic+plaque+psoriasis%3A+a+phase+3+randomised+non-inferiority+trial&doi=10.1016%2FS0140-6736%2814%2962113-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span></div><div class="casAuthors">Bachelez, Herve; van de Kerkhof, Peter C. M.; Strohal, Robert; Kubanov, Alexey; Valenzuela, Fernando; Lee, Joo-Heung; Yakusevich, Vladimir; Chimenti, Sergio; Papacharalambous, Jocelyne; Proulx, James; Gupta, Pankaj; Tan, Huaming; Tawadrous, Margaret; Valdez, Hernan; Wolk, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9993</span>),
    <span class="NLM_cas:pages">552-561</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New therapeutic options are needed for patients with psoriasis.  Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis.  In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.  In this phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-wk, non-inferiority trial, adult patients with chronic stable plaque psoriasis (for ≥12 mo) who were candidates for systemic or phototherapy and had a Psoriasis Area and Severity Index (PASI) score of 12 or higher and a Physician's Global Assessment (PGA) of moderate or severe, and had failed to respond to, had a contraindication to, or were intolerant to at least one conventional systemic therapy, were enrolled from 122 investigational dermatol. centers worldwide.  Eligible patients were randomly assigned in a 3:3:3:1 ratio to receive tofacitinib 5 mg or 10 mg twice daily at about 12 h intervals, etanercept 50 mg s.c. twice weekly at about 3-4 day intervals, or placebo.  Randomisation was done by a computer-generated randomisation schedule, and all patients and study personnel were masked to treatment assignment.  The co-primary endpoints were the proportion of patients at week 12 with at least a 75% redn. in the PASI score from baseline (PASI75 response) and the proportion of patients achieving a PGA score of "clear" or "almost clear" (PGA response), analyzed in the full anal. set (all patients who were randomised and received at least one dose of study drug).  This study is registered with ClinicalTrials.gov, no. NCT01241591.  Between Nov 29, 2010, and Sept 13, 2012, we enrolled 1106 eligible adult patients with chronic plaque psoriasis and randomly assigned them to the four treatment groups (330 to tofacitinib 5 mg twice daily, 332 to tofacitinib 10 mg twice daily, 336 to etanercept 50 mg twice weekly, and 108 to placebo).  Of these patients, 1101 actually received their assigned study medication (329 in the tofactinib 5 mg group, 330 in the tofacitinib 10 mg group, 335 in the etanercept group, and 107 in the placebo group).  At week 12, PASI75 responses were recorded in 130 (39·5%) of 329 patients in the tofacitinib 5 mg group, 210 (63·6%) of 330 in the tofacitinib 10 mg group, 197 (58·8%) of 335 in the etanercept group, and six (5·6%) of 107 in the placebo group.  A PGA response was achieved by 155 (47·1%) of 329 patients in the tofacitinib 5 mg group, 225 (68·2%) of 330 in the tofacitinib 10 mg group, 222 (66·3%) of 335 in the etanercept group, and 16 (15·0%) of 107 in the placebo group.  The rate of adverse events was similar across the four groups, with serious adverse events occurring in seven (2%) of 329 patients in the tofacitinib 5 mg group, five (2%) of 330 in the tofacitinib 10 mg group, seven (2%) of 335 in the etanercept group, and two (2%) of 107 in the placebo group.  Three (1%) of 329 patients in the tofacitinib 5 mg group, ten (3%) of 330 in the tofacitinib 10 mg group, 11 (3%) of 335 in the etanercept group, and four (4%) of 107 patients in the placebo group discontinued their assigned treatment because of adverse events.  In patients with moderate-to-severe plaque psoriasis, the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was superior to placebo, but the 5 mg twice daily dose did not show non-inferiority to etanercept 50 mg twice weekly.  The adverse event rates over 12 wk were similar for tofacitinib and etanercept.  This study indicates that in the future tofacitinib could provide a convenient and well-tolerated therapeutic option for patients with moderate-to-severe plaque psoriasis.Pfizer Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYcpF-XDavrVg90H21EOLACvtfcHk0lg6VZsInQtdCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J&md5=797adf1a67423e82ce47d96aa87daa6b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962113-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962113-9%26sid%3Dliteratum%253Aachs%26aulast%3DBachelez%26aufirst%3DH.%26aulast%3Dvan%2Bde%2BKerkhof%26aufirst%3DP.%2BC.%2BM.%26aulast%3DStrohal%26aufirst%3DR.%26aulast%3Dubanov%26aufirst%3DA.%26aulast%3DValenzuela%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DYakusevich%26aufirst%3DV.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTawadrous%26aufirst%3DM.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%2520versus%2520etanercept%2520or%2520placebo%2520in%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%253A%2520a%2520phase%25203%2520randomised%2520non-inferiority%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D552%26epage%3D561%26doi%3D10.1016%2FS0140-6736%2814%2962113-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0lg6VZsInQtdCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayamada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus kinases to jakinibs: from basic insights to clinical practice</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">i4</span>– <span class="NLM_lpage">i16</span>, <span class="refDoi"> DOI: 10.1093/rheumatology/key432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1093%2Frheumatology%2Fkey432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=30806710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkt12jsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=i4-i16&author=M.+Gadinaauthor=M.+T.+Leauthor=D.+M.+Schwartzauthor=O.+Silvennoinenauthor=S.+Nakayamadaauthor=K.+Yamaokaauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+to+jakinibs%3A+from+basic+insights+to+clinical+practice&doi=10.1093%2Frheumatology%2Fkey432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases to jakinibs: from basic insights to clinical practice</span></div><div class="casAuthors">Gadina, Massimo; Le, Mimi T.; Schwartz, Daniella M.; Silvennoinen, Olli; Nakayamada, Shingo; Yamaoka, Kunihiro; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">Suppl._1</span>),
    <span class="NLM_cas:pages">i4-i16</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0332</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. mediators of diverse immune and inflammatory diseases.  Targeting cytokines and cytokine receptors with biologics has revolutionized the treatment of many of these diseases, but targeting intracellular signalling with Janus kinase (JAK) inhibitors (jakinibs) now represents a major new therapeutic advance.  We are still in the first decade since these drugs were approved and there is still much to be learned about the mechanisms of action of these drugs and the practical use of these agents.  Herein we will review cytokines that do, and just as importantly, do not signal by JAKs, as well as explain how this relates to both efficacy and side effects in various diseases.  We will review new, next-generation selective jakinibs, as well as the prospects and challenges ahead in targeting JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn66WHVxwb5bVg90H21EOLACvtfcHk0lg6VZsInQtdCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkt12jsbk%253D&md5=6448a623884cd2e066c5b6cfcdaebe63</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkey432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkey432%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DM.%2BT.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DNakayamada%26aufirst%3DS.%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520to%2520jakinibs%253A%2520from%2520basic%2520insights%2520to%2520clinical%2520practice%26jtitle%3DRheumatology%26date%3D2019%26volume%3D58%26spage%3Di4%26epage%3Di16%26doi%3D10.1093%2Frheumatology%2Fkey432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span> </span><span class="NLM_article-title">Drug Trials Snapshots: RINVOQ. Drug Approvals
and Databases. U.S.
Food & Drug Administration</span>. <a href="https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rinvoq" class="extLink">https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rinvoq</a> (accessed May 19, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drug+Trials+Snapshots%3A+RINVOQ.+Drug+Approvals%0Aand+Databases.+U.S.%0AFood+%26+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Fdrug-trials-snapshots-rinvoq+%28accessed+May+19%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%2520Trials%2520Snapshots%253A%2520RINVOQ.%2520Drug%2520Approvals%250Aand%2520Databases.%2520U.S.%250AFood%2520%2526%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Peficitinib: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01131-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs40265-019-01131-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=31093950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=887-891&author=A.+Markhamauthor=S.+J.+Keam&title=Peficitinib%3A+First+global+approval&doi=10.1007%2Fs40265-019-01131-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-891</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Peficitinib [Smyraf (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis.  Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in rheumatoid arthritis.  Peficitinib has been shown to significantly improve ACR20 and other measures of disease severity and to reduce the mean modified total Sharp score change from baseline in clin. trials.  This article summarizes the milestones in the development of peficitinib leading to this first approval as a treatment for rheumatoid arthritis in patients who have an inadequate response to conventional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0H33aqSsFn7Vg90H21EOLACvtfcHk0lhi-Zw-jGWbGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtLzI&md5=eb2d2061829fc515854130050139871c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01131-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01131-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPeficitinib%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D887%26epage%3D891%26doi%3D10.1007%2Fs40265-019-01131-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of <i>N</i>-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5Bmethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+A+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lhi-Zw-jGWbGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255Bmethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520A%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pfizer Inc.</span> <span> </span><span class="NLM_article-title">Pfizer
Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib
for Moderate to Severe Atopic Dermatitis, Which Showed Improvements
in Skin Clearance, Disease Extent and Severity, and Itch</span>. <a href="https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-Announces-Positive-Top-Line-Results-from-Third-Phase-3-Trial-of-Abrocitinib-for-Moderate-to-Severe-Atopic-Dermatitis-Which-Showed-Improvements-in-Skin-Clearance-Disease-Extent-and-Severity-and-Itch/default.aspx" class="extLink">https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-Announces-Positive-Top-Line-Results-from-Third-Phase-3-Trial-of-Abrocitinib-for-Moderate-to-Severe-Atopic-Dermatitis-Which-Showed-Improvements-in-Skin-Clearance-Disease-Extent-and-Severity-and-Itch/default.aspx</a> (accessed May 19, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Pfizer+Inc.&title=Pfizer%0AAnnounces+Positive+Top-Line+Results+from+Third+Phase+3+Trial+of+Abrocitinib%0Afor+Moderate+to+Severe+Atopic+Dermatitis%2C+Which+Showed+Improvements%0Ain+Skin+Clearance%2C+Disease+Extent+and+Severity%2C+and+Itch"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DPfizer%250AAnnounces%2520Positive%2520Top-Line%2520Results%2520from%2520Third%2520Phase%25203%2520Trial%2520of%2520Abrocitinib%250Afor%2520Moderate%2520to%2520Severe%2520Atopic%2520Dermatitis%252C%2520Which%2520Showed%2520Improvements%250Ain%2520Skin%2520Clearance%252C%2520Disease%2520Extent%2520and%2520Severity%252C%2520and%2520Itch%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritzén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greve, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnerup, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rytved, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagger-Bahnsen, J.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of 6-arylindazole JAK inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00087</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00087" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFSms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=641-646&author=A.+Ritz%C3%A9nauthor=M.+D.+S%C3%B8rensenauthor=K.+N.+Dackauthor=D.+R.+Greveauthor=A.+Jerreauthor=M.+A.+Carnerupauthor=K.+A.+Rytvedauthor=J.+Bagger-Bahnsen&title=Fragment-based+discovery+of+6-arylindazole+JAK+inhibitors&doi=10.1021%2Facsmedchemlett.6b00087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors</span></div><div class="casAuthors">Ritzen, Andreas; Soerensen, Morten D.; Dack, Kevin N.; Greve, Daniel R.; Jerre, Anders; Carnerup, Martin A.; Rytved, Klaus A.; Bagger-Bahnsen, Jesper</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">641-646</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinase (JAK) inhibitors are emerging as novel and efficacious drugs for treating psoriasis and other inflammatory skin disorders, but their full potential is hampered by systemic side effects.  To overcome this limitation, the authors set out to discover soft drug JAK inhibitors for topical use.  A fragment screen yielded an indazole hit that was elaborated into a potent JAK inhibitor using structure-based design.  Growing the fragment by installing a phenol moiety in the 6-position afforded a greatly improved potency.  Fine-tuning the substituents on the phenol and sulfonamide moieties afforded a set of compds. with lead-like properties, but they were found to be phototoxic and unstable in the presence of light.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEyvlishRuYrVg90H21EOLACvtfcHk0ljV-F1y5YrRAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFSms7Y%253D&md5=b2b7b783765cb7aa8673ecf01a9585f9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00087%26sid%3Dliteratum%253Aachs%26aulast%3DRitz%25C3%25A9n%26aufirst%3DA.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DM.%2BD.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DGreve%26aufirst%3DD.%2BR.%26aulast%3DJerre%26aufirst%3DA.%26aulast%3DCarnerup%26aufirst%3DM.%2BA.%26aulast%3DRytved%26aufirst%3DK.%2BA.%26aulast%3DBagger-Bahnsen%26aufirst%3DJ.%26atitle%3DFragment-based%2520discovery%2520of%25206-arylindazole%2520JAK%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D641%26epage%3D646%26doi%3D10.1021%2Facsmedchemlett.6b00087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marenich, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">Prediction of SAMPL2 aqueous solvation free energies and tautomeric ratios using the SM8, SM8AD, and SMD solvation models</span>. <i>Curr. Comput.-Aided Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1007/s10822-010-9333-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs10822-010-9333-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=317-333&author=R.+F.+Ribeiroauthor=A.+V.+Marenichauthor=C.+J.+Cramerauthor=D.+G.+Truhlar&title=Prediction+of+SAMPL2+aqueous+solvation+free+energies+and+tautomeric+ratios+using+the+SM8%2C+SM8AD%2C+and+SMD+solvation+models&doi=10.1007%2Fs10822-010-9333-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs10822-010-9333-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-010-9333-9%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DR.%2BF.%26aulast%3DMarenich%26aufirst%3DA.%2BV.%26aulast%3DCramer%26aufirst%3DC.%2BJ.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DPrediction%2520of%2520SAMPL2%2520aqueous%2520solvation%2520free%2520energies%2520and%2520tautomeric%2520ratios%2520using%2520the%2520SM8%252C%2520SM8AD%252C%2520and%2520SMD%2520solvation%2520models%26jtitle%3DCurr.%2520Comput.-Aided%2520Drug%2520Des.%26date%3D2010%26volume%3D24%26spage%3D317%26epage%3D333%26doi%3D10.1007%2Fs10822-010-9333-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marenich, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">Self-consistent reaction field model for aqueous and nonaqueous solutions based on accurate polarized partial charges</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2011</span>– <span class="NLM_lpage">2033</span>, <span class="refDoi"> DOI: 10.1021/ct7001418</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct7001418" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSqsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=2011-2033&author=A.+V.+Marenichauthor=R.+M.+Olsonauthor=C.+P.+Kellyauthor=C.+J.+Cramerauthor=D.+G.+Truhlar&title=Self-consistent+reaction+field+model+for+aqueous+and+nonaqueous+solutions+based+on+accurate+polarized+partial+charges&doi=10.1021%2Fct7001418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Self-Consistent Reaction Field Model for Aqueous and Nonaqueous Solutions Based on Accurate Polarized Partial Charges</span></div><div class="casAuthors">Marenich, Aleksandr V.; Olson, Ryan M.; Kelly, Casey P.; Cramer, Christopher J.; Truhlar, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2011-2033</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new universal continuum solvation model (where "universal" denotes applicable to all solvents), called SM8, is presented.  It is an implicit solvation model, also called a continuum solvation model, and it improves on earlier SMx universal solvation models by including free energies of solvation of ions in nonaq. media in the parametrization.  SM8 is applicable to any charged or uncharged solute composed of H, C, N, O, F, Si, P, S, Cl, and/or Br in any solvent or liq. medium for which a few key descriptors are known, in particular dielec. const., refractive index, bulk surface tension, and acidity and basicity parameters.  It does not require the user to assign mol.-mechanics types to an atom or group; all parameters are unique and continuous functions of geometry.  It may be used with any level of electronic structure theory as long as accurate partial charges can be computed for that level of theory; the authors recommend using it with self-consistently polarized Charge Model 4 or other self-consistently polarized class IV charges, in which case analytic gradients are available.  The model separates the observable solvation free energy into two components: the long-range bulk electrostatic contribution arising from a self-consistent reaction field treatment using the generalized Born approxn. for electrostatics is augmented by the non-bulk-electrostatic contribution arising from short-range interactions between the solute and solvent mols. in the first solvation shell.  The cavities for the bulk electrostatics calcn. are defined by superpositions of nuclear-centered spheres whose sizes are detd. by intrinsic at. Coulomb radii.  The radii used for aq. soln. are the same as parametrized previously for the SM6 aq. solvation model, and the radii for nonaq. soln. are parametrized by a training set of 220 bare ions and 21 clustered ions in acetonitrile, methanol, and DMSO.  The non-bulk-electrostatic terms are proportional to the solvent-accessible surface areas of the atoms of the solute and have been parametrized using solvation free energies for a training set of 2346 solvation free energies for 318 neutral solutes in 90 nonaq. solvents and water and 143 transfer free energies for 93 neutral solutes between water and 15 org. solvents.  The model is tested with three d. functionals and with four basis sets: 6-31+G(d,p), 6-31+G(d), 6-31G(d), and MIDI!6D.  The SM8 model achieves mean unsigned errors of 0.5-0.8 kcal/mol in the solvation free energies of tested neutrals and mean unsigned errors of 2.2-7.0 kcal/mol for ions.  The model outperforms the earlier SM5.43R and SM7 universal solvation models as well as the default Polarizable Continuum Model (PCM) implemented in Gaussian 98/03, the Conductor-like PCM as implemented in GAMESS, Jaguar's continuum model based on numerical soln. of the Poisson equation, and the GCOSMO model implemented in NWChem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWtaEOCSgegLVg90H21EOLACvtfcHk0ljV-F1y5YrRAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSqsrbJ&md5=002518393e08359394f671a73ca9a548</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fct7001418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct7001418%26sid%3Dliteratum%253Aachs%26aulast%3DMarenich%26aufirst%3DA.%2BV.%26aulast%3DOlson%26aufirst%3DR.%2BM.%26aulast%3DKelly%26aufirst%3DC.%2BP.%26aulast%3DCramer%26aufirst%3DC.%2BJ.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DSelf-consistent%2520reaction%2520field%2520model%2520for%2520aqueous%2520and%2520nonaqueous%2520solutions%2520based%2520on%2520accurate%2520polarized%2520partial%2520charges%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2007%26volume%3D3%26spage%3D2011%26epage%3D2033%26doi%3D10.1021%2Fct7001418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">The M06 suite of density functionals for main group thermochemistry, kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06 functionals and twelve other functionals</span>. <i>Theor. Chem. Acc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1007/s00214-007-0310-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs00214-007-0310-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFyltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2008&pages=215-241&author=Y.+Zhaoauthor=D.+G.+Truhlar&title=The+M06+suite+of+density+functionals+for+main+group+thermochemistry%2C+kinetics%2C+noncovalent+interactions%2C+excited+states%2C+and+transition+elements%3A+two+new+functionals+and+systematic+testing+of+four+M06+functionals+and+twelve+other+functionals&doi=10.1007%2Fs00214-007-0310-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals</span></div><div class="casAuthors">Zhao, Yan; Truhlar, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Theoretical Chemistry Accounts</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">215-241</span>CODEN:
                <span class="NLM_cas:coden">TCACFW</span>;
        ISSN:<span class="NLM_cas:issn">1432-881X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">We present two new hybrid meta exchange-correlation functionals, called M06 and M06-2X.  The M06 functional is parametrized including both transition metals and nonmetals, whereas the M06-2X functional is a high-nonlocality functional with double the amt. of nonlocal exchange (2X), and it is parametrized only for nonmetals.  The functionals, along with the previously published M06-L local functional and the M06-HF full-Hartree-Fock functionals, constitute the M06 suite of complementary functionals.  We assess these four functionals by comparing their performance to that of 12 other functionals and Hartree-Fock theory for 403 energetic data in 29 diverse databases, including ten databases for thermochem., four databases for kinetics, eight databases for noncovalent interactions, three databases for transition metal bonding, one database for metal atom excitation energies, and three databases for mol. excitation energies.  We also illustrate the performance of these 17 methods for three databases contg. 40 bond lengths and for databases contg. 38 vibrational frequencies and 15 vibrational zero point energies.  We recommend the M06-2X functional for applications involving main-group thermochem., kinetics, noncovalent interactions, and electronic excitation energies to valence and Rydberg states.  We recommend the M06 functional for application in organometallic and inorganometallic chem. and for noncovalent interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJNWFt06psLVg90H21EOLACvtfcHk0lg4UX9UNw6ByA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFyltbY%253D&md5=c31d6f319d7c7a45aa9b716220e4a422</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs00214-007-0310-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00214-007-0310-x%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DThe%2520M06%2520suite%2520of%2520density%2520functionals%2520for%2520main%2520group%2520thermochemistry%252C%2520kinetics%252C%2520noncovalent%2520interactions%252C%2520excited%2520states%252C%2520and%2520transition%2520elements%253A%2520two%2520new%2520functionals%2520and%2520systematic%2520testing%2520of%2520four%2520M06%2520functionals%2520and%2520twelve%2520other%2520functionals%26jtitle%3DTheor.%2520Chem.%2520Acc.%26date%3D2008%26volume%3D120%26spage%3D215%26epage%3D241%26doi%3D10.1007%2Fs00214-007-0310-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span> <span> </span><span class="NLM_article-title">Advances in the discovery of selective JAK inhibitors</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/B978-0-444-62652-3.00004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2FB978-0-444-62652-3.00004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=23384668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=153-223&author=C.+J.+Menetauthor=L.+Van+Rompaeyauthor=R.+Geney&title=Advances+in+the+discovery+of+selective+JAK+inhibitors&doi=10.1016%2FB978-0-444-62652-3.00004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of selective JAK inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Van Rompaey, Luc; Geney, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-223</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the advances in the discovery of selective JAK inhibitors.  JAK inhibitor includes JAK1, JAK2 and JAK3 and tyrosine kinase2.  Medicinal chem. and structural biol. fronts in designing and synthesizing selective or mixed JAK small-mol. inhibitors were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg_zxiK5GGLVg90H21EOLACvtfcHk0lg4UX9UNw6ByA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D&md5=3d7e6f0481e3a891c84c49ece6421d74</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGeney%26aufirst%3DR.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520selective%2520JAK%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D153%26epage%3D223%26doi%3D10.1016%2FB978-0-444-62652-3.00004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Ramos, M.</span></span> <span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+J.+Menetauthor=O.+Mammolitiauthor=M.+L%C3%B3pez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of γc cytokine (γc = common γ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0lg4UX9UNw6ByA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DL%25C3%25B3pez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucet, I. S.</span></span> <span> </span><span class="NLM_article-title">Dissecting specificity in the janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+janus+kinases%3A+The+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0ljedMHP52H07Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520janus%2520kinases%253A%2520The%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Lowering Lipophilicity by Adding Carbon: One-carbon bridges of morpholines and piperazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8934</span>– <span class="NLM_lpage">8943</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KhtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8934-8943&author=S.+L.+Degorceauthor=M.+S.+Bodnarchukauthor=I.+A.+Cummingauthor=J.+S.+Scott&title=Lowering+Lipophilicity+by+Adding+Carbon%3A+One-carbon+bridges+of+morpholines+and+piperazines&doi=10.1021%2Facs.jmedchem.8b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines</span></div><div class="casAuthors">Degorce, Sebastien L.; Bodnarchuk, Michael S.; Cumming, Iain A.; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8934-8943</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this article, we report our investigation of a phenomenon by which bridging morpholines across the ring with one-carbon tethers leads to a counterintuitive redn. in lipophilicity.  This effect was also found to occur in piperazines and piperidines and lowered the measured log D7.4 of the bridged mols. by as much as -0.8 relative to their unbridged counterparts.  As lowering lipophilicity without introducing addnl. heteroatoms can be desirable, we believe this potentially provides a useful tactic to improve the drug-like properties of mols. contg. morpholine-, piperazine-, and piperidine-like motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhZJB3SYRKD7Vg90H21EOLACvtfcHk0ljedMHP52H07Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KhtbzK&md5=27f30b8220ea767d6ef1e492f3fa1aba</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01148%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBodnarchuk%26aufirst%3DM.%2BS.%26aulast%3DCumming%26aufirst%3DI.%2BA.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DLowering%2520Lipophilicity%2520by%2520Adding%2520Carbon%253A%2520One-carbon%2520bridges%2520of%2520morpholines%2520and%2520piperazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8934%26epage%3D8943%26doi%3D10.1021%2Facs.jmedchem.8b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komarova, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granik, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Párkányi, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of pyrazolo[3,4-b]pyridin-6-ones</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">969</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1002/jhet.986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1002%2Fjhet.986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2ku7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=969-998&author=E.+S.+Komarovaauthor=V.+A.+Makarovauthor=V.+G.+Granikauthor=C.+P%C3%A1rk%C3%A1nyi&title=Synthesis+of+pyrazolo%5B3%2C4-b%5Dpyridin-6-ones&doi=10.1002%2Fjhet.986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of pyrazolo[3,4-b]pyridin-6-ones</span></div><div class="casAuthors">Komarova, Elena S.; Makarov, Vadim A.; Granik, Vladimir G.; Parkanyi, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">969-998</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review was given on the synthesis of substituted pyrazolo[3,4-b]pyridin-6-ones and some of their properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWnsH3iiSUDbVg90H21EOLACvtfcHk0ljedMHP52H07Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2ku7fM&md5=d548d0d877d8367a41764e0ccf0de4fe</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fjhet.986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.986%26sid%3Dliteratum%253Aachs%26aulast%3DKomarova%26aufirst%3DE.%2BS.%26aulast%3DMakarov%26aufirst%3DV.%2BA.%26aulast%3DGranik%26aufirst%3DV.%2BG.%26aulast%3DP%25C3%25A1rk%25C3%25A1nyi%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520pyrazolo%255B3%252C4-b%255Dpyridin-6-ones%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2012%26volume%3D49%26spage%3D969%26epage%3D998%26doi%3D10.1002%2Fjhet.986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balicki, R.</span></span> <span> </span><span class="NLM_article-title">Studies in the field of nitrogen heterocyclic compounds. Part XI. Abnormal cyclocondensation of ethyl 4,4,4-trifluoroacetoacetate with aminopyrazoles</span>. <i>Pol. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">797</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADyaL2MXpsFGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1983&pages=789-797&author=R.+Balicki&title=Studies+in+the+field+of+nitrogen+heterocyclic+compounds.+Part+XI.+Abnormal+cyclocondensation+of+ethyl+4%2C4%2C4-trifluoroacetoacetate+with+aminopyrazoles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Studies in the field of nitrogen heterocyclic compounds.  Part XI.  Abnormal cyclocondensation of ethyl 4,4,4-trifluoroacetoacetate with aminopyrazoles</span></div><div class="casAuthors">Balicki, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Polish Journal of Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7-8-9</span>),
    <span class="NLM_cas:pages">789-97</span>CODEN:
                <span class="NLM_cas:coden">PJCHDQ</span>;
        ISSN:<span class="NLM_cas:issn">0137-5083</span>.
    </div><div class="casAbstract">The cyclocondensation of F3CCOCH2CO2Et with 3-amino-5-phenylpyrazole, 5-amino-1,3-dimethylpyrazole, 3-aminopyrazole, and 3-amino-4-phenylpyrazole occurs differently from analogous reactions, e.g. with MeCOCH2CO2Et.  Thus, F3CCOCH2CO2Et underwent cyclocondensation with 5-amino-1,3-dimethylpyrazole in EtOH to give mainly the pyrazole I.  The same reaction in benzene gave the pyrazolopyridine II.  I and II were converted to the pyrazolopyridine III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqojU67uLJKX7Vg90H21EOLACvtfcHk0ljedMHP52H07Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXpsFGksA%253D%253D&md5=af295f63237e71f3896e93654ee932b9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBalicki%26aufirst%3DR.%26atitle%3DStudies%2520in%2520the%2520field%2520of%2520nitrogen%2520heterocyclic%2520compounds.%2520Part%2520XI.%2520Abnormal%2520cyclocondensation%2520of%2520ethyl%25204%252C4%252C4-trifluoroacetoacetate%2520with%2520aminopyrazoles%26jtitle%3DPol.%2520J.%2520Chem.%26date%3D1983%26volume%3D57%26spage%3D789%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcouffe, C.</span>; <span class="NLM_string-name">Bjegarde, K.</span>; <span class="NLM_string-name">Mauger, J.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine Derivatives, Preparation Process therefor and Therapeutic Use thereof</span>. Patent <span class="NLM_patent">WO2013087744</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=C.+Alcouffe&author=K.+Bjegarde&author=J.+Mauger&title=Pyrazolopyridine+Derivatives%2C+Preparation+Process+therefor+and+Therapeutic+Use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcouffe%26aufirst%3DC.%26atitle%3DPyrazolopyridine%2520Derivatives%252C%2520Preparation%2520Process%2520therefor%2520and%2520Therapeutic%2520Use%2520thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcouffe, C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine Derivatives for use in the Treatment of Bladder Cancer</span>. Patent <span class="NLM_patent">WO2014198942</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+Alcouffe&title=Pyrazolopyridine+Derivatives+for+use+in+the+Treatment+of+Bladder+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcouffe%26aufirst%3DC.%26atitle%3DPyrazolopyridine%2520Derivatives%2520for%2520use%2520in%2520the%2520Treatment%2520of%2520Bladder%2520Cancer%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 Inhibitors</span>. Patent <span class="NLM_patent">WO2005000303</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+T.+Wager&title=Pyrazolo%5B3%2C4-b%5Dpyridin-6-ones+as+GSK-3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26atitle%3DPyrazolo%255B3%252C4-b%255Dpyridin-6-ones%2520as%2520GSK-3%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desenko, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirobokova, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkin, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkina, S. V.</span></span> <span> </span><span class="NLM_article-title">Heterocyclization of 5-methylpyrazol-3-amine with unsaturated arylaliphatic carboxylic acid derivatives</span>. <i>Russ. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1027</span>, <span class="refDoi"> DOI: 10.1134/S1070428006070153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1134%2FS1070428006070153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvFKqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=1022-1027&author=V.+V.+Lipsonauthor=S.+M.+Desenkoauthor=M.+G.+Shirobokovaauthor=O.+V.+Shishkinauthor=S.+V.+Shishkina&title=Heterocyclization+of+5-methylpyrazol-3-amine+with+unsaturated+arylaliphatic+carboxylic+acid+derivatives&doi=10.1134%2FS1070428006070153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocyclization of 5-methylpyrazol-3-amine with unsaturated arylaliphatic carboxylic acid derivatives</span></div><div class="casAuthors">Lipson, V. V.; Desenko, S. M.; Shirobokova, M. G.; Shishkin, O. V.; Shishkina, S. V.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1022-1027</span>CODEN:
                <span class="NLM_cas:coden">RJOCEQ</span>;
        ISSN:<span class="NLM_cas:issn">1070-4280</span>.
    
            (<span class="NLM_cas:orgname">Pleiades Publishing, Inc.</span>)
        </div><div class="casAbstract">Cyclocondensation of 5-methyl-3-pyrazolamine with Me cinnamate and (arylmethylene)malonic acids in DMF and methanol leads to the formation of 7-aryl-2-methyl-6,7-dihydropyrazolo[1,5-a]-pyrimidin-5(4H)-one derivs.  (Arylmethylene)malonic acids react with the title amine at a ratio of 1:2 in nitrobenzene to give 4-aryl-3,5-dimethyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine derivs.  Heterocyclization of 5-methyl-3-pyrazolamine with 5-(arylmethylene)-2,2-dimethyl-1,3-dioxane-4,6-diones or their precursors, para-substituted benzaldehydes and 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) in all solvents (methanol, DMF, and nitrobenzene) give the corresponding 4-aryl-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-one derivs.  The structure of 3-methyl-4-(4-nitrophenyl)-2,4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-one was proved by X-ray anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr69FiS4JhzLbVg90H21EOLACvtfcHk0liVglZF83Ff5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvFKqtrw%253D&md5=000d54f9b99d716ed5b2093dfac731bf</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1134%2FS1070428006070153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS1070428006070153%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DV.%2BV.%26aulast%3DDesenko%26aufirst%3DS.%2BM.%26aulast%3DShirobokova%26aufirst%3DM.%2BG.%26aulast%3DShishkin%26aufirst%3DO.%2BV.%26aulast%3DShishkina%26aufirst%3DS.%2BV.%26atitle%3DHeterocyclization%2520of%25205-methylpyrazol-3-amine%2520with%2520unsaturated%2520arylaliphatic%2520carboxylic%2520acid%2520derivatives%26jtitle%3DRuss.%2520J.%2520Org.%2520Chem.%26date%3D2006%26volume%3D42%26spage%3D1022%26epage%3D1027%26doi%3D10.1134%2FS1070428006070153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrova, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamigajlo, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gella, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musatov, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkina, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkin, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vashchenko, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borisov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, V. V.</span></span> <span> </span><span class="NLM_article-title">Three-component synthesis of 4-aroyl-2(1),4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-ones and their properties</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1007/s10593-014-1502-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs10593-014-1502-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=514-527&author=O.+N.+Petrovaauthor=L.+L.+Zamigajloauthor=I.+M.+Gellaauthor=V.+I.+Musatovauthor=S.+V.+Shishkinaauthor=O.+V.+Shishkinauthor=E.+V.+Vashchenkoauthor=A.+V.+Borisovauthor=V.+V.+Lipson&title=Three-component+synthesis+of+4-aroyl-2%281%29%2C4%2C5%2C7-tetrahydropyrazolo%5B3%2C4-b%5Dpyridin-6-ones+and+their+properties&doi=10.1007%2Fs10593-014-1502-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Three-Component Synthesis of 4-Aroyl-2(1),4,5,7-Tetrahydropyrazolo[3,4-b]Pyridin-6-Ones and Their Properties</span></div><div class="casAuthors">Petrova, O. N.; Zamigajlo, L. L.; Gella, I. M.; Musatov, V. I.; Shishkina, S. V.; Shishkin, O. V.; Vashchenko, E. V.; Borisov, A. V.; Lipson, V. V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">514-527</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inspired by the concept of multicomponent reactions, a novel one-pot synthesis involving arylglyoxals, 5-aminopyrazoles, and Meldrum's acid was developed and employed for the creation of a small library of 4-aroyl-2(1),4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-ones.  The alkylation, acylation, redn., and oxidn. reactions of 4-aroyl-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-ones were studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNhxfkCMZ5lLVg90H21EOLACvtfcHk0liVglZF83Ff5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrP&md5=3b86a3923cb4c3a0df0d27aa534aaf05</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs10593-014-1502-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-014-1502-7%26sid%3Dliteratum%253Aachs%26aulast%3DPetrova%26aufirst%3DO.%2BN.%26aulast%3DZamigajlo%26aufirst%3DL.%2BL.%26aulast%3DGella%26aufirst%3DI.%2BM.%26aulast%3DMusatov%26aufirst%3DV.%2BI.%26aulast%3DShishkina%26aufirst%3DS.%2BV.%26aulast%3DShishkin%26aufirst%3DO.%2BV.%26aulast%3DVashchenko%26aufirst%3DE.%2BV.%26aulast%3DBorisov%26aufirst%3DA.%2BV.%26aulast%3DLipson%26aufirst%3DV.%2BV.%26atitle%3DThree-component%2520synthesis%2520of%25204-aroyl-2%25281%2529%252C4%252C5%252C7-tetrahydropyrazolo%255B3%252C4-b%255Dpyridin-6-ones%2520and%2520their%2520properties%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2014%26volume%3D50%26spage%3D514%26epage%3D527%26doi%3D10.1007%2Fs10593-014-1502-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodina, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirobokova, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desenko, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkin, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubatyuk, R. I.</span></span> <span> </span><span class="NLM_article-title">Interaction of aminoazoles with Meldrum’s acid and dialkyl ketones or cyclohexanone</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">490</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1007/s10593-007-0071-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs10593-007-0071-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsleqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=490-495&author=V.+V.+Lipsonauthor=V.+V.+Borodinaauthor=M.+G.+Shirobokovaauthor=S.+M.+Desenkoauthor=O.+V.+Shishkinauthor=R.+I.+Zubatyuk&title=Interaction+of+aminoazoles+with+Meldrum%E2%80%99s+acid+and+dialkyl+ketones+or+cyclohexanone&doi=10.1007%2Fs10593-007-0071-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of aminoazoles with Meldrum's acid and dialkyl ketones or cyclohexanone</span></div><div class="casAuthors">Lipson, V. V.; Borodina, V. V.; Shirobokova, M. G.; Desenko, S. M.; Shishkin, O. V.; Zubatyuk, R. I.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">490-495</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Interaction of 3-amino-5-methylpyrazole, 3-amino-5-methylthio-, and 3,5-diamino-1,2,4-triazole with Meldrum's acid, acetone, Et Me ketone, and cyclohexanone leads to alkyl-substituted pyrazolo[3,4-b]pyridin-6-ones and 1,2,4-triazolo[1,5-a]pyrimidin-7-ones, resp.  The structure of 5,5-dimethyl-2-methylthio-4,5,6,7-tetrahydro-1,2,4-triazolo[1,5-a]pyrimidin-7-one was demonstrated by an x-ray structural investigation [triclinic, space group P1, a 8.371(2), b 9.810(2), c 13.520(4) Å, α 70.41(2), β 82.51(2), γ 81.93(2)°, V 1031.4(5) Å3, Z 4].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDcnUvDRTR6LVg90H21EOLACvtfcHk0liVglZF83Ff5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsleqsrc%253D&md5=9c5eb58e6bf93113ef921244c77b9b92</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10593-007-0071-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-007-0071-4%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DV.%2BV.%26aulast%3DBorodina%26aufirst%3DV.%2BV.%26aulast%3DShirobokova%26aufirst%3DM.%2BG.%26aulast%3DDesenko%26aufirst%3DS.%2BM.%26aulast%3DShishkin%26aufirst%3DO.%2BV.%26aulast%3DZubatyuk%26aufirst%3DR.%2BI.%26atitle%3DInteraction%2520of%2520aminoazoles%2520with%2520Meldrum%25E2%2580%2599s%2520acid%2520and%2520dialkyl%2520ketones%2520or%2520cyclohexanone%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2007%26volume%3D43%26spage%3D490%26epage%3D495%26doi%3D10.1007%2Fs10593-007-0071-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fache, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehuede, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, M.</span></span> <span> </span><span class="NLM_article-title">A catalytic stereo- and chemo-selective method for the reduction of substituted aromatics</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(94)02386-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2F0040-4039%2894%2902386-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADyaK2MXjs1Kmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=885-888&author=F.+Facheauthor=S.+Lehuedeauthor=M.+Lemaire&title=A+catalytic+stereo-+and+chemo-selective+method+for+the+reduction+of+substituted+aromatics&doi=10.1016%2F0040-4039%2894%2902386-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A catalytic stereo- and chemo-selective method for the reduction of substituted aromatics</span></div><div class="casAuthors">Fache, Fabienne; Lehuede, Stephan; Lemaire, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">885-8</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Various substituted aroms. have been reduced using colloidal ruthenium under H2 pressure with good stereoselectivity (cis/trans up to 60).  Interesting chemoselectivities are also obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoruxDgF4pkHrVg90H21EOLACvtfcHk0lgHZToXTlpgxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjs1Kmsr8%253D&md5=2cc361be64ad07c0bf03484bf2f3d2d3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2894%2902386-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252894%252902386-P%26sid%3Dliteratum%253Aachs%26aulast%3DFache%26aufirst%3DF.%26aulast%3DLehuede%26aufirst%3DS.%26aulast%3DLemaire%26aufirst%3DM.%26atitle%3DA%2520catalytic%2520stereo-%2520and%2520chemo-selective%2520method%2520for%2520the%2520reduction%2520of%2520substituted%2520aromatics%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D885%26epage%3D888%26doi%3D10.1016%2F0040-4039%2894%2902386-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricks, M. J.</span>; <span class="NLM_string-name">Dent, W. H.</span>; <span class="NLM_string-name">Rogers, R. B.</span>; <span class="NLM_string-name">Yao, C.</span>; <span class="NLM_string-name">Nader, B. S.</span>; <span class="NLM_string-name">Miesel, J. L.</span>; <span class="NLM_string-name">Fitzpatrick, G. M.</span>; <span class="NLM_string-name">Meyer, K. G.</span>; <span class="NLM_string-name">Niyaz, N. M.</span>; <span class="NLM_string-name">Morrison, I. M.</span>; <span class="NLM_string-name">Henry, M. J.</span>; <span class="NLM_string-name">Adamski, B. J. L.</span>; <span class="NLM_string-name">Gajewski, R. P.</span></span> <span> </span><span class="NLM_article-title">Fungicidal Heterocyclic Aromatic Amides and their Compositions, Methods of Use and Preparation</span>. Patent <span class="NLM_patent">WO0114339</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+J.+Ricks&author=W.+H.+Dent&author=R.+B.+Rogers&author=C.+Yao&author=B.+S.+Nader&author=J.+L.+Miesel&author=G.+M.+Fitzpatrick&author=K.+G.+Meyer&author=N.+M.+Niyaz&author=I.+M.+Morrison&author=M.+J.+Henry&author=B.+J.+L.+Adamski&author=R.+P.+Gajewski&title=Fungicidal+Heterocyclic+Aromatic+Amides+and+their+Compositions%2C+Methods+of+Use+and+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRicks%26aufirst%3DM.%2BJ.%26atitle%3DFungicidal%2520Heterocyclic%2520Aromatic%2520Amides%2520and%2520their%2520Compositions%252C%2520Methods%2520of%2520Use%2520and%2520Preparation%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastida, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span> <span> </span><span class="NLM_article-title">Building C(sp3)-rich complexity by combining cycloaddition and C-C cross-coupling reactions</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>560</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0391-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1038%2Fs41586-018-0391-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=30061620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWru7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=560&publication_year=2018&pages=350-354&author=T.-G.+Chenauthor=L.+M.+Bartonauthor=Y.+Linauthor=J.+Tsienauthor=D.+Kosslerauthor=I.+Bastidaauthor=S.+Asaiauthor=C.+Biauthor=J.+S.+Chenauthor=M.+Shanauthor=H.+Fangauthor=F.+G.+Fangauthor=H.-w.+Choiauthor=L.+Hawkinsauthor=T.+Qinauthor=P.+S.+Baran&title=Building+C%28sp3%29-rich+complexity+by+combining+cycloaddition+and+C-C+cross-coupling+reactions&doi=10.1038%2Fs41586-018-0391-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Building C(sp3)-rich complexity by combining cycloaddition and C-C cross-coupling reactions</span></div><div class="casAuthors">Chen, Tie-Gen; Barton, Lisa M.; Lin, Yutong; Tsien, Jet; Kossler, David; Bastida, Inaki; Asai, Shota; Bi, Cheng; Chen, Jason S.; Shan, Mingde; Fang, Hui; Fang, Francis G.; Choi, Hyeong-wook; Hawkins, Lynn; Qin, Tian; Baran, Phil S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">560</span>
        (<span class="NLM_cas:issue">7718</span>),
    <span class="NLM_cas:pages">350-354</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prized for their ability to rapidly generate chem. complexity by building new ring systems and stereocentres, cycloaddn. reactions have featured in numerous total syntheses and are a key component in the education of chem. students.  Similarly, carbon-carbon (C-C) cross-coupling methods are integral to synthesis because of their programmability, modularity and reliability.  Within the area of drug discovery, an overreliance on cross-coupling has led to a disproportionate representation of flat architectures that are rich in carbon atoms with orbitals hybridized in an sp2 manner.  Despite the ability of cycloaddns. to introduce multiple carbon sp3 centers in a single step, they are less used.  This is probably because of their lack of modularity, stemming from the idiosyncratic steric and electronic rules for each specific type of cycloaddn.  Here we demonstrate a strategy for combining the optimal features of these two chem. transformations into one simple sequence, to enable the modular, enantioselective, scalable and programmable prepn. of useful building blocks, natural products and lead scaffolds for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRd_64A4rNc7Vg90H21EOLACvtfcHk0lgHZToXTlpgxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWru7rK&md5=c088cccdbddd0355b9392533a1677367</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0391-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0391-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.-G.%26aulast%3DBarton%26aufirst%3DL.%2BM.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DTsien%26aufirst%3DJ.%26aulast%3DKossler%26aufirst%3DD.%26aulast%3DBastida%26aufirst%3DI.%26aulast%3DAsai%26aufirst%3DS.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%2BS.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DF.%2BG.%26aulast%3DChoi%26aufirst%3DH.-w.%26aulast%3DHawkins%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26atitle%3DBuilding%2520C%2528sp3%2529-rich%2520complexity%2520by%2520combining%2520cycloaddition%2520and%2520C-C%2520cross-coupling%2520reactions%26jtitle%3DNature%26date%3D2018%26volume%3D560%26spage%3D350%26epage%3D354%26doi%3D10.1038%2Fs41586-018-0391-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span>; <span class="NLM_string-name">Carroll, J. N.</span>; <span class="NLM_string-name">Hanau, C. E.</span>; <span class="NLM_string-name">McReynolds, M. D.</span>; <span class="NLM_string-name">Scholten, J. A.</span>; <span class="NLM_string-name">McDonald, J. J.</span>; <span class="NLM_string-name">Grapperhaus, M. L.</span>; <span class="NLM_string-name">Massa, M. A.</span>; <span class="NLM_string-name">Ruminski, P. G.</span>; <span class="NLM_string-name">Schmidt, M. A.</span>; <span class="NLM_string-name">Strohback, J. W.</span>; <span class="NLM_string-name">Hamper, B. C.</span>; <span class="NLM_string-name">Fletcher, T. R.</span>; <span class="NLM_string-name">Rogers, M. D.</span>; <span class="NLM_string-name">O’Brien, P. M.</span>; <span class="NLM_string-name">Nahra, J.</span>; <span class="NLM_string-name">Morris, M. A.</span>; <span class="NLM_string-name">Roark, W. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrimidine and Pyridine Derivatives as Antiinflammatory Agents</span>. Patent <span class="NLM_patent">WO2009016498</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+E.+Schnute&author=J.+N.+Carroll&author=C.+E.+Hanau&author=M.+D.+McReynolds&author=J.+A.+Scholten&author=J.+J.+McDonald&author=M.+L.+Grapperhaus&author=M.+A.+Massa&author=P.+G.+Ruminski&author=M.+A.+Schmidt&author=J.+W.+Strohback&author=B.+C.+Hamper&author=T.+R.+Fletcher&author=M.+D.+Rogers&author=P.+M.+O%E2%80%99Brien&author=J.+Nahra&author=M.+A.+Morris&author=W.+H.+Roark&title=Preparation+of+Pyrimidine+and+Pyridine+Derivatives+as+Antiinflammatory+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520and%2520Pyridine%2520Derivatives%2520as%2520Antiinflammatory%2520Agents%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, Y.</span></span> <span> </span><span class="NLM_article-title">Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3213</span>– <span class="NLM_lpage">3215</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2Fj.bmcl.2016.05.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=27261178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVymsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3213-3215&author=H.+Kimauthor=M.+K.+Kimauthor=H.+Chooauthor=Y.+Chong&title=Novel+JAK1-selective+benzimidazole+inhibitors+with+enhanced+membrane+permeability&doi=10.1016%2Fj.bmcl.2016.05.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability</span></div><div class="casAuthors">Kim, Hyungmi; Kim, Mi Kyoung; Choo, Hyunah; Chong, Youhoon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3213-3215</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The previously identified Janus kinase 1 (JAK1)-selective inhibitor, 1-(2-aminoethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole-5-carboxamide, suffered from low cell permeability, which resulted in poor pharmacokinetic properties.  In this study, by introducing less polar hydrogen bond donors at N1 (a hydroxyalkyl or a methylaminoalkyl group) and C2 (a cyclohexanol group) positions, a series of novel benzimidazole derivs. I (R 1 = (CH2)2OH, (CH2)3OH, (CH2)2NHMe, (CH2)3NH2, (R)-CH2CHOHMe) and II (R2 = (CH2)2NHMe, (CH2)3NH2) were prepd., which exhibited selective JAK1 inhibitory activity (IC50 against JAK1 = 0.08-0.15 μM; JAK1-selectivity = 26-40 fold vs JAK2, 12-23 fold vs JAK3, and 38-54 fold vs Tyk2) along with significantly increased lipophilicity (3.3-15.8 times) as well as membrane permeability (6.3-12 times).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHBsrUVqqnmbVg90H21EOLACvtfcHk0lij86jTtfcq7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVymsbc%253D&md5=8c7888e1b158c7fed9f84a47b43984bf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.078%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DChoo%26aufirst%3DH.%26aulast%3DChong%26aufirst%3DY.%26atitle%3DNovel%2520JAK1-selective%2520benzimidazole%2520inhibitors%2520with%2520enhanced%2520membrane%2520permeability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3213%26epage%3D3215%26doi%3D10.1016%2Fj.bmcl.2016.05.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Siyeon Jeong, Eunmin Kim, Minkyu Kim, Ye Ji Hwang, Birakishore Padhi, Jonghoon Choi, Yunho Lee, <span class="NLM_string-name hlFld-ContribAuthor">Jung Min Joo</span>. </span><span class="cited-content_cbyCitation_article-title">Divergent Strategies for the π-Extension of Heteroaryl Halides Using Norbornadiene as an Acetylene Synthon. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (24)
                                     , 9670-9676. <a href="https://doi.org/10.1021/acs.orglett.0c03732" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03732</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03732%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDivergent%252BStrategies%252Bfor%252Bthe%252B%2525CF%252580-Extension%252Bof%252BHeteroaryl%252BHalides%252BUsing%252BNorbornadiene%252Bas%252Ban%252BAcetylene%252BSynthon%26aulast%3DJeong%26aufirst%3DSiyeon%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09112020%26date%3D10122020%26volume%3D22%26issue%3D24%26spage%3D9670%26epage%3D9676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kajal  Sharma</span>, <span class="hlFld-ContribAuthor ">Shalki  Choudhary</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Portraying molecular modulation and therapeutic aspects of psoriasis: Retrospection and current status. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1243 </em>, 130770. <a href="https://doi.org/10.1016/j.molstruc.2021.130770" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130770</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130770%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DPortraying%252Bmolecular%252Bmodulation%252Band%252Btherapeutic%252Baspects%252Bof%252Bpsoriasis%25253A%252BRetrospection%252Band%252Bcurrent%252Bstatus%26aulast%3DSharma%26aufirst%3DKajal%26date%3D2021%26volume%3D1243%26spage%3D130770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sivanna  Chithanna</span>, <span class="hlFld-ContribAuthor ">Ding-Yah  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of 2-pyridones
              via
              oxidative cyclization of enamides: access to Pechmann dye derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (7)
                                     , 1565-1574. <a href="https://doi.org/10.1039/D0OB02376K" title="DOI URL">https://doi.org/10.1039/D0OB02376K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB02376K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB02376K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConstruction%252Bof%252B2-pyridones%252Bvia%252Boxidative%252Bcyclization%252Bof%252Benamides%25253A%252Baccess%252Bto%252BPechmann%252Bdye%252Bderivatives%26aulast%3DChithanna%26aufirst%3DSivanna%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D7%26spage%3D1565%26epage%3D1574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingxiu  Li</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Cong  Chen</span>, <span class="hlFld-ContribAuthor ">Tianyu  Ye</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104361. <a href="https://doi.org/10.1016/j.bioorg.2020.104361" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104361%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Band%252Brational%252Bdesign%252Bof%252B2-aminopyrimidine-based%252Bderivatives%252Btargeting%252BJanus%252Bkinase%252B2%252B%252528JAK2%252529%252Band%252BFMS-like%252Btyrosine%252Bkinase%252B3%252B%252528FLT3%252529%26aulast%3DLi%26aufirst%3DYingxiu%26date%3D2020%26volume%3D104%26spage%3D104361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adriana  Coricello</span>, <span class="hlFld-ContribAuthor ">Francesco  Mesiti</span>, <span class="hlFld-ContribAuthor ">Antonio  Lupia</span>, <span class="hlFld-ContribAuthor ">Annalisa  Maruca</span>, <span class="hlFld-ContribAuthor ">Stefano  Alcaro</span>. </span><span class="cited-content_cbyCitation_article-title">Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (15)
                                     , 3321. <a href="https://doi.org/10.3390/molecules25153321" title="DOI URL">https://doi.org/10.3390/molecules25153321</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25153321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25153321%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DInside%252BPerspective%252Bof%252Bthe%252BSynthetic%252Band%252BComputational%252BToolbox%252Bof%252BJAK%252BInhibitors%25253A%252BRecent%252BUpdates%26aulast%3DCoricello%26aufirst%3DAdriana%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D15%26spage%3D3321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0001.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray crystal structure of compound <b>6</b> in complex with JAK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPD">6TPD</a>, 2.0 Å resolution). The ligand <b>6</b> is colored green, the hinge loop is colored purple, the P-loop is colored orange, the DFG loop is colored blue, and the αC helix is colored red. Hydrogen bonds are shown as green dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0002.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Strategy for lead generation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0003.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking pose of <b>21</b> (cyan) overlaid with the X-ray structures of <b>6</b> (green) bound to JAK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPD">6TPD</a>) and tofacitinib <b>20</b> (yellow) bound to JAK1 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG">3EYG</a>). The protein from PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG">3EYG</a> is shown, and this was used to dock <b>21</b>. The hinge loop is colored purple, the P-loop is colored orange, the DFG loop is colored blue, and the αC helix is colored red. Hydrogen bonds are shown as green dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0004.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of compound <b>21</b> (cyan) in complex with JAK1 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPE">6TPE</a>, 2.9 Å resolution). The ligand electron density is shown in blue mesh. Hydrogen bonds are shown as green dotted lines. The nitrile functional group is modeled in an arbitrary rotameric state because no electron density was observed for it.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0005.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of compound <b>27</b> in complex with JAK1 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPF">6TPF</a>, 2.3 Å resolution). The ligand <b>27</b> is colored green, the hinge loop is colored purple, the P-loop is colored orange, and the DFG loop is colored blue. Hydrogen bonds are shown as green dotted lines. Side-chain conformations from the second protein molecule in the crystallographic unit cell are shown in cyan for Arg 879 and Glu 966.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0006.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat PK study with compound <b>40</b>. <i>T</i><sub>1/2</sub> = 0.3 h, Cl = 53 mL/min/kg, <i>V</i><sub>β</sub> = 1.2 L/kg, <i>F</i> = 14%. Inset: Blood concentration on a logarithmic scale vs time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. First Route to the Pyrazolopyridone Scaffold<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AcOH, reflux, 76–82%; (b) AcOH, reflux, 88%; (c) AcOH, 135 °C (microwave heating), 23%; (d) AcOH, 110 °C, 12–98%; (e) TFA, 70 °C, 16–68%.</p></p></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Three-Component Reaction Route to the Pyrazolopyridone Scaffold<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH, 60–70 °C or reflux, 23–86%; (b) DDQ, 1,4-dioxane, 100 °C, 12–87%; (c) 4 M HCl in 1,4-dioxane, room temperature (rt), 86%; (d) 1 M tetra-<i>n</i>-butylammonium fluoride (TBAF) in THF, dichloromethane (DCM), 40 °C, 40%; (e) H<sub>2</sub>, Pt/C, MeOH, rt.</p></p></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0013.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>17</b> and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) POCl<sub>3</sub>, <i>N</i>,<i>N</i>-dimethylformamide (DMF), 100 °C, then MnO<sub>2</sub>, MeCN, rt, 15%; (b) 4.4 M NaOMe in MeOH, 120 °C, microwave heating, then NaBH<sub>4</sub>, MeOH, rt, 81%; (c) 5 M HBr in AcOH, 40 °C, 23%; (d) 4.4 M NaOMe in MeOH, 120 °C, microwave heating, 99%; (e) PPh<sub>3</sub>MeBr, 2.5 M <i>n</i>-BuLi, THF, 0 °C to rt, 91%; (f) 0.5 M 9-BBN, THF, then H<sub>2</sub>O<sub>2</sub>, NaOH, rt, 47%; (g) Pyridine hydrochloride, neat, 90 °C, 4.4%.</p></p></figure><figure data-id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0014.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MeOH, 60 °C, 47%; (b) NBS, DBU, MeCN, rt, 9.1%.</p></p></figure><figure data-id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0015.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, PMBCl, DMF, rt, 53%; (b) DDQ, 1,4-dioxane, 100 °C, 50%; (c) 1.0 M DIBAL-H, toluene, 0 °C, 82%; (d) NaBH<sub>4</sub>, THF, rt, 71%; (e) MsCl, Et<sub>3</sub>N, DCM, rt, 69%; (f) NaCN, DMF, 90 °C, 66%; (g) TFA, reflux, 25%.</p></p></figure><figure data-id="sch6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0016.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>24</b> and <b>26-31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) RCO<sub>2</sub>H, HATU, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMF, rt, library format; (b) RSO<sub>2</sub>Cl, DIPEA, DMSO, rt, library format; (c) (1<i>S</i>)-2,2-difluorocyclopropanecarboxylic acid, HATU, DMAP, DMF, rt, 13%.</p></p></figure><figure data-id="sch7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0017.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compound <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, PMBCl, DMF, rt, 92%; (b) DDQ, 1,4-dioxane, 100 °C, 87%; (c) LiOH·H<sub>2</sub>O, THF, 40 °C, 50%; (d) cyclopropylamine, HATU, DIPEA, DMF, rt, then TFA, 90 °C, 9%.</p></p></figure><figure data-id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0018.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>34</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) conc. HCl, 1,4-dioxane, 100 °C, 83%; (b) amine, HATU, DIPEA, DMF, rt, library format.</p></p></figure><figure data-id="sch9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0019.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Compounds <b>39</b>–<b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) H<sub>2</sub>, Pt/C, MeOH, rt, then chiral SFC separation of stereoisomers. Compound <b>39a</b> is a mixture of <i>E</i> and <i>Z</i> isomers, and the <i>E</i> and <i>Z</i> isomers are racemic. Compounds <b>39</b> and <b>40</b> are enantiomers of unknown absolute configurations, as are compounds <b>41</b> and <b>42</b>.</p></p></figure><figure data-id="sch10" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Aldehyde Building Block <b>59d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiAlH<sub>4</sub>, THF, −30 °C, 83%; (b) Dess–Martin periodinane, NaHCO<sub>3</sub>, DCM, rt, 30%.</p></p></figure><figure data-id="sch11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Aldehyde Building Blocks <b>59e</b> and <b>59f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-propanol, EDCI, DMAP, 1,2-dichloroethane, rt, 14% (<b>82</b>), 55% (<b>83</b>); (b) LiAlH<sub>4</sub>, THF, 40 °C; (c) H<sub>2</sub>, Pd/C, EtOAc, rt, 96%; (d) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, DCM, −78 °C, 68%.</p></p></figure><figure data-id="sch12" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Aldehyde Building Block <b>59j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MsCl, Et<sub>3</sub>N, DCM, 0 °C, 99%; (b) KCN, DMSO, rt, 81%; (c) LiBH<sub>4</sub>, THF, 40 °C, 84%; (d) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, DCM, −78 °C, 75%.</p></p></figure><figure data-id="sch13" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/medium/jm0c00359_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Aldehyde Building Block <b>59o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00359/20200701/images/large/jm0c00359_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00359&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Benzyl alcohol, DCC, DMAP, DCM, rt, 26% (<b>92</b>), 10% (<b>93</b>); (b) BH<sub>3</sub>. THF, THF, −5 °C, then KH<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>O<sub>2</sub>, −5 °C, 25% (<b>94</b>), 25% (<b>95</b>); (c) Dess–Martin periodinane, DCM, rt, 54%; (d) NCCH<sub>2</sub>PO(OEt)<sub>2</sub>, <i>t</i>-BuOK, THF, rt, 68%; (e) LiBH<sub>4</sub>, THF, rt, 87%; (f) Dess–Martin periodinane, DCM, rt, 94%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lg7ZIv5bsR_kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">B. Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lg7ZIv5bsR_kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DB.%2BLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R.</span></span> <span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0lgKfMqfi1lNjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span> <span> </span><span class="NLM_article-title">Case History: Xeljanz (tofacitinib citrate), a first-in-class janus kinase inhibitor for the treatment of rheumatoid arthritis</span>. <i>Annu. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-800167-7.00025-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2FB978-0-12-800167-7.00025-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOqtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2014&pages=399-416&author=M.+E.+Flanaganauthor=M.+F.+Brownauthor=C.+Subramanyamauthor=M.+J.+Munchhof&title=Case+History%3A+Xeljanz+%28tofacitinib+citrate%29%2C+a+first-in-class+janus+kinase+inhibitor+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2FB978-0-12-800167-7.00025-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Case history: Xeljanz (Tofacitinib citrate), a first-in-class janus kinase inhibitor for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Flanagan, Mark E.; Brown, Matthew F.; Subramanyam, Chakrapani; Munchhof, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">399-416, 3 plates</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Xeljanz is a first-in-class janus kinase inhibitor for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVulYxfr7x07Vg90H21EOLACvtfcHk0lgKfMqfi1lNjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOqtLzN&md5=c91e0e9e6f918dcb01cd861bbd8358ee</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-800167-7.00025-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-800167-7.00025-0%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26atitle%3DCase%2520History%253A%2520Xeljanz%2520%2528tofacitinib%2520citrate%2529%252C%2520a%2520first-in-class%2520janus%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2014%26volume%3D49%26spage%3D399%26epage%3D416%26doi%3D10.1016%2FB978-0-12-800167-7.00025-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting cytokine signaling in autoimmunity: back to the future and beyond</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.coi.2016.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2Fj.coi.2016.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=27821272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWht7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=89-97&author=K.+Hiraharaauthor=D.+Schwartzauthor=M.+Gadinaauthor=Y.+Kannoauthor=J.+J.+O%E2%80%99Shea&title=Targeting+cytokine+signaling+in+autoimmunity%3A+back+to+the+future+and+beyond&doi=10.1016%2Fj.coi.2016.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cytokine signaling in autoimmunity: back to the future and beyond</span></div><div class="casAuthors">Hirahara, Kiyoshi; Schwartz, Daniella; Gadina, Massimo; Kanno, Yuka; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-97</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cytokines represent structurally diverse sol. factors with crit. roles in normal immune function and the pathogenesis of autoimmunity.  The emergence of many successful biol. therapies targeting cytokines and cytokine receptors exemplifies the importance of cytokines in driving human autoimmune disease; unsurprisingly, there is no paucity of reviews on this subject.  Nonetheless, many patients with autoimmune disease do not respond to biologicals, and cure remains an unmet goal.  Thus, targeting the intracellular pathways employed by cytokines provides new therapeutic opportunities.  A subset of cytokines utilizes the Janus kinase-signal transducer of activators of transcription (JAK-STAT) pathway as a mode of signal transduction.  First generation JAK inhibitors (jakinibs) are used to treat rheumatol. disease, and second-generation jakinibs are being developed.  Simultaneously, rapid advances are being made in our understanding of the genomic and epigenomic impact of cytokines.  In this review, we will briefly review the role of JAK-STAT-dependent cytokines in immune-mediated disease, the current status of Jakinibs, and future possibilities for therapeutic intervention using genomic insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoU3YQbIRsnLVg90H21EOLACvtfcHk0lgKfMqfi1lNjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWht7zF&md5=7330f7c6a749cebfa90305e771d63d66</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2016.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2016.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DSchwartz%26aufirst%3DD.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520cytokine%2520signaling%2520in%2520autoimmunity%253A%2520back%2520to%2520the%2520future%2520and%2520beyond%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2016%26volume%3D43%26spage%3D89%26epage%3D97%26doi%3D10.1016%2Fj.coi.2016.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craiglow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B.</span></span> <span> </span><span class="NLM_article-title">Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">2988</span>– <span class="NLM_lpage">2990</span>, <span class="refDoi"> DOI: 10.1038/jid.2014.260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1038%2Fjid.2014.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=24940651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOjsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=2988-2990&author=B.+Craiglowauthor=B.+King&title=Killing+two+birds+with+one+stone%3A+oral+tofacitinib+reverses+alopecia+universalis+in+a+patient+with+plaque+psoriasis&doi=10.1038%2Fjid.2014.260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis</span></div><div class="casAuthors">Craiglow, Brittany G.; King, Brett A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2988-2990</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TO THE EDITOR The patient is a 25-yr-old male who presented for evaluation and management of plaque psoriasis, which had begun 5 years earlier.  Treatment with topical corticosteroids had not been particularly helpful, and, because of the involvement of psoriasis over an increasing body surface area, systemic therapy with adalimumab had been initiated 1 yr before.  Although clearing of psoriasis was experienced early in the course of adalimumab, the improvement faded.  In addn. to psoriasis, the patient reported a history of alopecia areata (AA) beginning at around age 2 years, which progressed to alopecia universalis (AU) by age 18 years.  Treatment of the alopecia with topical corticosteroids had not been effective, and he had received no other therapy for it.  He had no family history of either psoriasis or AA, and his past medical history was otherwise unremarkable.  On examn., the patient demonstrated numerous well-marginated pink-red scaly plaques on the scalp, torso, and elbows.  He had no eyebrows, eyelashes (Figure 1a), or facial hair, and no hair on his arms, legs, torso, axillae, or groin.  Notably, the only prominent hair growth on the scalp was within areas of psoriasis (Figure 2a), reminiscent of hair growth that occurs in areas of irritant contact dermatitis generated by topical anthralin (Schmoeckel et al., 1979).  As treatment options for the patient were considered, we sought a therapeutic agent that could potentially target both psoriasis and AU simultaneously.  We identified tofacitinib as a promising agent and began treatment.  Tofacitinib citrate (Xeljanz), formerly CP-690550 and tasocitinib, is a novel small-mol. selective Janus kinase 1/3 (JAK 1/3) inhibitor that was FDA-approved in late 2012 for the treatment of moderate-to-severe rheumatoid arthritis (RA).  JAK inhibition has myriad effects on T-lymphocytes, and therefore it is not surprising that this medication may be useful in the treatment of many inflammatory diseases (Pesu et al., 2005).  Indeed, both oral and topical formulations of tofacitinib have been demonstrated to be safe and effective for the treatment of plaque psoriasis (Boy et al., 2009; Papp et al., 2012; Mamolo et al., 2013; Ports et al., 2013; Strober et al., 2013), with addnl. clin. trials for psoriasis and other inflammatory disorders now underway (clinicaltrials.gov).  In the case of psoriasis, increased interleukin-15 (IL-15) expression is obsd. in lesional skin and may lead to epidermal hyperproliferation via keratinocyte apoptotic resistance (Ruckert et al., 2000).  Tofacitinib, which abrogates IL-15 signaling (Johnston et al., 1995), might therefore be effective in psoriasis by normalizing keratinocyte apoptosis (Ruckert et al., 2000).  In a murine model of AA, a type I cytotoxic pathway has been demonstrated to be responsible for the disease state, with NKG2D-expressing CD8+ cytolytic T-lymphocytes identified as both necessary and sufficient for induction of disease.  Upregulation of IL-15 in the outer root sheath of the hair follicle activates cytolytic T-lymphocytes, which in turn produce IFNγ, leading to activation of the hair follicle and upregulation of IL-15, NKG2D ligands, and MHC mols., all of which target the hair follicle for attack (Jabbari et al., 2013).  The same group has demonstrated that systemic treatment with the JAK inhibitors tofacitinib and ruxolitinib (a JAK 1/2 inhibitor) prevents the onset of AA in grafted AA mice (Dai et al., 2012; Jabbari et al., 2012) and that topical treatment reverses AA in these mice (Jabbari et al., 2013).  JAK 1/3 signaling mediates IL-15 activation of T-lymphocytes (Ghoreschi et al., 2011), explaining the success of these therapies.  After 2 mo of tofacitinib at 5 mg twice daily (the approved RA dose), there was some improvement in psoriasis with partial hair regrowth on the scalp (Figure 2b) and face.  Given that higher doses of tofacitinib (up to 15 mg twice daily) have been shown to be more effective in psoriasis (Papp et al., 2012), the dose was increased to 10 mg in the morning and 5 mg at night.  After 3 more months of therapy, there was complete regrowth of the scalp hair (Figure 2c) along with significant regrowth of eyebrows, eyelashes, and facial hair along with axillary and pubic hair.  After 8 mo of therapy, there was full regrowth of hair at all body sites (Figures 1b and 2d), except for the arms and legs, locations where the patient reports never having more than sparse hair growth prior to the onset of AU.  Improvement of psoriasis has lagged behind reversal of alopecia, which is likely dose-related (Papp et al., 2012).  Although we considered increasing the dose of tofacitinib, the patient is so pleased with the regrowth of his hair (and is not particularly bothered by the remaining psoriasis) that he has chosen to continue at the present dose.  The patient has tolerated tofacitinib without subjective complaints.  Lab. monitoring has revealed no abnormalities in serum creatinine, electrolytes, glucose, complete blood count, hepatic function, or lipids.  To our knowledge, this is the first report of effective pathogenesis-based therapy for a patient with alopecia universalis.  Although the results in this patient are provocative, a clin. trial would more fully and systematically address the safety and efficacy of tofacitinib and other JAK inhibitors in the treatment of AA and its variants.  Aptly, an open-label pilot study evaluating the efficacy of ruxolitinib in moderate-to-severe AA is currently underway (Mackay-Wiggan, 2014).  Given the potential for serious adverse effects from oral JAK inhibitors, it would be particularly useful to explore the use of topical formulations for these disorders.  The era of biol. therapy has greatly enhanced the ability to make nuanced therapeutic decisions.  With every new agent, more thoughtful treatment algorithms become possible, permitting better treatment of complex patients with multiple comorbidities.  As in the case presented herein, seemingly disparate diseases with different pathomechanisms may be affected pos. by a single agent.  This case highlights the interplay between advances in basic science and therapeutics and provides a compelling example of the ways in which an increasingly complex understanding of medicine and ingenuity in treatment benefit patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLel5_J-hmObVg90H21EOLACvtfcHk0lgKfMqfi1lNjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOjsbrM&md5=352a8f2a4fdeee0d338a961099886866</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fjid.2014.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2014.260%26sid%3Dliteratum%253Aachs%26aulast%3DCraiglow%26aufirst%3DB.%26aulast%3DKing%26aufirst%3DB.%26atitle%3DKilling%2520two%2520birds%2520with%2520one%2520stone%253A%2520oral%2520tofacitinib%2520reverses%2520alopecia%2520universalis%2520in%2520a%2520patient%2520with%2520plaque%2520psoriasis%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2014%26volume%3D134%26spage%3D2988%26epage%3D2990%26doi%3D10.1038%2Fjid.2014.260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachelez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kerkhof, P. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ubanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakusevich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papacharalambous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawadrous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)62113-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2FS0140-6736%2814%2962113-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=26051365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=552-561&author=H.+Bachelezauthor=P.+C.+M.+van+de+Kerkhofauthor=R.+Strohalauthor=A.+ubanovauthor=F.+Valenzuelaauthor=J.-H.+Leeauthor=V.+Yakusevichauthor=S.+Chimentiauthor=J.+Papacharalambousauthor=J.+Proulxauthor=P.+Guptaauthor=H.+Tanauthor=M.+Tawadrousauthor=H.+Valdezauthor=R.+Wolk&title=Tofacitinib+versus+etanercept+or+placebo+in+moderate-to-severe+chronic+plaque+psoriasis%3A+a+phase+3+randomised+non-inferiority+trial&doi=10.1016%2FS0140-6736%2814%2962113-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span></div><div class="casAuthors">Bachelez, Herve; van de Kerkhof, Peter C. M.; Strohal, Robert; Kubanov, Alexey; Valenzuela, Fernando; Lee, Joo-Heung; Yakusevich, Vladimir; Chimenti, Sergio; Papacharalambous, Jocelyne; Proulx, James; Gupta, Pankaj; Tan, Huaming; Tawadrous, Margaret; Valdez, Hernan; Wolk, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9993</span>),
    <span class="NLM_cas:pages">552-561</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New therapeutic options are needed for patients with psoriasis.  Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis.  In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.  In this phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-wk, non-inferiority trial, adult patients with chronic stable plaque psoriasis (for ≥12 mo) who were candidates for systemic or phototherapy and had a Psoriasis Area and Severity Index (PASI) score of 12 or higher and a Physician's Global Assessment (PGA) of moderate or severe, and had failed to respond to, had a contraindication to, or were intolerant to at least one conventional systemic therapy, were enrolled from 122 investigational dermatol. centers worldwide.  Eligible patients were randomly assigned in a 3:3:3:1 ratio to receive tofacitinib 5 mg or 10 mg twice daily at about 12 h intervals, etanercept 50 mg s.c. twice weekly at about 3-4 day intervals, or placebo.  Randomisation was done by a computer-generated randomisation schedule, and all patients and study personnel were masked to treatment assignment.  The co-primary endpoints were the proportion of patients at week 12 with at least a 75% redn. in the PASI score from baseline (PASI75 response) and the proportion of patients achieving a PGA score of "clear" or "almost clear" (PGA response), analyzed in the full anal. set (all patients who were randomised and received at least one dose of study drug).  This study is registered with ClinicalTrials.gov, no. NCT01241591.  Between Nov 29, 2010, and Sept 13, 2012, we enrolled 1106 eligible adult patients with chronic plaque psoriasis and randomly assigned them to the four treatment groups (330 to tofacitinib 5 mg twice daily, 332 to tofacitinib 10 mg twice daily, 336 to etanercept 50 mg twice weekly, and 108 to placebo).  Of these patients, 1101 actually received their assigned study medication (329 in the tofactinib 5 mg group, 330 in the tofacitinib 10 mg group, 335 in the etanercept group, and 107 in the placebo group).  At week 12, PASI75 responses were recorded in 130 (39·5%) of 329 patients in the tofacitinib 5 mg group, 210 (63·6%) of 330 in the tofacitinib 10 mg group, 197 (58·8%) of 335 in the etanercept group, and six (5·6%) of 107 in the placebo group.  A PGA response was achieved by 155 (47·1%) of 329 patients in the tofacitinib 5 mg group, 225 (68·2%) of 330 in the tofacitinib 10 mg group, 222 (66·3%) of 335 in the etanercept group, and 16 (15·0%) of 107 in the placebo group.  The rate of adverse events was similar across the four groups, with serious adverse events occurring in seven (2%) of 329 patients in the tofacitinib 5 mg group, five (2%) of 330 in the tofacitinib 10 mg group, seven (2%) of 335 in the etanercept group, and two (2%) of 107 in the placebo group.  Three (1%) of 329 patients in the tofacitinib 5 mg group, ten (3%) of 330 in the tofacitinib 10 mg group, 11 (3%) of 335 in the etanercept group, and four (4%) of 107 patients in the placebo group discontinued their assigned treatment because of adverse events.  In patients with moderate-to-severe plaque psoriasis, the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was superior to placebo, but the 5 mg twice daily dose did not show non-inferiority to etanercept 50 mg twice weekly.  The adverse event rates over 12 wk were similar for tofacitinib and etanercept.  This study indicates that in the future tofacitinib could provide a convenient and well-tolerated therapeutic option for patients with moderate-to-severe plaque psoriasis.Pfizer Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYcpF-XDavrVg90H21EOLACvtfcHk0li3wV67OoY-LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J&md5=797adf1a67423e82ce47d96aa87daa6b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962113-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962113-9%26sid%3Dliteratum%253Aachs%26aulast%3DBachelez%26aufirst%3DH.%26aulast%3Dvan%2Bde%2BKerkhof%26aufirst%3DP.%2BC.%2BM.%26aulast%3DStrohal%26aufirst%3DR.%26aulast%3Dubanov%26aufirst%3DA.%26aulast%3DValenzuela%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DYakusevich%26aufirst%3DV.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTawadrous%26aufirst%3DM.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%2520versus%2520etanercept%2520or%2520placebo%2520in%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%253A%2520a%2520phase%25203%2520randomised%2520non-inferiority%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D552%26epage%3D561%26doi%3D10.1016%2FS0140-6736%2814%2962113-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0li3wV67OoY-LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayamada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus kinases to jakinibs: from basic insights to clinical practice</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">i4</span>– <span class="NLM_lpage">i16</span>, <span class="refDoi"> DOI: 10.1093/rheumatology/key432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1093%2Frheumatology%2Fkey432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=30806710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkt12jsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=i4-i16&author=M.+Gadinaauthor=M.+T.+Leauthor=D.+M.+Schwartzauthor=O.+Silvennoinenauthor=S.+Nakayamadaauthor=K.+Yamaokaauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+to+jakinibs%3A+from+basic+insights+to+clinical+practice&doi=10.1093%2Frheumatology%2Fkey432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases to jakinibs: from basic insights to clinical practice</span></div><div class="casAuthors">Gadina, Massimo; Le, Mimi T.; Schwartz, Daniella M.; Silvennoinen, Olli; Nakayamada, Shingo; Yamaoka, Kunihiro; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">Suppl._1</span>),
    <span class="NLM_cas:pages">i4-i16</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0332</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. mediators of diverse immune and inflammatory diseases.  Targeting cytokines and cytokine receptors with biologics has revolutionized the treatment of many of these diseases, but targeting intracellular signalling with Janus kinase (JAK) inhibitors (jakinibs) now represents a major new therapeutic advance.  We are still in the first decade since these drugs were approved and there is still much to be learned about the mechanisms of action of these drugs and the practical use of these agents.  Herein we will review cytokines that do, and just as importantly, do not signal by JAKs, as well as explain how this relates to both efficacy and side effects in various diseases.  We will review new, next-generation selective jakinibs, as well as the prospects and challenges ahead in targeting JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn66WHVxwb5bVg90H21EOLACvtfcHk0libhN_Fk-vKpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkt12jsbk%253D&md5=6448a623884cd2e066c5b6cfcdaebe63</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkey432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkey432%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DM.%2BT.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DNakayamada%26aufirst%3DS.%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520to%2520jakinibs%253A%2520from%2520basic%2520insights%2520to%2520clinical%2520practice%26jtitle%3DRheumatology%26date%3D2019%26volume%3D58%26spage%3Di4%26epage%3Di16%26doi%3D10.1093%2Frheumatology%2Fkey432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span> </span><span class="NLM_article-title">Drug Trials Snapshots: RINVOQ. Drug Approvals
and Databases. U.S.
Food & Drug Administration</span>. <a href="https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rinvoq" class="extLink">https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rinvoq</a> (accessed May 19, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drug+Trials+Snapshots%3A+RINVOQ.+Drug+Approvals%0Aand+Databases.+U.S.%0AFood+%26+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Fdrug-trials-snapshots-rinvoq+%28accessed+May+19%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%2520Trials%2520Snapshots%253A%2520RINVOQ.%2520Drug%2520Approvals%250Aand%2520Databases.%2520U.S.%250AFood%2520%2526%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Peficitinib: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01131-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs40265-019-01131-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=31093950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=887-891&author=A.+Markhamauthor=S.+J.+Keam&title=Peficitinib%3A+First+global+approval&doi=10.1007%2Fs40265-019-01131-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-891</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Peficitinib [Smyraf (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis.  Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in rheumatoid arthritis.  Peficitinib has been shown to significantly improve ACR20 and other measures of disease severity and to reduce the mean modified total Sharp score change from baseline in clin. trials.  This article summarizes the milestones in the development of peficitinib leading to this first approval as a treatment for rheumatoid arthritis in patients who have an inadequate response to conventional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0H33aqSsFn7Vg90H21EOLACvtfcHk0libhN_Fk-vKpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtLzI&md5=eb2d2061829fc515854130050139871c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01131-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01131-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPeficitinib%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D887%26epage%3D891%26doi%3D10.1007%2Fs40265-019-01131-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of <i>N</i>-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5Bmethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+A+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0li2UceonNs5Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255Bmethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520A%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pfizer Inc.</span> <span> </span><span class="NLM_article-title">Pfizer
Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib
for Moderate to Severe Atopic Dermatitis, Which Showed Improvements
in Skin Clearance, Disease Extent and Severity, and Itch</span>. <a href="https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-Announces-Positive-Top-Line-Results-from-Third-Phase-3-Trial-of-Abrocitinib-for-Moderate-to-Severe-Atopic-Dermatitis-Which-Showed-Improvements-in-Skin-Clearance-Disease-Extent-and-Severity-and-Itch/default.aspx" class="extLink">https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-Announces-Positive-Top-Line-Results-from-Third-Phase-3-Trial-of-Abrocitinib-for-Moderate-to-Severe-Atopic-Dermatitis-Which-Showed-Improvements-in-Skin-Clearance-Disease-Extent-and-Severity-and-Itch/default.aspx</a> (accessed May 19, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Pfizer+Inc.&title=Pfizer%0AAnnounces+Positive+Top-Line+Results+from+Third+Phase+3+Trial+of+Abrocitinib%0Afor+Moderate+to+Severe+Atopic+Dermatitis%2C+Which+Showed+Improvements%0Ain+Skin+Clearance%2C+Disease+Extent+and+Severity%2C+and+Itch"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DPfizer%250AAnnounces%2520Positive%2520Top-Line%2520Results%2520from%2520Third%2520Phase%25203%2520Trial%2520of%2520Abrocitinib%250Afor%2520Moderate%2520to%2520Severe%2520Atopic%2520Dermatitis%252C%2520Which%2520Showed%2520Improvements%250Ain%2520Skin%2520Clearance%252C%2520Disease%2520Extent%2520and%2520Severity%252C%2520and%2520Itch%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritzén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greve, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnerup, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rytved, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagger-Bahnsen, J.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of 6-arylindazole JAK inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00087</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00087" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFSms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=641-646&author=A.+Ritz%C3%A9nauthor=M.+D.+S%C3%B8rensenauthor=K.+N.+Dackauthor=D.+R.+Greveauthor=A.+Jerreauthor=M.+A.+Carnerupauthor=K.+A.+Rytvedauthor=J.+Bagger-Bahnsen&title=Fragment-based+discovery+of+6-arylindazole+JAK+inhibitors&doi=10.1021%2Facsmedchemlett.6b00087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors</span></div><div class="casAuthors">Ritzen, Andreas; Soerensen, Morten D.; Dack, Kevin N.; Greve, Daniel R.; Jerre, Anders; Carnerup, Martin A.; Rytved, Klaus A.; Bagger-Bahnsen, Jesper</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">641-646</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinase (JAK) inhibitors are emerging as novel and efficacious drugs for treating psoriasis and other inflammatory skin disorders, but their full potential is hampered by systemic side effects.  To overcome this limitation, the authors set out to discover soft drug JAK inhibitors for topical use.  A fragment screen yielded an indazole hit that was elaborated into a potent JAK inhibitor using structure-based design.  Growing the fragment by installing a phenol moiety in the 6-position afforded a greatly improved potency.  Fine-tuning the substituents on the phenol and sulfonamide moieties afforded a set of compds. with lead-like properties, but they were found to be phototoxic and unstable in the presence of light.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEyvlishRuYrVg90H21EOLACvtfcHk0li2UceonNs5Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFSms7Y%253D&md5=b2b7b783765cb7aa8673ecf01a9585f9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00087%26sid%3Dliteratum%253Aachs%26aulast%3DRitz%25C3%25A9n%26aufirst%3DA.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DM.%2BD.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DGreve%26aufirst%3DD.%2BR.%26aulast%3DJerre%26aufirst%3DA.%26aulast%3DCarnerup%26aufirst%3DM.%2BA.%26aulast%3DRytved%26aufirst%3DK.%2BA.%26aulast%3DBagger-Bahnsen%26aufirst%3DJ.%26atitle%3DFragment-based%2520discovery%2520of%25206-arylindazole%2520JAK%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D641%26epage%3D646%26doi%3D10.1021%2Facsmedchemlett.6b00087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marenich, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">Prediction of SAMPL2 aqueous solvation free energies and tautomeric ratios using the SM8, SM8AD, and SMD solvation models</span>. <i>Curr. Comput.-Aided Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1007/s10822-010-9333-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs10822-010-9333-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=317-333&author=R.+F.+Ribeiroauthor=A.+V.+Marenichauthor=C.+J.+Cramerauthor=D.+G.+Truhlar&title=Prediction+of+SAMPL2+aqueous+solvation+free+energies+and+tautomeric+ratios+using+the+SM8%2C+SM8AD%2C+and+SMD+solvation+models&doi=10.1007%2Fs10822-010-9333-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs10822-010-9333-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-010-9333-9%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DR.%2BF.%26aulast%3DMarenich%26aufirst%3DA.%2BV.%26aulast%3DCramer%26aufirst%3DC.%2BJ.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DPrediction%2520of%2520SAMPL2%2520aqueous%2520solvation%2520free%2520energies%2520and%2520tautomeric%2520ratios%2520using%2520the%2520SM8%252C%2520SM8AD%252C%2520and%2520SMD%2520solvation%2520models%26jtitle%3DCurr.%2520Comput.-Aided%2520Drug%2520Des.%26date%3D2010%26volume%3D24%26spage%3D317%26epage%3D333%26doi%3D10.1007%2Fs10822-010-9333-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marenich, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">Self-consistent reaction field model for aqueous and nonaqueous solutions based on accurate polarized partial charges</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2011</span>– <span class="NLM_lpage">2033</span>, <span class="refDoi"> DOI: 10.1021/ct7001418</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct7001418" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSqsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=2011-2033&author=A.+V.+Marenichauthor=R.+M.+Olsonauthor=C.+P.+Kellyauthor=C.+J.+Cramerauthor=D.+G.+Truhlar&title=Self-consistent+reaction+field+model+for+aqueous+and+nonaqueous+solutions+based+on+accurate+polarized+partial+charges&doi=10.1021%2Fct7001418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Self-Consistent Reaction Field Model for Aqueous and Nonaqueous Solutions Based on Accurate Polarized Partial Charges</span></div><div class="casAuthors">Marenich, Aleksandr V.; Olson, Ryan M.; Kelly, Casey P.; Cramer, Christopher J.; Truhlar, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2011-2033</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new universal continuum solvation model (where "universal" denotes applicable to all solvents), called SM8, is presented.  It is an implicit solvation model, also called a continuum solvation model, and it improves on earlier SMx universal solvation models by including free energies of solvation of ions in nonaq. media in the parametrization.  SM8 is applicable to any charged or uncharged solute composed of H, C, N, O, F, Si, P, S, Cl, and/or Br in any solvent or liq. medium for which a few key descriptors are known, in particular dielec. const., refractive index, bulk surface tension, and acidity and basicity parameters.  It does not require the user to assign mol.-mechanics types to an atom or group; all parameters are unique and continuous functions of geometry.  It may be used with any level of electronic structure theory as long as accurate partial charges can be computed for that level of theory; the authors recommend using it with self-consistently polarized Charge Model 4 or other self-consistently polarized class IV charges, in which case analytic gradients are available.  The model separates the observable solvation free energy into two components: the long-range bulk electrostatic contribution arising from a self-consistent reaction field treatment using the generalized Born approxn. for electrostatics is augmented by the non-bulk-electrostatic contribution arising from short-range interactions between the solute and solvent mols. in the first solvation shell.  The cavities for the bulk electrostatics calcn. are defined by superpositions of nuclear-centered spheres whose sizes are detd. by intrinsic at. Coulomb radii.  The radii used for aq. soln. are the same as parametrized previously for the SM6 aq. solvation model, and the radii for nonaq. soln. are parametrized by a training set of 220 bare ions and 21 clustered ions in acetonitrile, methanol, and DMSO.  The non-bulk-electrostatic terms are proportional to the solvent-accessible surface areas of the atoms of the solute and have been parametrized using solvation free energies for a training set of 2346 solvation free energies for 318 neutral solutes in 90 nonaq. solvents and water and 143 transfer free energies for 93 neutral solutes between water and 15 org. solvents.  The model is tested with three d. functionals and with four basis sets: 6-31+G(d,p), 6-31+G(d), 6-31G(d), and MIDI!6D.  The SM8 model achieves mean unsigned errors of 0.5-0.8 kcal/mol in the solvation free energies of tested neutrals and mean unsigned errors of 2.2-7.0 kcal/mol for ions.  The model outperforms the earlier SM5.43R and SM7 universal solvation models as well as the default Polarizable Continuum Model (PCM) implemented in Gaussian 98/03, the Conductor-like PCM as implemented in GAMESS, Jaguar's continuum model based on numerical soln. of the Poisson equation, and the GCOSMO model implemented in NWChem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWtaEOCSgegLVg90H21EOLACvtfcHk0lhtbqdfLhV8OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSqsrbJ&md5=002518393e08359394f671a73ca9a548</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fct7001418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct7001418%26sid%3Dliteratum%253Aachs%26aulast%3DMarenich%26aufirst%3DA.%2BV.%26aulast%3DOlson%26aufirst%3DR.%2BM.%26aulast%3DKelly%26aufirst%3DC.%2BP.%26aulast%3DCramer%26aufirst%3DC.%2BJ.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DSelf-consistent%2520reaction%2520field%2520model%2520for%2520aqueous%2520and%2520nonaqueous%2520solutions%2520based%2520on%2520accurate%2520polarized%2520partial%2520charges%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2007%26volume%3D3%26spage%3D2011%26epage%3D2033%26doi%3D10.1021%2Fct7001418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, D. G.</span></span> <span> </span><span class="NLM_article-title">The M06 suite of density functionals for main group thermochemistry, kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06 functionals and twelve other functionals</span>. <i>Theor. Chem. Acc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1007/s00214-007-0310-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs00214-007-0310-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFyltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2008&pages=215-241&author=Y.+Zhaoauthor=D.+G.+Truhlar&title=The+M06+suite+of+density+functionals+for+main+group+thermochemistry%2C+kinetics%2C+noncovalent+interactions%2C+excited+states%2C+and+transition+elements%3A+two+new+functionals+and+systematic+testing+of+four+M06+functionals+and+twelve+other+functionals&doi=10.1007%2Fs00214-007-0310-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals</span></div><div class="casAuthors">Zhao, Yan; Truhlar, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Theoretical Chemistry Accounts</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">215-241</span>CODEN:
                <span class="NLM_cas:coden">TCACFW</span>;
        ISSN:<span class="NLM_cas:issn">1432-881X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">We present two new hybrid meta exchange-correlation functionals, called M06 and M06-2X.  The M06 functional is parametrized including both transition metals and nonmetals, whereas the M06-2X functional is a high-nonlocality functional with double the amt. of nonlocal exchange (2X), and it is parametrized only for nonmetals.  The functionals, along with the previously published M06-L local functional and the M06-HF full-Hartree-Fock functionals, constitute the M06 suite of complementary functionals.  We assess these four functionals by comparing their performance to that of 12 other functionals and Hartree-Fock theory for 403 energetic data in 29 diverse databases, including ten databases for thermochem., four databases for kinetics, eight databases for noncovalent interactions, three databases for transition metal bonding, one database for metal atom excitation energies, and three databases for mol. excitation energies.  We also illustrate the performance of these 17 methods for three databases contg. 40 bond lengths and for databases contg. 38 vibrational frequencies and 15 vibrational zero point energies.  We recommend the M06-2X functional for applications involving main-group thermochem., kinetics, noncovalent interactions, and electronic excitation energies to valence and Rydberg states.  We recommend the M06 functional for application in organometallic and inorganometallic chem. and for noncovalent interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJNWFt06psLVg90H21EOLACvtfcHk0lhtbqdfLhV8OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFyltbY%253D&md5=c31d6f319d7c7a45aa9b716220e4a422</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs00214-007-0310-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00214-007-0310-x%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DTruhlar%26aufirst%3DD.%2BG.%26atitle%3DThe%2520M06%2520suite%2520of%2520density%2520functionals%2520for%2520main%2520group%2520thermochemistry%252C%2520kinetics%252C%2520noncovalent%2520interactions%252C%2520excited%2520states%252C%2520and%2520transition%2520elements%253A%2520two%2520new%2520functionals%2520and%2520systematic%2520testing%2520of%2520four%2520M06%2520functionals%2520and%2520twelve%2520other%2520functionals%26jtitle%3DTheor.%2520Chem.%2520Acc.%26date%3D2008%26volume%3D120%26spage%3D215%26epage%3D241%26doi%3D10.1007%2Fs00214-007-0310-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span> <span> </span><span class="NLM_article-title">Advances in the discovery of selective JAK inhibitors</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/B978-0-444-62652-3.00004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2FB978-0-444-62652-3.00004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=23384668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=153-223&author=C.+J.+Menetauthor=L.+Van+Rompaeyauthor=R.+Geney&title=Advances+in+the+discovery+of+selective+JAK+inhibitors&doi=10.1016%2FB978-0-444-62652-3.00004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of selective JAK inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Van Rompaey, Luc; Geney, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-223</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the advances in the discovery of selective JAK inhibitors.  JAK inhibitor includes JAK1, JAK2 and JAK3 and tyrosine kinase2.  Medicinal chem. and structural biol. fronts in designing and synthesizing selective or mixed JAK small-mol. inhibitors were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg_zxiK5GGLVg90H21EOLACvtfcHk0lhtbqdfLhV8OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D&md5=3d7e6f0481e3a891c84c49ece6421d74</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGeney%26aufirst%3DR.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520selective%2520JAK%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D153%26epage%3D223%26doi%3D10.1016%2FB978-0-444-62652-3.00004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Ramos, M.</span></span> <span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+J.+Menetauthor=O.+Mammolitiauthor=M.+L%C3%B3pez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of γc cytokine (γc = common γ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0ljCpFZRvoVA4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DL%25C3%25B3pez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucet, I. S.</span></span> <span> </span><span class="NLM_article-title">Dissecting specificity in the janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+janus+kinases%3A+The+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0ljCpFZRvoVA4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520janus%2520kinases%253A%2520The%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Lowering Lipophilicity by Adding Carbon: One-carbon bridges of morpholines and piperazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8934</span>– <span class="NLM_lpage">8943</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KhtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8934-8943&author=S.+L.+Degorceauthor=M.+S.+Bodnarchukauthor=I.+A.+Cummingauthor=J.+S.+Scott&title=Lowering+Lipophilicity+by+Adding+Carbon%3A+One-carbon+bridges+of+morpholines+and+piperazines&doi=10.1021%2Facs.jmedchem.8b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines</span></div><div class="casAuthors">Degorce, Sebastien L.; Bodnarchuk, Michael S.; Cumming, Iain A.; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8934-8943</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this article, we report our investigation of a phenomenon by which bridging morpholines across the ring with one-carbon tethers leads to a counterintuitive redn. in lipophilicity.  This effect was also found to occur in piperazines and piperidines and lowered the measured log D7.4 of the bridged mols. by as much as -0.8 relative to their unbridged counterparts.  As lowering lipophilicity without introducing addnl. heteroatoms can be desirable, we believe this potentially provides a useful tactic to improve the drug-like properties of mols. contg. morpholine-, piperazine-, and piperidine-like motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhZJB3SYRKD7Vg90H21EOLACvtfcHk0lgoYW7ff64a7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KhtbzK&md5=27f30b8220ea767d6ef1e492f3fa1aba</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01148%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBodnarchuk%26aufirst%3DM.%2BS.%26aulast%3DCumming%26aufirst%3DI.%2BA.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DLowering%2520Lipophilicity%2520by%2520Adding%2520Carbon%253A%2520One-carbon%2520bridges%2520of%2520morpholines%2520and%2520piperazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8934%26epage%3D8943%26doi%3D10.1021%2Facs.jmedchem.8b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komarova, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granik, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Párkányi, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of pyrazolo[3,4-b]pyridin-6-ones</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">969</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1002/jhet.986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1002%2Fjhet.986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2ku7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=969-998&author=E.+S.+Komarovaauthor=V.+A.+Makarovauthor=V.+G.+Granikauthor=C.+P%C3%A1rk%C3%A1nyi&title=Synthesis+of+pyrazolo%5B3%2C4-b%5Dpyridin-6-ones&doi=10.1002%2Fjhet.986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of pyrazolo[3,4-b]pyridin-6-ones</span></div><div class="casAuthors">Komarova, Elena S.; Makarov, Vadim A.; Granik, Vladimir G.; Parkanyi, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">969-998</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review was given on the synthesis of substituted pyrazolo[3,4-b]pyridin-6-ones and some of their properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWnsH3iiSUDbVg90H21EOLACvtfcHk0lgoYW7ff64a7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2ku7fM&md5=d548d0d877d8367a41764e0ccf0de4fe</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fjhet.986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.986%26sid%3Dliteratum%253Aachs%26aulast%3DKomarova%26aufirst%3DE.%2BS.%26aulast%3DMakarov%26aufirst%3DV.%2BA.%26aulast%3DGranik%26aufirst%3DV.%2BG.%26aulast%3DP%25C3%25A1rk%25C3%25A1nyi%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520pyrazolo%255B3%252C4-b%255Dpyridin-6-ones%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2012%26volume%3D49%26spage%3D969%26epage%3D998%26doi%3D10.1002%2Fjhet.986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balicki, R.</span></span> <span> </span><span class="NLM_article-title">Studies in the field of nitrogen heterocyclic compounds. Part XI. Abnormal cyclocondensation of ethyl 4,4,4-trifluoroacetoacetate with aminopyrazoles</span>. <i>Pol. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">797</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADyaL2MXpsFGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1983&pages=789-797&author=R.+Balicki&title=Studies+in+the+field+of+nitrogen+heterocyclic+compounds.+Part+XI.+Abnormal+cyclocondensation+of+ethyl+4%2C4%2C4-trifluoroacetoacetate+with+aminopyrazoles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Studies in the field of nitrogen heterocyclic compounds.  Part XI.  Abnormal cyclocondensation of ethyl 4,4,4-trifluoroacetoacetate with aminopyrazoles</span></div><div class="casAuthors">Balicki, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Polish Journal of Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7-8-9</span>),
    <span class="NLM_cas:pages">789-97</span>CODEN:
                <span class="NLM_cas:coden">PJCHDQ</span>;
        ISSN:<span class="NLM_cas:issn">0137-5083</span>.
    </div><div class="casAbstract">The cyclocondensation of F3CCOCH2CO2Et with 3-amino-5-phenylpyrazole, 5-amino-1,3-dimethylpyrazole, 3-aminopyrazole, and 3-amino-4-phenylpyrazole occurs differently from analogous reactions, e.g. with MeCOCH2CO2Et.  Thus, F3CCOCH2CO2Et underwent cyclocondensation with 5-amino-1,3-dimethylpyrazole in EtOH to give mainly the pyrazole I.  The same reaction in benzene gave the pyrazolopyridine II.  I and II were converted to the pyrazolopyridine III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqojU67uLJKX7Vg90H21EOLACvtfcHk0lgoYW7ff64a7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXpsFGksA%253D%253D&md5=af295f63237e71f3896e93654ee932b9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBalicki%26aufirst%3DR.%26atitle%3DStudies%2520in%2520the%2520field%2520of%2520nitrogen%2520heterocyclic%2520compounds.%2520Part%2520XI.%2520Abnormal%2520cyclocondensation%2520of%2520ethyl%25204%252C4%252C4-trifluoroacetoacetate%2520with%2520aminopyrazoles%26jtitle%3DPol.%2520J.%2520Chem.%26date%3D1983%26volume%3D57%26spage%3D789%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcouffe, C.</span>; <span class="NLM_string-name">Bjegarde, K.</span>; <span class="NLM_string-name">Mauger, J.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine Derivatives, Preparation Process therefor and Therapeutic Use thereof</span>. Patent <span class="NLM_patent">WO2013087744</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=C.+Alcouffe&author=K.+Bjegarde&author=J.+Mauger&title=Pyrazolopyridine+Derivatives%2C+Preparation+Process+therefor+and+Therapeutic+Use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcouffe%26aufirst%3DC.%26atitle%3DPyrazolopyridine%2520Derivatives%252C%2520Preparation%2520Process%2520therefor%2520and%2520Therapeutic%2520Use%2520thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcouffe, C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine Derivatives for use in the Treatment of Bladder Cancer</span>. Patent <span class="NLM_patent">WO2014198942</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+Alcouffe&title=Pyrazolopyridine+Derivatives+for+use+in+the+Treatment+of+Bladder+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcouffe%26aufirst%3DC.%26atitle%3DPyrazolopyridine%2520Derivatives%2520for%2520use%2520in%2520the%2520Treatment%2520of%2520Bladder%2520Cancer%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 Inhibitors</span>. Patent <span class="NLM_patent">WO2005000303</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+T.+Wager&title=Pyrazolo%5B3%2C4-b%5Dpyridin-6-ones+as+GSK-3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26atitle%3DPyrazolo%255B3%252C4-b%255Dpyridin-6-ones%2520as%2520GSK-3%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desenko, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirobokova, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkin, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkina, S. V.</span></span> <span> </span><span class="NLM_article-title">Heterocyclization of 5-methylpyrazol-3-amine with unsaturated arylaliphatic carboxylic acid derivatives</span>. <i>Russ. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1027</span>, <span class="refDoi"> DOI: 10.1134/S1070428006070153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1134%2FS1070428006070153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvFKqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=1022-1027&author=V.+V.+Lipsonauthor=S.+M.+Desenkoauthor=M.+G.+Shirobokovaauthor=O.+V.+Shishkinauthor=S.+V.+Shishkina&title=Heterocyclization+of+5-methylpyrazol-3-amine+with+unsaturated+arylaliphatic+carboxylic+acid+derivatives&doi=10.1134%2FS1070428006070153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocyclization of 5-methylpyrazol-3-amine with unsaturated arylaliphatic carboxylic acid derivatives</span></div><div class="casAuthors">Lipson, V. V.; Desenko, S. M.; Shirobokova, M. G.; Shishkin, O. V.; Shishkina, S. V.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1022-1027</span>CODEN:
                <span class="NLM_cas:coden">RJOCEQ</span>;
        ISSN:<span class="NLM_cas:issn">1070-4280</span>.
    
            (<span class="NLM_cas:orgname">Pleiades Publishing, Inc.</span>)
        </div><div class="casAbstract">Cyclocondensation of 5-methyl-3-pyrazolamine with Me cinnamate and (arylmethylene)malonic acids in DMF and methanol leads to the formation of 7-aryl-2-methyl-6,7-dihydropyrazolo[1,5-a]-pyrimidin-5(4H)-one derivs.  (Arylmethylene)malonic acids react with the title amine at a ratio of 1:2 in nitrobenzene to give 4-aryl-3,5-dimethyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine derivs.  Heterocyclization of 5-methyl-3-pyrazolamine with 5-(arylmethylene)-2,2-dimethyl-1,3-dioxane-4,6-diones or their precursors, para-substituted benzaldehydes and 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) in all solvents (methanol, DMF, and nitrobenzene) give the corresponding 4-aryl-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-one derivs.  The structure of 3-methyl-4-(4-nitrophenyl)-2,4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-one was proved by X-ray anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr69FiS4JhzLbVg90H21EOLACvtfcHk0ljXgo0_61faiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvFKqtrw%253D&md5=000d54f9b99d716ed5b2093dfac731bf</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1134%2FS1070428006070153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS1070428006070153%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DV.%2BV.%26aulast%3DDesenko%26aufirst%3DS.%2BM.%26aulast%3DShirobokova%26aufirst%3DM.%2BG.%26aulast%3DShishkin%26aufirst%3DO.%2BV.%26aulast%3DShishkina%26aufirst%3DS.%2BV.%26atitle%3DHeterocyclization%2520of%25205-methylpyrazol-3-amine%2520with%2520unsaturated%2520arylaliphatic%2520carboxylic%2520acid%2520derivatives%26jtitle%3DRuss.%2520J.%2520Org.%2520Chem.%26date%3D2006%26volume%3D42%26spage%3D1022%26epage%3D1027%26doi%3D10.1134%2FS1070428006070153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrova, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamigajlo, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gella, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musatov, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkina, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkin, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vashchenko, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borisov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, V. V.</span></span> <span> </span><span class="NLM_article-title">Three-component synthesis of 4-aroyl-2(1),4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-ones and their properties</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1007/s10593-014-1502-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs10593-014-1502-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=514-527&author=O.+N.+Petrovaauthor=L.+L.+Zamigajloauthor=I.+M.+Gellaauthor=V.+I.+Musatovauthor=S.+V.+Shishkinaauthor=O.+V.+Shishkinauthor=E.+V.+Vashchenkoauthor=A.+V.+Borisovauthor=V.+V.+Lipson&title=Three-component+synthesis+of+4-aroyl-2%281%29%2C4%2C5%2C7-tetrahydropyrazolo%5B3%2C4-b%5Dpyridin-6-ones+and+their+properties&doi=10.1007%2Fs10593-014-1502-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Three-Component Synthesis of 4-Aroyl-2(1),4,5,7-Tetrahydropyrazolo[3,4-b]Pyridin-6-Ones and Their Properties</span></div><div class="casAuthors">Petrova, O. N.; Zamigajlo, L. L.; Gella, I. M.; Musatov, V. I.; Shishkina, S. V.; Shishkin, O. V.; Vashchenko, E. V.; Borisov, A. V.; Lipson, V. V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">514-527</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inspired by the concept of multicomponent reactions, a novel one-pot synthesis involving arylglyoxals, 5-aminopyrazoles, and Meldrum's acid was developed and employed for the creation of a small library of 4-aroyl-2(1),4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-ones.  The alkylation, acylation, redn., and oxidn. reactions of 4-aroyl-3-methyl-2,4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-ones were studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNhxfkCMZ5lLVg90H21EOLACvtfcHk0ljXgo0_61faiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrP&md5=3b86a3923cb4c3a0df0d27aa534aaf05</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs10593-014-1502-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-014-1502-7%26sid%3Dliteratum%253Aachs%26aulast%3DPetrova%26aufirst%3DO.%2BN.%26aulast%3DZamigajlo%26aufirst%3DL.%2BL.%26aulast%3DGella%26aufirst%3DI.%2BM.%26aulast%3DMusatov%26aufirst%3DV.%2BI.%26aulast%3DShishkina%26aufirst%3DS.%2BV.%26aulast%3DShishkin%26aufirst%3DO.%2BV.%26aulast%3DVashchenko%26aufirst%3DE.%2BV.%26aulast%3DBorisov%26aufirst%3DA.%2BV.%26aulast%3DLipson%26aufirst%3DV.%2BV.%26atitle%3DThree-component%2520synthesis%2520of%25204-aroyl-2%25281%2529%252C4%252C5%252C7-tetrahydropyrazolo%255B3%252C4-b%255Dpyridin-6-ones%2520and%2520their%2520properties%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2014%26volume%3D50%26spage%3D514%26epage%3D527%26doi%3D10.1007%2Fs10593-014-1502-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodina, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirobokova, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desenko, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishkin, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubatyuk, R. I.</span></span> <span> </span><span class="NLM_article-title">Interaction of aminoazoles with Meldrum’s acid and dialkyl ketones or cyclohexanone</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">490</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1007/s10593-007-0071-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1007%2Fs10593-007-0071-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsleqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=490-495&author=V.+V.+Lipsonauthor=V.+V.+Borodinaauthor=M.+G.+Shirobokovaauthor=S.+M.+Desenkoauthor=O.+V.+Shishkinauthor=R.+I.+Zubatyuk&title=Interaction+of+aminoazoles+with+Meldrum%E2%80%99s+acid+and+dialkyl+ketones+or+cyclohexanone&doi=10.1007%2Fs10593-007-0071-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of aminoazoles with Meldrum's acid and dialkyl ketones or cyclohexanone</span></div><div class="casAuthors">Lipson, V. V.; Borodina, V. V.; Shirobokova, M. G.; Desenko, S. M.; Shishkin, O. V.; Zubatyuk, R. I.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">490-495</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Interaction of 3-amino-5-methylpyrazole, 3-amino-5-methylthio-, and 3,5-diamino-1,2,4-triazole with Meldrum's acid, acetone, Et Me ketone, and cyclohexanone leads to alkyl-substituted pyrazolo[3,4-b]pyridin-6-ones and 1,2,4-triazolo[1,5-a]pyrimidin-7-ones, resp.  The structure of 5,5-dimethyl-2-methylthio-4,5,6,7-tetrahydro-1,2,4-triazolo[1,5-a]pyrimidin-7-one was demonstrated by an x-ray structural investigation [triclinic, space group P1, a 8.371(2), b 9.810(2), c 13.520(4) Å, α 70.41(2), β 82.51(2), γ 81.93(2)°, V 1031.4(5) Å3, Z 4].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDcnUvDRTR6LVg90H21EOLACvtfcHk0ljXgo0_61faiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsleqsrc%253D&md5=9c5eb58e6bf93113ef921244c77b9b92</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10593-007-0071-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-007-0071-4%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DV.%2BV.%26aulast%3DBorodina%26aufirst%3DV.%2BV.%26aulast%3DShirobokova%26aufirst%3DM.%2BG.%26aulast%3DDesenko%26aufirst%3DS.%2BM.%26aulast%3DShishkin%26aufirst%3DO.%2BV.%26aulast%3DZubatyuk%26aufirst%3DR.%2BI.%26atitle%3DInteraction%2520of%2520aminoazoles%2520with%2520Meldrum%25E2%2580%2599s%2520acid%2520and%2520dialkyl%2520ketones%2520or%2520cyclohexanone%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2007%26volume%3D43%26spage%3D490%26epage%3D495%26doi%3D10.1007%2Fs10593-007-0071-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fache, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehuede, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, M.</span></span> <span> </span><span class="NLM_article-title">A catalytic stereo- and chemo-selective method for the reduction of substituted aromatics</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(94)02386-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2F0040-4039%2894%2902386-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADyaK2MXjs1Kmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=885-888&author=F.+Facheauthor=S.+Lehuedeauthor=M.+Lemaire&title=A+catalytic+stereo-+and+chemo-selective+method+for+the+reduction+of+substituted+aromatics&doi=10.1016%2F0040-4039%2894%2902386-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A catalytic stereo- and chemo-selective method for the reduction of substituted aromatics</span></div><div class="casAuthors">Fache, Fabienne; Lehuede, Stephan; Lemaire, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">885-8</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Various substituted aroms. have been reduced using colloidal ruthenium under H2 pressure with good stereoselectivity (cis/trans up to 60).  Interesting chemoselectivities are also obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoruxDgF4pkHrVg90H21EOLACvtfcHk0lgLSCgBXrPQxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjs1Kmsr8%253D&md5=2cc361be64ad07c0bf03484bf2f3d2d3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2894%2902386-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252894%252902386-P%26sid%3Dliteratum%253Aachs%26aulast%3DFache%26aufirst%3DF.%26aulast%3DLehuede%26aufirst%3DS.%26aulast%3DLemaire%26aufirst%3DM.%26atitle%3DA%2520catalytic%2520stereo-%2520and%2520chemo-selective%2520method%2520for%2520the%2520reduction%2520of%2520substituted%2520aromatics%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D885%26epage%3D888%26doi%3D10.1016%2F0040-4039%2894%2902386-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricks, M. J.</span>; <span class="NLM_string-name">Dent, W. H.</span>; <span class="NLM_string-name">Rogers, R. B.</span>; <span class="NLM_string-name">Yao, C.</span>; <span class="NLM_string-name">Nader, B. S.</span>; <span class="NLM_string-name">Miesel, J. L.</span>; <span class="NLM_string-name">Fitzpatrick, G. M.</span>; <span class="NLM_string-name">Meyer, K. G.</span>; <span class="NLM_string-name">Niyaz, N. M.</span>; <span class="NLM_string-name">Morrison, I. M.</span>; <span class="NLM_string-name">Henry, M. J.</span>; <span class="NLM_string-name">Adamski, B. J. L.</span>; <span class="NLM_string-name">Gajewski, R. P.</span></span> <span> </span><span class="NLM_article-title">Fungicidal Heterocyclic Aromatic Amides and their Compositions, Methods of Use and Preparation</span>. Patent <span class="NLM_patent">WO0114339</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+J.+Ricks&author=W.+H.+Dent&author=R.+B.+Rogers&author=C.+Yao&author=B.+S.+Nader&author=J.+L.+Miesel&author=G.+M.+Fitzpatrick&author=K.+G.+Meyer&author=N.+M.+Niyaz&author=I.+M.+Morrison&author=M.+J.+Henry&author=B.+J.+L.+Adamski&author=R.+P.+Gajewski&title=Fungicidal+Heterocyclic+Aromatic+Amides+and+their+Compositions%2C+Methods+of+Use+and+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRicks%26aufirst%3DM.%2BJ.%26atitle%3DFungicidal%2520Heterocyclic%2520Aromatic%2520Amides%2520and%2520their%2520Compositions%252C%2520Methods%2520of%2520Use%2520and%2520Preparation%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastida, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span> <span> </span><span class="NLM_article-title">Building C(sp3)-rich complexity by combining cycloaddition and C-C cross-coupling reactions</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>560</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0391-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1038%2Fs41586-018-0391-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=30061620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWru7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=560&publication_year=2018&pages=350-354&author=T.-G.+Chenauthor=L.+M.+Bartonauthor=Y.+Linauthor=J.+Tsienauthor=D.+Kosslerauthor=I.+Bastidaauthor=S.+Asaiauthor=C.+Biauthor=J.+S.+Chenauthor=M.+Shanauthor=H.+Fangauthor=F.+G.+Fangauthor=H.-w.+Choiauthor=L.+Hawkinsauthor=T.+Qinauthor=P.+S.+Baran&title=Building+C%28sp3%29-rich+complexity+by+combining+cycloaddition+and+C-C+cross-coupling+reactions&doi=10.1038%2Fs41586-018-0391-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Building C(sp3)-rich complexity by combining cycloaddition and C-C cross-coupling reactions</span></div><div class="casAuthors">Chen, Tie-Gen; Barton, Lisa M.; Lin, Yutong; Tsien, Jet; Kossler, David; Bastida, Inaki; Asai, Shota; Bi, Cheng; Chen, Jason S.; Shan, Mingde; Fang, Hui; Fang, Francis G.; Choi, Hyeong-wook; Hawkins, Lynn; Qin, Tian; Baran, Phil S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">560</span>
        (<span class="NLM_cas:issue">7718</span>),
    <span class="NLM_cas:pages">350-354</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prized for their ability to rapidly generate chem. complexity by building new ring systems and stereocentres, cycloaddn. reactions have featured in numerous total syntheses and are a key component in the education of chem. students.  Similarly, carbon-carbon (C-C) cross-coupling methods are integral to synthesis because of their programmability, modularity and reliability.  Within the area of drug discovery, an overreliance on cross-coupling has led to a disproportionate representation of flat architectures that are rich in carbon atoms with orbitals hybridized in an sp2 manner.  Despite the ability of cycloaddns. to introduce multiple carbon sp3 centers in a single step, they are less used.  This is probably because of their lack of modularity, stemming from the idiosyncratic steric and electronic rules for each specific type of cycloaddn.  Here we demonstrate a strategy for combining the optimal features of these two chem. transformations into one simple sequence, to enable the modular, enantioselective, scalable and programmable prepn. of useful building blocks, natural products and lead scaffolds for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRd_64A4rNc7Vg90H21EOLACvtfcHk0lgLSCgBXrPQxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWru7rK&md5=c088cccdbddd0355b9392533a1677367</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0391-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0391-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.-G.%26aulast%3DBarton%26aufirst%3DL.%2BM.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DTsien%26aufirst%3DJ.%26aulast%3DKossler%26aufirst%3DD.%26aulast%3DBastida%26aufirst%3DI.%26aulast%3DAsai%26aufirst%3DS.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%2BS.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DF.%2BG.%26aulast%3DChoi%26aufirst%3DH.-w.%26aulast%3DHawkins%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26atitle%3DBuilding%2520C%2528sp3%2529-rich%2520complexity%2520by%2520combining%2520cycloaddition%2520and%2520C-C%2520cross-coupling%2520reactions%26jtitle%3DNature%26date%3D2018%26volume%3D560%26spage%3D350%26epage%3D354%26doi%3D10.1038%2Fs41586-018-0391-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span>; <span class="NLM_string-name">Carroll, J. N.</span>; <span class="NLM_string-name">Hanau, C. E.</span>; <span class="NLM_string-name">McReynolds, M. D.</span>; <span class="NLM_string-name">Scholten, J. A.</span>; <span class="NLM_string-name">McDonald, J. J.</span>; <span class="NLM_string-name">Grapperhaus, M. L.</span>; <span class="NLM_string-name">Massa, M. A.</span>; <span class="NLM_string-name">Ruminski, P. G.</span>; <span class="NLM_string-name">Schmidt, M. A.</span>; <span class="NLM_string-name">Strohback, J. W.</span>; <span class="NLM_string-name">Hamper, B. C.</span>; <span class="NLM_string-name">Fletcher, T. R.</span>; <span class="NLM_string-name">Rogers, M. D.</span>; <span class="NLM_string-name">O’Brien, P. M.</span>; <span class="NLM_string-name">Nahra, J.</span>; <span class="NLM_string-name">Morris, M. A.</span>; <span class="NLM_string-name">Roark, W. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrimidine and Pyridine Derivatives as Antiinflammatory Agents</span>. Patent <span class="NLM_patent">WO2009016498</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+E.+Schnute&author=J.+N.+Carroll&author=C.+E.+Hanau&author=M.+D.+McReynolds&author=J.+A.+Scholten&author=J.+J.+McDonald&author=M.+L.+Grapperhaus&author=M.+A.+Massa&author=P.+G.+Ruminski&author=M.+A.+Schmidt&author=J.+W.+Strohback&author=B.+C.+Hamper&author=T.+R.+Fletcher&author=M.+D.+Rogers&author=P.+M.+O%E2%80%99Brien&author=J.+Nahra&author=M.+A.+Morris&author=W.+H.+Roark&title=Preparation+of+Pyrimidine+and+Pyridine+Derivatives+as+Antiinflammatory+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520and%2520Pyridine%2520Derivatives%2520as%2520Antiinflammatory%2520Agents%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, Y.</span></span> <span> </span><span class="NLM_article-title">Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3213</span>– <span class="NLM_lpage">3215</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=10.1016%2Fj.bmcl.2016.05.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=27261178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVymsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3213-3215&author=H.+Kimauthor=M.+K.+Kimauthor=H.+Chooauthor=Y.+Chong&title=Novel+JAK1-selective+benzimidazole+inhibitors+with+enhanced+membrane+permeability&doi=10.1016%2Fj.bmcl.2016.05.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability</span></div><div class="casAuthors">Kim, Hyungmi; Kim, Mi Kyoung; Choo, Hyunah; Chong, Youhoon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3213-3215</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The previously identified Janus kinase 1 (JAK1)-selective inhibitor, 1-(2-aminoethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole-5-carboxamide, suffered from low cell permeability, which resulted in poor pharmacokinetic properties.  In this study, by introducing less polar hydrogen bond donors at N1 (a hydroxyalkyl or a methylaminoalkyl group) and C2 (a cyclohexanol group) positions, a series of novel benzimidazole derivs. I (R 1 = (CH2)2OH, (CH2)3OH, (CH2)2NHMe, (CH2)3NH2, (R)-CH2CHOHMe) and II (R2 = (CH2)2NHMe, (CH2)3NH2) were prepd., which exhibited selective JAK1 inhibitory activity (IC50 against JAK1 = 0.08-0.15 μM; JAK1-selectivity = 26-40 fold vs JAK2, 12-23 fold vs JAK3, and 38-54 fold vs Tyk2) along with significantly increased lipophilicity (3.3-15.8 times) as well as membrane permeability (6.3-12 times).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHBsrUVqqnmbVg90H21EOLACvtfcHk0lgLSCgBXrPQxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVymsbc%253D&md5=8c7888e1b158c7fed9f84a47b43984bf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.078%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DChoo%26aufirst%3DH.%26aulast%3DChong%26aufirst%3DY.%26atitle%3DNovel%2520JAK1-selective%2520benzimidazole%2520inhibitors%2520with%2520enhanced%2520membrane%2520permeability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3213%26epage%3D3215%26doi%3D10.1016%2Fj.bmcl.2016.05.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPD','PDB','6TPD'); return false;">PDB: 6TPD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG','PDB','3EYG'); return false;">PDB: 3EYG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPE','PDB','6TPE'); return false;">PDB: 6TPE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPF','PDB','6TPF'); return false;">PDB: 6TPF</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i96"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00359">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_27078"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00359?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00359</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">General biological experimental procedures; NMR spectra for the structure elucidation of compound <b>50</b> and determination of the relative stereochemistry of compounds <b>39</b>–<b>42</b>; UPLC chromatograms of compounds <b>21</b>, <b>27</b>, and <b>40</b>; and details of the kinase panel screen (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_001.pdf">jm0c00359_si_001.pdf (602.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00359/suppl_file/jm0c00359_si_002.csv">jm0c00359_si_002.csv (7.88 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPD">6TPD</a> for <b>6</b>; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPE">6TPE</a> for <b>21</b>; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TPF">6TPF</a> for <b>27</b>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00359&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-13%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00359%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00359" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797e72fcee196f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
